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ABSTRACT
Background
The annual incidence rate of type 1 diabetes is increasing on average by 2.5–3%
worldwide. Notably, among Finnish children aged below 15 years the rate is continuously
the world’s highest. About one-third of the patients develop diabetic nephropathy (DN),
which is the most severe and burdensome complication, ultimately leading to end-stage
renal disease (ESRD), requiring dialysis or kidney transplantation. DN is frequently
related to other microvascular complications and cardiovascular diseases. In addition, type
1 diabetes is associated with other chronic conditions such as autoimmune diseases and
psychiatric disorders. Therefore, pharmaceutical interventions play an important role not
only in controlling glycaemia, but also in treating related co-morbidities. Prescription
medications cover about one-third of the total costs of type 1 diabetes. However, patients
with type 1 diabetes at different disease severity stages are likely to require different types
and amounts of medication as well as other treatments, consequently having different
resource needs. Hence, it is important to identify the potential subgroups of patients with
greater needs as well as the major cost drivers in order to improve understanding of the
cost structure of diabetes care. There is strong evidence that guidelines-based care can
improve patient outcomes. Thus, it is also crucial to analyse to what extent the targets of
the guidelines are achieved in normal clinical settings, and furthermore, how achievement
of the most relevant targets affects the prognosis of patients.
Aims
The use and costs of prescription medication in patients with type 1 diabetes, stratified by
various severity stages of the diabetic kidney disease, were evaluated. The implementation
of the American Diabetes Association (ADA) guidelines was also studied by evaluating
the achievement of treatment targets and how these achievements predict the prognosis of
patients at different severity stages of the disease.
Subjects and methods
All participants included in the study were part of the ongoing, nationwide, multicentre
Finnish Diabetic Nephropathy Study (FinnDiane), with the main aim of identifying
genetic, clinical and environmental risks factors for diabetic complications among patients
with type 1 diabetes. The study was launched in 1997 and approximately 4800 individuals
have been recruited from 92 centres all over Finland. To obtain information on all
purchases of prescription medications as well as co-morbidities and premature mortality,
the FinnDiane data were linked with several national registers. Substudies I–III and V
have a longitudinal and prospective design, while Study IV was cross-sectional, using
baseline data only.
Results
Although diabetes itself generates high medication costs, the progression to more severe
stages of DN increases the costs considerably, even before the development of ESRD. In
patients with ESRD, the 11-year cumulative costs increased fourfold
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(12 470 € vs. 65 480 €), or even 15-fold (3830 € vs. 60 140 €), when diabetes medications
were excluded compared with those without severe complications. The cost of diabetes
medications remained quite stable irrespective of the presence of complications and
duration of diabetes. The major cost drivers were immunosuppressants, peritoneal
dialytics and erythropoietin. In general, the increasing trend in the total costs of
prescription medications reflects the general development of drug costs in Finland. After
generic substitution was introduced in 2003, the cost of lipid-lowering drugs and agents
acting on the renin-angiotensin-aldosterone system dropped, although the number of users
increased  at  the  same  time  in  all  renal  status  groups  prior  to  ESRD.  The  costs  were
significantly higher in patients with macroalbuminuria than in those with earlier stages of
DN, and the gap continued to increase until the end of follow-up. A large gap exists
between evidence-based diabetes guidelines and clinical practice since only a minority of
all patients with type 1 diabetes reached the targets for glycosylated haemoglobin
(HbA1C), blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) proposed
by the ADA. One of the novel findings was the high prevalence of treatment-resistant
hypertension  (RH)  in  patients  with  type  1  diabetes.  RH  increased  in  parallel  with  the
worsening of DN; while less than one-tenth of antihypertensive drug-treated normo- or
microalbuminuric patients met the criteria for RH, up to one-third of patients with
macroalbuminuria and 40% of patients on dialysis were classified as having RH. Notably,
glycaemic, BP and lipid control were also suboptimal among those with no signs or with
early signs of diabetic complications. According to our data, failure to reach the ADA
targets was associated with increased risk of cardiovascular disease (CVD) and all-cause
mortality in patients with type 1 diabetes.
Conclusions
Progression to a more severe stage of DN has a substantial impact on prescription
medication costs, highlighting the importance of early intervention to prevent or delay the
onset  of  diabetic  kidney  disease  in  patients  with  type  1  diabetes.  In  addition,  this  study
revealed that the treatment targets of HbA1C, BP and LDL-C proposed by the ADA have
not been achieved. Achievement of these targets would be desirable for the optimal
prevention of CVD and mortality in patients with type 1 diabetes.
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TIIVISTELMÄ
Taustaa
Tyypin 1 diabeteksen ilmaantuvuus lisääntyy maailmanlaajuisesti keskimäärin 2.5–3%
vuodessa. Kansainvälisesti katsoen Suomella on kuitenkin erityisasema tyypin 1
diabeteksen suhteen: suomalaisen lapsen riski sairastua diabetekseen on edelleen
maailman korkein. Noin kolmasosa tyypin 1 diabeetikoista sairastuu munuaissairauteen,
niin kutsuttuun diabeettisen nefropatiaan. Se on yksi vakavimmista ja hankalimmista
komplikaatioista, erityisesti johtaessaan loppuvaiheen munuaissairauteen (ESRD), joka
vaatii dialyysihoitoa tai munuaisen siirron. Nefropatiaan liittyy usein myös muita
mikrovaskulaarisia komplikaatioita sekä sydän- ja verisuonitauteja. Lisäksi tyypin 1
diabeteetikolla voi olla muita kroonisia sairauksia, kuten autoimmuunisairauksia tai
psyykkisiä häiriöitä. Siksi lääkehoidolla on keskeinen merkitys paitsi diabeteksen, myös
lisäsairauksien hoidossa. Tyypin 1 diabeteksen kokonaiskustannuksista noin kolmannes
aiheutuu reseptilääkkeistä. On kuitenkin todennäköistä, että munuaissairauden vaikeusaste
vaikuttaa käytettyihin lääkkeisiin ja niiden määrään, kuten myös muihin tarvittaviin
hoitoihin ja taloudellisiin resursseihin. Diabeteksen hoidon kustannusrakenteen
ymmärtämiseksi on tärkeää tarkastella lääkkeiden käyttöä eri potilasryhmissä sairauden
vaikeusasteiden mukaan sekä määritellä suurimmat kustannusten aiheuttajat. On vahvaa
näyttöä siitä, että diabeteksen hoitosuositusten tavoitteiden toteutuminen vaikuttaa
suotuisasti hoitotuloksiin. Siksi on tärkeää myös arvioida, kuinka nämä hoitosuositukset
toteutuvat käytännössä ja kuinka kaikkein tärkeimpien hoitotavoitteiden saavuttaminen
vaikuttaa potilaan ennusteeseen.
Tavoitteet
Väitöskirjassa tavoitteena oli tarkastella tyypin 1 diabeetikoiden reseptilääkkeiden käyttöä
ja kustannuksia munuaissairauden eri vaikeusasteiden mukaan. Toisena tavoitteena oli
arvioida American Diabetes Associationin (ADA) hoitosuositusten toteutumista sekä sitä,
miten tavoitteiden toteutuminen vaikuttaa potilaan ennusteeseen munuaissairauden eri
vaiheissa.
Tutkimusaineisto ja menetelmät
Tutkimuksen aineisto muodostui FinnDiane-tutkimukseen (Finnish Diabetic Nephropathy
Study) osallistuneista tyypin 1 diabeetikoista. FinnDiane on vuonna 1997 aloitettu, yhä
jatkuva kansallinen monikeskustutkimus (mukana noin 4800 potilasta 92 keskuksesta
kaikkialta Suomesta), jonka keskeisenä tavoitteena on tunnistaa perintö- ja
ympäristötekijöiden joukosta diabeteksen lisäsairauksille altistavia riskitekijöitä. Tiedot
potilaiden reseptilääkeostoista, lisäsairauksista ja kuolleisuudesta saatiin yhdistämällä
FinnDiane-aineisto kansallisiin rekistereihin. Osatutkimukset I–III sekä V ovat
prospektiivisia pitkittäistutkimuksia, kun taas osatutkimus IV on poikittaistutkimus, jossa
tiedot kerättiin ensimmäiseltä tutkimuskäynniltä.
Tulokset
Vaikka diabetes itsessään aiheuttaa merkittäviä lääkekustannuksia, munuaissairauden
eteneminen lisää kustannuksia huomattavasti, jopa ennen loppuvaiheen munuaissairauden
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kehittymistä. Munuaissairauden loppuvaiheessa potilaiden 11 vuoden kumulatiiviset
lääkekustannukset olivat nelinkertaiset verrattuna niihin, joilla ei ollut vakavia
komplikaatioita. Kun diabeteslääkkeet suljettiin pois tarkastelusta, nousivat kustannukset
15-kertaisiksi. Sitä vastoin diabeteslääkkeiden kustannukset eivät juuri vaihdelleet
diabeteksen keston ja vakavien komplikaatioiden esiintymisen mukaan. Suurimmat
kustannukset aiheutuivat hyljinnänestolääkkeistä, peritoneaalidialyysinesteistä ja
erytropoietiinista. Yleisesti ottaen tyypin 1 diabeetikoiden reseptilääkkeiden
kokonaiskustannukset kasvoivat seurantajakson aikana, mikä heijastelee yleistä
lääkekustannusten kehitystä Suomessa. Vuonna 2003 voimaan tullut lääkevaihto eli
geneerinen substituutio alensi erityisesti lipidejä muuntavien ja reniini-
angiotensiinijärjestelmään vaikuttavien lääkkeiden kustannuksia, vaikka kyseisten
lääkkeiden käyttäjien määrät lisääntyivät samanaikaisesti sekä normo-, mikro- että
makroalbumiiniuria ryhmissä. Reseptilääkekustannukset olivat merkittävästi korkeammat
makroalbumiiniuria ryhmässä kuin normo- ja mikroalbumiiniuriaryhmissä, ja erot
suurenivat seurantajakson aikana. Tutkimuksemme osoitti, että näyttöön perustuvien
diabeteksen hoitosuositusten ja käytännön välillä on suuri ero, sillä vain pieni osa tyypin 1
diabeetikoista saavutti ADA:n suosittelemat HbA1C:n, verenpaineen ja LDL-kolesterolin
hoitotavoitteet. Yksi tutkimuksemme keskeisistä ja uusista tuloksista osoitti, että hoidolle
resistentti verenpaine on varsin yleistä tyypin 1 diabeetikoilla. Hoidolle resistentti
verenpaine lisääntyy kuitenkin munuaissairauden edetessä: verenpainelääkkeitä
käyttävistä normo- ja mikroalbumiiniuriapotilaista noin joka kymmenennellä,
makroalbumiiniuria- ja munuaisensiirtopotilaista kolmasosalla sekä dialyysipotilaista 40
%:lla esiintyi resistenttiä verenpainetta. On kuitenkin tärkeää huomata, että myös ne, joilla
ei ollut lainkaan tai joilla oli vasta alkavia merkkejä munuaissairaudesta, eivät
saavuttaneet HbA1C:lle, verenpaineelle ja LDL-kolesterolille asetettuja tavoitteita.
Tutkimustulostemme mukaan niillä, jotka eivät saavuttaneet hoitotavoitteita, oli suurempi
sydän- ja verisuonitautien ja kuoleman riski.
Johtopäätökset
Munuaissairauden etenemisellä on huomattava vaikutus reseptilääkekustannuksiin, jopa
ennen munuaissairauden loppuvaiheen kehittymistä. Tutkimustulostemme valossa
munuaissairauden ennaltaehkäisyllä, varhaisella toteamisella ja hoidolla on tärkeä
merkitys tyypin 1 diabeetikoiden lääkekustannusten hillitsemisessä. Tulokset kuitenkin
osoittavat, että ADA:n suosittelemia HbA1C:n verenpaineen ja LDL-kolesterolin
hoitotavoitteita ei ole saavutettu, vaikka niiden menestyksellinen täytäntöön paneminen
olisi tärkeää sydän- ja verisuonisairauksien ennaltaehkäisemiseksi ja tyypin 1
diabetespotilaiden kuolleisuuden vähentämiseksi.
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1 INTRODUCTION
Diabetes is one of the most costly and burdensome chronic diseases of our time, reaching
pandemic proportions (1) and also becoming more common in young adults and children
(2). Currently, 382 million people suffer from diabetes, about 175 million of them remain
undiagnosed (3). As a consequence of population growth, ageing, urbanization and the
increasing prevalence of obesity and physical inactivity, more than half a billion people
are expected to develop the disease by 2035 (3). Although type 2 diabetes may account for
up  to  90%  of  all  diagnosed  cases  (3),  in  parallel,  the  incidence  of  type  1  diabetes  has
increased worldwide for several decades, on average 2.5–3% per year, with the most
substantial increase in children younger than 5 years (4, 5). In Finland, approximately 300
000 people have been diagnosed with diabetes, and about 40 000 of them have type 1
diabetes (6). Notably, among Finnish children below the age of 15 the incidence rate of
type 1 diabetes is continuously the world’s highest; at the beginning of the millennium, the
incidence exceeded 60 per 100 000/year (4). Due to the disconcerting trend towards
younger people developing diabetes, also micro- and macrovascular complications are
more likely to occur at younger ages than before, with huge economic consequences.
Diabetes is a complex chronic disease, requiring continuous medical care, with the
main focus on enabling as normal a life as possible and minimizing the risks of diabetic
complications (7). Nevertheless, about one-third of patients with type 1 diabetes develop
diabetic nephropathy (DN), which is the leading cause of end-stage renal disease (ESRD)
in the Western world, requiring dialysis or kidney transplantation (8). DN is frequently
related to retinopathy and neuropathy, as well as to cardiac and cerebrovascular disease.
These long-term complications are the major cause of premature mortality, morbidity,
reduced quality of life and increased health care costs (9). The American Diabetes
Association (ADA) provides, on a yearly basis, evidence-based guidelines for the
management of diabetes (7). Also national recommendations for implementation in
clinical practice exist. Despite strong evidence that intensive treatment of glycaemia,
elevated blood pressure (BP) and dyslipidaemia reduces the risk of complications and
improves  the  prognosis  of  patients  with  DN,  these  guidelines  have  not always been
successfully implemented in clinical practice (7, 10-12).
In Finland, but also in the US and several  European countries,  the annual health care
costs for diabetes represent more than 10% of health care expenditure, and these costs are
to a large extent due to the escalating costs of complications (9, 13, 14). In addition, type 1
diabetes is associated with other chronic conditions such as autoimmune diseases and
psychiatric disorders (15). Thus, patients with type 1 diabetes are often prescribed a
variety of medications, which non-diabetic individuals do not use (16-19). The cost of
prescription medication has been estimated to cover approximately one-third of the total
cost of type 1 diabetes in Finland and constitutes the second largest component of the
direct cost of type 1 diabetes, after the cost of hospitalization (13, 20).
As health care resources are limited, their efficient use is essential. It is obvious that
treatment of type 1 diabetes patients at different stages of disease severity and duration is
likely to require different levels of resources. To improve understanding of the
consequences of diabetic complications, and especially the value of early diagnosis and
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timely start of treatment to prevent or delay diabetic kidney disease, policymakers should
be familiar with the cost structure of diabetes care. Pharmaceutical intervention plays an
important role in controlling glycaemia, hypertension and other risk factors associated
with progression of renal disease (7). Exploration of the changes in medication use and
cost over time and identification of the main elements contributing to costs could help
policymakers to focus their attention on the major cost drivers related to type 1 diabetes
and its complications. This, in turn, could lead to a better utilization of available health
care resources and motivate the development of strategies to reduce the incidence and
progression of diabetic complications and associated costs.
Previous studies have shown that patients with diabetes take more medication than
non-diabetic individuals (16-19). However, in these studies the majority of patients have
had  type  2  diabetes.  Longitudinal  studies  have  been  rare,  and  the  use  and  costs  of
medication have typically been evaluated only over a one-year period. Furthermore, scart
data  are  available  on  type  1  diabetes  patients´  overall  drug  use  and  costs  according  to  a
predefined disease stage. Therefore, inadequate attention is paid to different disease
severity stages in type 1 diabetes requiring different types and amounts of medication as
well as other treatments, and consequently, different levels of resources.
Given  this  background,  the  aim of  this  thesis  was  to  investigate  the  use  and  costs  of
prescription medication in patients with type 1 diabetes, stratified by severity stages of
diabetic kidney disease. Similarly, we studied the implementation of the ADA guidelines
by evaluating the achievement of treatment targets and how these achievements predict the
prognosis of patients at different severity stages of the disease.
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2 REVIEW OF THE LITERATURE
2.1 Diabetes mellitus
Diabetes mellitus is a heterogeneous group of metabolic disorders characterized by
chronic hyperglycaemia secondary to inadequate production of insulin by the pancreas or
a combination of insulin resistance and insulin deficiency (21). According to the World
Health Organization’s (WHO) criteria, diabetes is currently diagnosed based on either a
fasting plasma glucose of ≥ 7.0 mmol/l in repeated measurements, a 2-h plasma glucose
value  of  ≥ 11.1  mmol/l  after  an  oral  glucose  tolerance  test  or  a  random plasma glucose
value of ≥ 11.1 mmol/l in a patient who has classic symptoms (i.e. thirst, polyuria, weight
loss) of diabetes (21). Recently, glycosylated haemoglobin (HbA1C)  with  a  threshold  of
≥ 6.5% (≥ 48 mmol/mol) has also been added as an option to diagnose diabetes (22).
2.1.1 Types of diabetes mellitus
Diabetes has traditionally been subdivided into type 1 diabetes in which autoimmune
destruction of the insulin-secreting β-cells leads to absolute insulin deficiency (15) and
type 2 diabetes in which insulin sensitivity and secretion are imbalanced and the increased
concentration of insulin is not sufficient to meet the increased demands imposed by
obesity and insulin resistance (23, 24). Although these major types of diabetes have
divergent aetiology, they both seem to develop as a result of an interaction between
genetic and environmental factors (15, 24). They also share the risk of developing long-
term micro- and macrovascular complications. Notably, obesity, metabolic syndrome and
other features of type 2 diabetes are becoming more common also in patients with type 1
diabetes, suggesting the presence of “double diabetes” (25, 26).
Over the past decades, knowledge about the pathogenesis and natural history of
diabetes has grown substantially, revealing a more heterogeneous picture of the disease
than merely the subdivision into type 1 and type 2 diabetes (23, 27). Type 1 diabetes
(previously called juvenile or insulin-dependent diabetes mellitus) is typically diagnosed
in children and young people, but it can occur at any age. By contrast, type 2 diabetes
(previously called adult-onset or non-insulin-dependent diabetes mellitus) has traditionally
been associated with older age, but it can also develop at any age, even during childhood.
Therefore, the cut-off for age at onset (35–40 years), previously used to distinguish
between type 1 and type 2 diabetes, is not decisive nowadays (23).
Although the majority of diabetes patients are currently classified as having type 1 or
type 2 diabetes, other forms of diabetes also exist. The ADA has divided diabetes into four
clinical classes (28). In addition to type 1 and type 2 diabetes, other forms of diabetes are
gestational diabetes and other specific types of diabetes, such as genetic defect in β-cell
function [e.g. various forms of maturity-onset diabetes of the young (MODY), genetic
defects in mitochondrial DNA, neonatal diabetes], genetic defects in insulin action,
diseases of exocrine pancreas or drug- or chemical-induced diabetes. MODY is a
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monogenic form of diabetes, usually inherited in an autosomal dominant pattern,
characterized by lower age at onset than in type 2 diabetes, but without ketoacidosis and
β-cell autoimmunity typical for type 1 diabetes (29). Gestational diabetes is diagnosed
during pregnancy (about 7% of all pregnancies) and has the same pathogenesis as type 2
diabetes (28). Although it is not yet an overt diabetes, up to half of the individuals with
this disorder will later develop type 2 diabetes (30).
2.1.2 Type 1 diabetes
2.1.2.1 Pathogenesis
Type 1 diabetes is a chronic autoimmune disease that develops as a consequence of
gradual destruction of the insulin-producing β-cells in the pancreatic islets of Langerhans,
leading to total insulin deficiency and complete dependence on exogenous insulin (15).
The disease process is initiated months or even years before onset of clinical symptoms; at
the time of diagnosis, about 80–90% of the β-cells have been destroyed (31). Type 1
diabetes is a polygenic disorder, and about one-half of the susceptibility is inherited
through the HLA region (on chromosome 6). In addition, more than 50 non-HLA loci
have been identified to affect disease susceptibility (32).  However, the disorder is
attributed to both genetic factors (33) and external factors that alter the immune system to
trigger or sustain the development of disease (15). Putative environmental triggers include
viral infections (34, 35), vaccinations (36, 37), toxins (38) and dietary factors (39). Despite
investigators devoting much effort to describing the mechanisms of the disease over the
past decades, it remains incompletely understood (27).
2.1.2.2 Epidemiology
The incidence of type 1 diabetes varies substantially between different countries. It is most
common in Finland (~ 60 cases per 100 000/year in children below the age of 15) and
Sardinia, Italy (~ 40 cases per 100 000/year), but is extremely rare in China and Venezuela
(~ 0.1 cases per 100 000/year) (40). Notably, the incidence varies even between
neighbouring areas; in Estonia, the incidence is less than one-third (41) and in Russian
Karelia only about one-sixth of the incidence reported in Finland (42). An interesting
observation is also that migrating populations adopt the incidence rate of their new
country within a short time (15). For example, the prevalence of type 1 diabetes is similar
among Somali and Finnish children in Helsinki, Finland (43). Globally, the incidence has
been increasing during the past decades, on average 2.5–3% per year, with the steepest
increase in children younger than 5 years (4, 5). The increase of the incidence rate has
been too rapid to be explained by genetic factors since the gene pool changes slowly over
many generations. Instead, potential hypotheses and exogenous factors have been
proposed, including the hygiene hypothesis, the accelerator hypothesis, the overload
hypothesis, the polio hypothesis, the hypothesis of early introduction of complex dietary
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proteins and the vitamin D deficiency hypothesis (44). However, based on the most recent
observations from the high-incidence-rate countries, it seems that the incidence rate has
levelled off for unknown reasons (45-48).
2.1.2.3 Treatment
Obviously, the discovery of exogenous insulin in 1921 has been a revolutionary milestone
in the history of diabetes: it saved the lives of patients with type 1 diabetes and became a
mainstay of diabetes management. The primary goals of insulin therapy are to maintain
near-normal glucose levels by mimicking the physiologic secretion of insulin by the
pancreas, to avoid acute complications and to prevent long-term micro- and macrovascular
complications, while enabling as normal a life as possible (49). Insulin preparations are
classified according to their pharmacokinetic and pharmacodynamic profiles (50). Animal
insulin, derived from cows and pigs, was the first type of insulin to be administered to
humans. However, human insulin and insulin analogues have largely replaced the use of
animal insulin. The first-generation synthetic human insulin was developed in the 1980s
(51). More recently, insulin analogues chemically modified to either act faster (rapid-
acting analogues) or slower (long-acting analogues) than human insulin provide more
flexible treatment regimens with lower risk of hypoglycaemia (52).
Modern insulin therapy, recommended to most individuals with type 1 diabetes,
consists of multiple daily injections or continuous subcutaneous insulin infusion (CSII)
therapy (7). With the multiple daily injection regimen, long-acting basal insulin is injected
once or twice a day, accompanied by a rapid-acting bolus insulin at meal-times. In CSII
therapy, rapid-acting insulin is administered via insulin pump using 24-h preselected, but
adjustable doses of insulin, along with patient-activated meal-time bolus doses (15). The
insulin treatment regimen should be flexible to match the insulin to the diet and physical
activity as well as to patient-related factors, including insulin sensitivity, stress, pubertal
status and self-management skills. The amount of bolus insulin depends on the patient’s
pre-meal glucose concentration as well as on the carbohydrate content of the meal (7).
Recently, probably the most promising innovation for diabetes care is the development
of  a  closed-loop  system  (i.e.  artificial  pancreas)  (53).  In  this  system,  insulin  pumps  and
continuous glucose monitors are combined with a computer algorithm. Currently,
wearable smart phone-based platforms connected with insulin pumps and continuous
glucose monitoring are tested in home-like conditions (54). Although abundant resources
and investigations have been directed to several promising areas, such as islet-cell
transplantation, pancreas transplantation, stem cells, primary and secondary disease
prevention and reversal of type 1 diabetes, thus far, the results have been disappointing
and have shown only limited benefit (27). Therefore, in light of present knowledge type 1
diabetes remains a disorder that cannot be prevented or cured (27).
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2.2 Diabetic complications
A subset of patients with type 1 diabetes develops acute and long-term diabetic
complications. These complications are not only responsible for morbidity and premature
mortality (55-57), but are also the major cost drivers related to diabetes in terms of direct
and productivity (previously called indirect) costs (13, 20, 58). In addition, these
complications impose high intangible costs in terms of reduced quality of life, pain and
suffering of afflicted individuals and their families (14, 58, 59).
Acute diabetic complications comprise hypoglycaemia, ketoacidosis and diabetic
coma. Although acute complications are largely preventable, they are an important cause
of early death in patients with type 1 diabetes (60, 61). Thus, acute complications are a
predominating cause of death before the age of 30 years, and thereafter, cardiovascular
disease (CVD) becomes the leading cause of death (62-64), accompanied frequently by
other long-term complications, particularly DN (57, 65, 66).
Long-term diabetic complications, affecting multiple organ systems, can be divided
into micro- and macrovascular complications. Microvascular complications affect small
vessels in the kidneys (nephropathy), the retina (retinopathy) and the nerves (neuropathy).
Macrovascular complications, by contrast, affect large vessels, especially coronary,
cerebral and peripheral arteries. The pathways leading to micro- and macrovascular
complications are complex and multifactorial, with both genetic and environmental factors
playing a role. In fact, nephropathy, retinopathy and neuropathy share similar pathogenetic
mechanisms in different cells and tissues (i.e. mesangial cells, microvessels and peripheral
neurons) (67). Accordingly, these complications are strongly associated with each other.
Also, many of the principles of care are the same.
2.2.1 Risk factors
Several non-modifiable risk factors (including age, duration of diabetes, onset age, male
sex and puberty) and modifiable risk factors predict the initiation and progression of DN
as well as other micro- and macrovascular complications in patients with type 1 diabetes
(68-71). The main traditional modifiable risk factors are poor glycaemic control, elevated
BP, smoking, lipid abnormalities and obesity (68). More recently discovered factors
include chronic inflammation, advanced glycation end-products (AGEs), metabolic
syndrome, physical inactivity and low exercise intensity (68). Notably, DN is more
prevalent among African Americans, Asians and Native Americans than among
Caucasians  (72).  The  risk  of  DN  and  retinopathy  also  clusters  in  families,  strongly
suggesting involvement of genetic factors (73, 74). Moreover, a parental history of
hypertension, type 2 diabetes, CVD and insulin resistance also seems to increase the risk
of DN, suggesting that the genes that modulate these conditions may also be involved in
the pathogenesis of DN (73, 75-77). The fact that some patients with strict glycaemic
control may develop DN, while some patients with poor control do not (78), further
supports the hypothesis that heritability factors may be involved.
Especially hyperglycaemia (79) and insulin resistance (80, 81) seem to play a major
role in the development of atherosclerosis and microvascular complications in patients
20
with diabetes. In fact, many risk factors for developing DN and CVD overlap (82).
Importantly, a major part of CVD in type 1 diabetes is associated with diabetic kidney
disease  (83).  Actually,  the  presence  of  DN  predicts  hard  CVD  events,  independently  of
hypertension, insulin resistance and dyslipidemia (84). Even a slight increase in urinary
albumin excretion rate (AER) predicts atherosclerotic vascular disease (85). The risk of
CVD further clusters by standard cardiovascular risk factors (such as smoking,
hypertension, dyslipidaemia, obesity and family history of CVD), which for the most part
are similar in diabetic and non-diabetic individuals (84, 86, 87).
2.2.2 Microvascular complications
2.2.2.1 Diabetic nephropathy (DN)
Diabetic nephropathy is the most severe and expensive late microvascular complication in
patients with type 1 diabetes, especially when it leads to renal failure, necessitating
dialysis or kidney transplantation (88). The risk of DN increases with duration of diabetes,
with a peak incidence occurring after 15 to 20 years of diabetes; thereafter, the number of
incident cases starts to decline (89-91), suggesting that a subset of patients with diabetes
carries a high risk of developing DN. Moreover, DN is frequently associated with other
microvascular complications and CVD (89, 92).
Diagnosis
DN is characterized by a progressive increase in proteinuria, a decline in glomerular
filtration rate (GFR) and an elevated BP (93-95). The first clinically detectable
manifestation of DN is often the appearance of a low, but abnormal amount of albumin in
the  urine  (96).  The  classical  course  of  DN  progresses  through  microalbuminuria  to
macroalbuminuria, culminating in ESRD. Especially in Europe, the clinical diagnosis of
DN is often based on the measurement of AER (96). The AER can be determined from
either a 24-hour (regarded as the gold standard) or an overnight timed urine collection.
Due to daily variation of AER, two out of three consecutive urine collections are needed to
confirm the diagnosis. Also the measurement of the albumin-to-creatinine ratio (ACR)
from a spot urine sample is suitable for screening. Table 1 summarizes the diagnostic
thresholds of different stages of DN based on these three measurements. These thresholds
are, in fact, artificial but are widely accepted.
Table 1. Diagnostic thresholds for different stages of diabetic nephropathy based on three
different  measurements.
Diagnosis 24-hour AER Overnight AER ACR
Normoalbuminuria < 30 mg/24 h < 20 μg/min < 2.5 mg/mmol for men
< 3.5 mg/mmol for women
Microalbuminuria ≥ 30 < 300 mg/24 h ≥ 20 < 200 μg/min ≥ 2.5 < 25 mg/mmol for men
≥ 3.5 < 35 mg/mmol for women
Macroalbuminuria ≥ 300 mg/24 h ≥ 200 μg/min ≥ 25 mg for men
≥ 35 mg for women
ESRD Dialysis or kidney transplantation
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Renal function
GFR has been most commonly used as the marker of renal function. During the course of
DN also GFR begins to decrease and may finally lead to impaired renal function. Some
patients, however, may follow a non-albuminuric pathway to renal impairment (97).
Moreover, some patients may develop glomerular hyperfiltration (increased GFR 125–140
mL/min/1.73 m2) at early stages of diabetes. Hyperfiltration is widely regarded as a
contributing factor to the development of DN (98, 99), but more recent studies have
reported contradictory results (100, 101). Historically, plasma inulin has been considered
the ideal filtration marker for determining GFR (102). However, the procedure for
measuring inulin clearance is complex, and therefore, such a direct measurement of GFR
is not feasible in routine clinical practice. Consequently, numerous equations to estimate
GFR have been developed. GFR is most often estimated from serum creatinine, corrected
for body mass, age, sex and ethnicity.
The most frequently used formulae are the Cockcroft–Gault equation (103), which
actually estimates creatinine clearance rather than GFR, and the Modification of Diet in
Renal Disease (MDRD) equation, derived from patients with chronic kidney disease
(104). The Cockcroft–Gault equation is more accurate in the normal and upper-normal
range of GFR, while the MDRD equation performs better in patients with chronic kidney
disease (105). The more recently developed Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation is superior to the MDRD throughout the GFR range
(106). Consequently, the CKD-EPI equation has been proposed to replace the MDRD
equation in routine clinical practice (107). On the basis of estimated GFR (eGFR)
(mL/min/1.73 m2), renal function can be classified into five stages: normal (eGFR ≥90),
mild decrease (eGFR 60–89), moderate decrease (eGFR 30–59) and severe decrease
(eGFR 15–29) in renal function, as well as renal failure (eGFR < 15) (108). Albuminuria
and  eGFR  play  complementary  roles  in  the  staging  and  stratification  of  the  risk  of
progressive diabetic chronic kidney disease. Roughly speaking, AER is a marker of the
rate of progression of renal disease, while eGFR represents the advancement stage of the
disease process (109). The recent clinical practice guidelines by the National Kidney
Foundation classify chronic kidney disease into five stages taking into account both the
presence of kidney damage and the level of kidney function (109).
Epidemiology
Without intervention, the clinical course of microalbuminuria has tended to be
progressive; studies in the early 1980s demonstrated an 80% risk of progression from
microalbuminuria to overt DN within 6–14 years (110, 111).  Since then, the incidence has
decreased considerably, suggesting that up to 30% of the patients may develop DN (112-
115). Notably, more recent studies indicate an additional decline in the incidence of DN,
especially in those with more recently diagnosed diabetes (92, 116, 117). By contrast,
some studies have reported an unchanged incidence of DN over time (118-120).
Increasing evidence has also emerged of spontaneous remission of albuminuria in patients
with type 1 diabetes. The Diabetes Control and Complications Trial/Epidemiology of
Diabetes Interventions and Complications (DCCT/EDIC) study reported that 10 years
after the first occurrence of persistent microalbuminuria, up to 40% of patients reverted to
normoalbuminuria, while 28% developed proteinuria and 4% ESRD (121). Remission is
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more likely at the lower level of microalbuminuria and in those with improved glucose,
BP and lipid control (122). Therefore, according to recent knowledge microalbuminuria is
not necessarily a permanent state and it is more likely to reverse in those with optimal
control of these three key factors (122). Thus, improvement of diabetes management,
including better glycaemic control with self-monitoring of blood glucose and modern
insulin therapy, new evidence-based treatment guidelines and the implementation of
angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists [also
known as angiotensin receptor blockers (ARBs)], as well as other pharmaceutical
interventions to control risk factors from the very beginning of the disease process may be
involved (68). At the moment, however, it is unclear whether these interventions have
succeeded in delaying or slowing down the progression of renal disease rather than
preventing its development entirely (123).
ESRD
The cumulative incidence of ESRD has declined since the 1980s, although the risk differs
substantially between study cohorts: from 1% to 13% at 20 years of diabetes duration
(124-127). In Finland, the cumulative incidence of ESRD was 2.2% at 20 years and 7.7%
at  30  years  after  diagnosis  of  diabetes  (125).  The  Finnish  study  also  showed  that  the
cumulative incidence of ESRD was lower in more recently diagnosed cohorts of patients.
Not only due to advanced prevention strategies and treatment of kidney disease, but also
because excess mortality risk is attributed to chronic kidney disease, only a small
proportion  of  the  patients  with  type  1  diabetes  will  finally  reach  ESRD  (88).  In  fact,
premature mortality is a competing outcome to ESRD in patients with type 1 diabetes and
overt  nephropathy  (128).  The  risk  of  death  is  almost  three  times  higher  in
microalbuminuric patients and over nine times higher in macroalbuminuric patients than
in age- and gender-matched controls (57).
2.2.2.2 Diabetic retinopathy
Diabetic retinopathy (DR) remains the most common microvascular complication of type
1 diabetes and the leading cause of visual impairment and blindness among the working
age population in developed countries (129). Eventually, after 20 years of diabetes nearly
all patients develop some degree of DR (130). Early signs of non-proliferative DR are
microaneurysms and increased vascular permeability, followed by moderate and severe
changes with haemorrhages and vascular closures (129, 131). The most severe form of the
disease is proliferative DR, characterized by the growth of new blood vessels (i.e.
ischaemia-induced neovascularization) in the retina and vitreous (129). Another vision-
threatening complication is diabetic macular oedema, characterized by retinal thickening
in the macular region. It can develop at any stage of DR (129).
The risk of proliferative DR increases with duration of diabetes and also varies
considerably between different diabetes onset cohorts (92, 117, 132-134). Notably, the
incidence of severe DR has declined, especially in those with more recent diabetes onset,
probably due to improved control of risk factors and advances in treatment. In Finland, the
cumulative incidence of severe DR (i.e. requiring laser treatment) after 20 years’ duration
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of diabetes was 23% and 33% in earlier cohorts (< 1975 and 1975–1979 cohorts) and 18%
and 6% in later cohorts (1980–1984 and ≥ 1985 cohorts) (133).  Similarly, in Denmark the
cumulative incidence after 20 years’ duration was 31% and 30% in earlier cohorts (1965–
1969 and 1979–1974) and 19% and 13% in later cohorts (1975–1984 and 1979–1984
cohorts) (92).
Notably, the occurrence of DR could be a clue to look for kidney disease since almost
all patients with DN have retinopathy; however, the reverse is not necessarily true (135).
Moreover, the Finnish Diabetic Nephropathy Study (FinnDiane) showed that the
prevalence of proliferative DR increases with the severity of DN (136). To detect early
and treatable changes, the ADA recommends screening by regular fundus photography or
ophthalmoscopy be initiated in patients with type 1 diabetes at the time of puberty or
within 5 years after the onset of diabetes and routine follow-up on a yearly basis (7). Over
the past decades, laser photocoagulation and vitrectomy for severe forms of DR (some
cases of severe non-proliferative DR, proliferative DR and macular oedema) have
improved the visual prognosis of patients with severe DR (131). A new potential treatment
for macular oedema is anti-vascular endothelial growth factor (VEGF) therapy,
administered by intraocular injection. It has been shown to improve vision and reduce the
need for laser treatment in patients with macular oedema (137).
2.2.2.3 Diabetic neuropathy
Diabetes is the most common cause of neuropathy and a major cause of morbidity owing
to  foot  ulceration  and  amputation  (138).  Eventually,  up  to  half  of  patients  with  diabetes
will develop neuropathy during the course of their disease (139, 140). However, the
assessment of the exact prevalence of neuropathy is challenging and depends on the
diagnostic methods, the criteria used to define neuropathy and the study population.
Diabetic neuropathy is defined by ADA as “the presence of symptoms and/or signs of
peripheral nerve dysfunction in people with diabetes after the exclusion of other causes”
(141). In fact, diabetic neuropathies are a heterogeneous group of disorders, affecting both
somatic and autonomic parts of the nervous system and may vary according to the clinical
manifestations, symptoms, risk factors and underlying mechanisms (71).
The most prevalent neuropathies are diabetic peripheral neuropathy (DPN)  and
diabetic autonomic neuropathy.  DPN often presents first in the most distal end of the feet
and spreads proximally in a length-dependent fashion. It is characterized by numbness,
prickling and tingling, burning, aching, weakness, allodynia and pain (139, 140).
Approximately 40–60% of patients with documented neuropathy suffer from neuropathic
pain (142-144). Neuropathic pain can be severe and difficult to treat, and therefore, it is
often associated with limited mobility and depression as well as with lower quality of life
(145). Moreover, DPN is, together with peripheral arterial disease, the major cause of
diabetic food ulcer and lower-extremity amputations (146). About 15% of patients with
diabetes may develop an ulcer during the course of their disease (147). Of note, up to 50%
of patients with neuropathy may be asymptomatic, therefore being at risk of painless
trauma to their feet (148). According to a European survey, the overall prevalence of DPN
ranged from 10% to 25% (149). Nearly one-fifth of these patients had developed foot
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ulcerations and 5% of the patients had undergone a lower-limb amputation. In Finland, the
risk of amputations has decreased considerably, probably due to improved care of
cardiovascular risk factors, better management of foot problems, and vascular surgical
advancements (150). However, in the diabetic population the risk of a first major
amputation is more than seven times higher than in the non-diabetic population (150).
Diabetic autonomic neuropathy, which may affect cardiovascular (e.g. cardiac
arrhythmia, exercise intolerance, postural hypotension), gastrointestinal (e.g.
gastroparesis, constipation), urogenital (e.g. urinary retention, erectile dysfunction) and
sudomotor  function  (e.g.  function  of  the  nerves  that  stimulate  the  sweat  glands),  is  also
common in patients with diabetes (148). However, it may be asymptomatic for years and
screening tests are therefore essential to detect the condition at an earlier stage. Notably,
especially dysfunction of the cardiac autonomic nervous system may lead to silent
myocardial ischaemia, which can be life-threatening (151). Patients with autonomic
neuropathy have over two times higher risk of death than patients without autonomic
neuropathy (152).
Specific treatment for the underlying nerve damage is currently not available.
However, for the neuropathic pain many effective therapies exist, including medications
designed to treat seizures and depression. Evidence-based guidelines have been created to
assist the use of these medications for neuropathic pain (153). The treatment of
neuropathic pain should be tailored to individual requirements. Duloxetine and pregabalin
are current first-line treatments (140). In chronic foot ulcers, regular foot examination,
including inspection, assessment of foot pulses and testing for loss of protective sensation,
combined with patient education, is essential (7).
2.2.3 Macrovascular complications
Atherosclerosis in the large arteries accelerates the development of coronary artery
disease, cerebrovascular disease and peripheral arterial disease in patients with diabetes
(154). As described earlier, cardiovascular events are the major cause of premature
morbidity and mortality (64, 155, 156) and the presence of DN further increases the risk of
the events in patients with type 1 diabetes (83, 86, 155, 157, 158). Although the risk of
CVD has been declining in patients with type 1 diabetes, the relative risk remains high:
two- to threefold in men and three- to fivefold in women, compared with the non-diabetic
population (159). Moreover, patients with DN have ten times higher risk of CVD than
those without DN (83). Consequently, DN has also been shown to predict CVD mortality
in patients with type 1 diabetes.
The relative risk of CVD mortality was up to 37 times higher in those with proteinuria
than in the general population (157). The results from a large Finnish study showed that
every percentage increase in HbA1C increases CVD mortality by 52% in patients with type
1 diabetes at the age 45–64 years (160). Despite improvement in life expectancy, the
overall  risk  of  CVD  mortality  remains  higher  in  patients  with  type  1  diabetes  than  in
people without diabetes. Depending on the study population, the risk of CVD death may
increase up to 10-fold in patients with type 1 diabetes relative to the general population
(55, 156). Importantly, in the general adult population, the risk of CVD mortality is much
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higher in men than in women at all ages, while in patients with type 1 diabetes the risk is
equal between the sexes under the age of 40 years, suggesting a loss of gender-associated
protection  from  CVD  (156).  Of  note,  under  the  age  of  40  years  the  relative  risk  of
mortality from coronary heart disease (CHD) was 10 times higher in men, but increased
40-fold in women, compared with the general population (156).
2.2.3.1 Coronary heart disease
The most common form of macrovascular complications is CHD, which can manifest as
sudden death, myocardial infarction (MI), chest pain and heart failure. Hypertension and
arterial stiffness (the surrogate markers of which are pulse pressure or pulse wave
velocity) may occur early in the arteriosclerotic process and are therefore risk factors for
the development of CHD (161). Treatment goals for CHD include reducing symptoms,
such as chest pain, improving physical capacity and lowering the risk of blood clots (162).
Besides managing the risk factors, targeted medical and revascularization procedures,
including coronary artery bypass graft (CABG) surgery or percutaneous coronary
intervention (PCI), may be considered. To prevent chest pain and CVD events, β-blockers,
nitroglycerides, calcium channel blockers, ACE inhibitors and antiplatelet agents are the
medical therapies of particular importance (162). Notably, after the revascularization
procedures the incidence of adverse events remains higher in patients with diabetes than in
non-diabetic controls (163, 164).
2.2.3.2 Cerebrovascular diseases
The two major types of cerebrovascular diseases are ischaemic and haemorrhagic stroke
(165). Type 1 diabetes clearly increases the risk of stroke, with a fivefold increase
compared with non-diabetic subjects (166) and up to a 20-fold increase in patients aged
under 50 years (167). Recently, the FinnDiane study reported that of 4083 patients 4%
suffered an incident stroke between 1998 and 2010, and two-thirds of the strokes were
cerebral infarctions and one-third cerebral haemorrhages (165). Notably, the incidence of
both cerebral infarction and cerebral haemorrhage increased with the presence of severe
retinopathy and advancing DN (165). A recent follow-up study from the UK showed that
also the cerebrovascular mortality rate is higher in patients with type 1 diabetes than in the
general population (168). In patients with type 1 diabetes, cerebrovascular disease
accounted for 4% of all deaths under the age of 40 and 8% of deaths in those over the age
of 40. Moreover, in the age group 20–39 years the risk of cerebrovascular mortality
increased fivefold in men and sevenfold in women compared with the general population.
2.2.3.3 Peripheral arterial disease
Diabetes and smoking are the strongest risk factors for peripheral arterial disease (PAD)
(169). PAD is characterized by narrowing or occlusion of the arteries, resulting in gradual
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reduction of the blood supply to the lower extremities (170). PAD may be asymptomatic
until it reaches a more severe form (169). The most common symptoms are intermittent
claudication and critical limb ischaemia, causing pain in the peripheries at rest, tissue lost
or gangrene (169). As mentioned earlier, PAD is a major risk factor for lower-extremity
amputation, and it is also accompanied by symptomatic CVD. Studies from the early
1980s  have  shown that  the  prevalence  of  PAD is  higher  in  patients  with  diabetes  (170).
However, only limited data on PAD exist in patients with type 1 diabetes. The Pittsburgh
Epidemiology of Diabetes Complications (EDC) Study examined the incidence of PAD in
586 patients with type 1 diabetes as well  as factors related to PAD. They found that the
incidence was 13 events/1000 person-years (171). During the 10-year follow-up, they
observed 70 PAD events, 40 of which were claudication, followed by 13 amputations, 10
ulcers  and  7  combined  events.  Duration  of  diabetes,  HbA1, hypertension, heart rate and
AER were the factors independently predicting the occurrence of PAD.
Major goals for the treatment of PAD are management of symptoms and prevention of
CVD  mortality  by stopping the progression of atherosclerosis (170, 172).  In  addition  to
lifestyle and risk factor modification, exercise therapy and antiplatelet agents, usually
aspirin or clopidogrel, improve walking distance, reduce the need for vascular
interventions and improve patency rates after vascular interventions (170). Some patients
may benefit from the use of pentoxifylline, which reduces blood viscosity and improves
erythrocyte flexibility (172). Moreover, timely referral for a revascularization procedure
might improve the outcomes of PAD (170).	The choice of the procedure depends on the
site  and  extent  of  disease,  distal  run-off  and  surgical  risk  due  to  associated  CVD (170).	
Proximal, short segment disease in the iliac or femoral segments is an indication for
percutaneous transluminal balloon angioplasty (PCTA) with or without stenting, while in
more distal disease in the popliteal and tibial arteries, surgical bypass grafting may be
better (170, 173). If vascular procedures are contraindicated, hyperbaric oxygen therapy
may be considered in some cases (173).
2.2.4 Prevention and treatment
Importantly, most of the micro- and macrovascular complications could be prevented,
delayed or reduced with early implementation of preventive and therapeutic strategies,
reducing the economic burden of diabetes and its complications (174, 175). Multifactorial
therapeutic approaches are the most effective in preventing the development of diabetic
complications, and halting the progression of chronic kidney disease. Therefore,
prevention/treatment is aimed at aggressive treatment of glycaemia, elevated BP and
dyslipidaemia and smoking cessation. Previous studies have shown that the prevalence of
obesity has risen in patients with type 1 diabetes, and metabolic syndrome is also a
common finding, especially among those with DN and poor glycaemic control (25, 176).
Therefore, behaviour modification, such as weight loss, exercise, dietary changes and
reduction in alcohol use, as well as assessment of mood disturbances should be included in
multifactorial strategies (177).
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2.2.4.1 Glycaemic control
Hyperglycaemia plays a major role in the initiation of all vascular complications through
many metabolic and structural changes, including the formation of AGEs, oxidative stress,
protein kinase C activation and abnormal stimulation of haemodynamic regulation
systems (i.e. the renin-angiotensin system) (178, 179). These changes contribute to the
damage of target organs.
The landmark DCCT study established the effectiveness of optimal glucose control in
reducing the risk of the development and progression of DN, DR and neuropathy (180).
The EDIC follow-up study further reinforced the concept by showing the long-lasting
benefits of intensive therapy (known as metabolic memory); intensive insulin therapy
reduced the risk of microalbuminuria by 39% and the risk of albuminuria by 54% (181).
Participants from the intensive therapy group continued to experience lower rates of
incident microalbuminuria and macroalbuminuria, with risk reductions of 59% and 84%,
respectively (182). The DCCT showed that intensive glycaemic control reduced the
incidence of DR by 76% and slowed the progression of existing DR by 54% (183). The
occurrence of clinical neuropathy diminished by 60% with intensive insulin therapy
compared with conventional therapy (56). A long-term beneficial influence of early
intensive glycaemic control was recently shown, translating into a lower subsequent risk
of DPN and cardiovascular autonomic neuropathy (CAN), as the EDIC follow-up study
demonstrated that the prevalence of confirmed DPN at years 13/14 was 25% in those with
intensive treatment therapy and 35% in those with conventional therapy during the DCCT
(184). The corresponding numbers for CAN were 29% and 35%. Thus, better glycaemic
control in the past translated into a lower risk several years later.
The DCCT/EDIC study finally demonstrated that intensive treatment during the 17
years of prospective analysis was associated with a 42% risk reduction in all CVD events
and a 57% reduction in the risk of non-fatal MI, stroke, or death from CVD (185).
Notably, the large variability in the HbA1C also predicts the progression of renal disease
and CVD events in patients with type 1 diabetes (186). These findings highlight the
importance of intensive insulin therapy implemented early in the course of diabetes in
order to achieve a blood glucose level as near to normal as possible, but without risk of
adverse events.
Insulin analogues and better delivery systems combined with intensive glucose
monitoring are key elements to achieve the desired glycaemic goals. Insulin analogues
have been associated with a lower risk of hypoglycaemia (187). Therefore, insulin
analogues delivered either by multiple daily injections or via CSII are recommended for
most individuals with type 1 diabetes (7). Nowadays, sensor-augmented insulin pump
therapy with a threshold-suspend feature is also making substantial progress in diabetes
care (27). A trial in which a sensor-augmented pump (insulin pump and continuous
glucose monitor together) has been compared with multiple daily injection therapy
showed significant improvement in HbA1C reduction with less hypoglycaemia in the
sensor-augmented cohort (188). These pumps and their supplies are, however, expensive.
Currently, limited data exist on the impact of these pumps on clinical results and costs
over time. By modelling the long-term effects of these modern insulin pumps, some
investigators have estimated a large reduction in future complications of the disease, and
28
consequently, on the spending needed to treat such complications (189). Based on recent
ADA guidelines, these pumps should be considered at least for patients with frequent
nocturnal hypoglycaemia and/or hypoglycaemia unawareness (7).
2.2.4.2 Blood pressure (BP) control
Hypertension is a major risk factor for microvascular complications and CVD (86, 190,
191). High BP both parallels (i.e. BP rises along with the increase in AER) and precedes
(i.e.  high  BP  accelerates  the  loss  of  kidney  function)  the  worsening  of  diabetic  kidney
disease in patients with type 1 diabetes (93-95, 192). Typically, hypertension manifests
when the patient develops microalbuminuria (193). Intensive treatment of elevated BP
reduces the risk of microvascular complications and CVD, and improves the prognosis of
patients  with  DN,  especially  combined  with  the  use  of  agents  acting  on  the  renin-
angiotensin-aldosterone system (RAAS), which are highly effective in slowing the
progression of renal disease (194-197). Beneficial effects have also been demonstrated in
slowing the progression of DR (198, 199).
The first-line drugs of choice include ACE inhibitors or ARBs, which have repeatedly
been shown to have a beneficial effect on albuminuria and renal function, beyond the BP-
lowering effect (200). ACE inhibitors or ARBs are recommended also for the treatment of
microalbuminuric normotensive patients. Most patients with hypertension might require
multiple-drug therapy to reach the BP treatment goals (201). Diuretics, calcium channel
blockers and β-blockers are recommended as additional therapy to achieve a further
lowering of BP, or alternate therapy if ACE inhibitors or ARBs are not tolerated (7). In
addition, patients with elevated BP should, if necessary, be advised on lifestyle changes,
including a healthy diet, weight control, reduction of sodium intake, moderate alcohol
intake, smoking cessation and increased physical activity (7).
2.2.4.3 Lipid control
Dyslipidaemia is not only a significant risk factor for CVD in patients with type 1 diabetes
(202, 203), but also a major independent risk factor for the development of chronic kidney
disease (204). In fact, dyslipidaemia plays a role in the progression of DN (205). Several
lipid abnormalities, such as increased triacylglycerol and low-density lipoprotein
cholesterol (LDL-C) or decreased high-density lipoprotein cholesterol (HDL-C) levels,
have frequently been observed in patients with poorly controlled type 1 diabetes or with
DN (206, 207). Patients with optimally controlled type 1 diabetes, without diabetic kidney
disease, may have a normal or even elevated HDL-C concentration. A recent FinnDiane
study demonstrated that different lipid abnormalities may also be involved at different
stages  of  DN.  High  triacylglycerol,  apolipoprotein  (Apo)B,  ApoA-II  and  HDL3-
cholesterol predicted incident microalbuminuria, while progression of macroalbuminuria
was predicted by high triacylglycerol and ApoB (205). A previous study demonstrated that
different sizes of very-low-density lipoprotein (VLDL) particles may be associated with
the  progression  of  DN;  cholesterol  in  the  large  VLDL  particles  was  associated  with
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incident albuminuria, whereas cholesterol in the medium-sized VLDL particles was
associated with microalbuminuria (208). Although these qualitative lipid changes might
have an even greater role than the quantity of the major lipoproteins in the development of
CVD or DN, their features are still not fully understood (68, 209). Undoubtedly, to reduce
the progression of DN and CVD it  is  important to pay attention to lipid abnormalities in
patients with type 1 diabetes.
Based  on  the  ADA  guidelines,  the  goals  of  LDL-C  <  2.6  mmol/L  (<  100  mg/dL),
triacylglycerol < 1.7 mmol/L (< 150 mg/dL) and HDL-C > 1.0 mmol/L (> 40 mg/dL)  and
> 1.3 mmol/L (> 50 mg/dL) in men and women, respectively, are desirable in most adult
patients with diabetes (7). In clinical practice, LDL-C is usually estimated indirectly with
the Friedewald equation (210). The Friedewald equation provides an adequate estimate of
LDL-C  for  most  fasting  specimens,  but  is  known  to  be  less  reliable  as  triacylglycerol
concentration increases. The Friedewald equation should not be used if plasma
triacylglycerol concentration exceeds 4.52 mmol/L (400 mg/dL) (211).
Statins are the first choice of lipid-lowering drugs in patients with diabetes (7, 212). A
previous prospective large-scale meta-analysis of 71 370 non-diabetic individuals and
18 686 persons with diabetes from 14 randomized trials has demonstrated that treatment
with  statins  significantly  reduced  the  risk  of  CHD  and  mortality  (213).  They  reported  a
20% reduction in major vascular events per mmol/L reduction in LDL-C in people with
and without diabetes. Therefore, in addition to lifestyle modification, including reduction
of saturated fat, trans fat and cholesterol intake, statin therapy should be considered if
LDL-C  remains  above  2.6  mmol/L,  or  in  those  with  multiple  CVD  risk  factors  (7).
Moreover,  in  those  with  overt  CVD  or  aged  over  40  years  and  with  other  CVD  risk
factors, pharmacological treatment should be added, regardless of baseline lipid levels. For
those with overt  CVD, a more stringent LDL-C target of < 1.8 mmol/L (< 70 mg/dL) is
desirable (7). If statins are contra-indicated (due to cholestasis and active liver disease) or
not tolerated (due to adverse effects on muscles, such as myopathy), alternative therapies,
e.g. fibrates or ezetinibe, may be used. In general, fibrates have a better effect on
triacylglycerol levels than on LDL-C and HDL-C levels, and therefore, they are more
frequently used in those with elevated triacylglycerol (214).
2.2.4.4 Smoking cessation
Several studies have shown that cigarette smoking is associated with increased risk of
onset  and  progression  of  DN  (215,  216),  as  well  as  with  other  microvascular
complications (217). Moreover, smoking is a leading cause of CVD (218), and indeed,
patients with type 1 diabetes who are smokers are undoubtedly at risk. It is important that
smokers  be  encouraged  to  stop  smoking.  Similarly,  the  risks  of  smoking  should  be
disclosed to type 1 diabetes patients as early as possible.
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2.2.4.5 Antiplatelet therapy
Aspirin (i.e. acetylsalicylic acid) has been shown to be effective in reducing CVD events
in high-risk patients with previous MI or stroke (secondary prevention) (219). Hence,
long-term low-dose aspirin therapy or clopidogrel (if aspirin allergy) are recommended for
those with a history of CVD, including MI, vascular bypass procedure, stroke, peripheral
vascular disease and claudication (7, 220). Aspirin as a primary prevention is
recommended  only  for  those  patients  with  type  1  diabetes  who  have  an  increased  CVD
risk (10-year risk > 10%), mostly men aged > 50 years or women aged > 60 years who
have at least one additional CVD risk factor (i.e. family history of CVD, hypertension,
hyperlipidaemia, smoking or albuminuria). It is not, however, recommended for patients
with low CVD risk (10-year risk <5% and no additional risk factors) since potential
adverse effects, such as gastrointestinal bleeding, are likely to outweigh the potential
benefits (7, 220, 221).
Moreover, to prevent thrombosis and thromboembolism, oral anticoagulants (the most
common of which is warfarin) are often prescribed for patients with atrial fibrillation or
pulmonary embolism or after artificial heart valve surgery or orthopaedic procedures
(222).
2.2.4.6 Other treatment options
Especially patients characterized by macroalbuminuria or renal failure are likely to display
multiple co-morbidities, including cardiovascular disease, secondary hyperparathyroidism,
electrolyte disturbances and anaemia, as well as bone and mineral metabolism disorders
(BMDs), requiring multiple pharmacological therapies. Anaemia with erythropoietin
(EPO) deficiency and BMD are common findings in patients with renal failure (223, 224).
However, these disorders often occur at an earlier stage in the course of diabetic renal
disease than in other forms of kidney diseases (223, 225).
Chronic anaemia stresses the heart by increasing cardiac output, volume overload and
pulse rate and contributes to left ventricular hypertrophy and diastolic dysfunction (226),
and thus, is a risk factor for CHD (227). Patients with renal anaemia can be treated with
injections of erythrocyte simulating agents (ESA) (e.g. EPO, darbepoetin alfa). The
treatment with ESA may improve the patient’s quality of life and reduce the need for red
blood cell transfusion. However, excess correction of the anaemia should be avoided due
to the risk of adverse events (i.e. death, serious adverse cardiovascular reactions, stroke)
(228). To optimize responsiveness to ESA, also iron stores should be replete by
administration of iron either orally or intravenously (229).
BMDs may be reflected by the following markers, either solely or in combination:
abnormalities of calcium, phosphorus, parathyroid hormone (PTH) and vitamin D
metabolism, as well as by abnormalities of bone turnover, mineralization, volume, growth
and strength, and vascular or soft tissue calcification (224, 230). Appropriate management
of bone disease is complex and requires not only modification of the diet, but may also be
treated by phosphorus binders (e.g. calcium carbonate, lanthanum carbonate, sevelamer),
vitamin D analogues and calcimimetic agents (230).
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Renal failure requires either haemodialysis or peritoneal dialysis, often followed by
kidney transplantation. Occasionally, the kidney is transplanted together with the pancreas
in patients with type 1 diabetes. Compared with dialysis, kidney transplantation prolongs
survival, improves quality of life and is more cost-effective (231-233). In order to prevent
rejection, all patients with an organ transplant require life-long use of immunosuppressive
therapy.  Typically,  combinations  of  two  to  three  drugs  with  different  mechanisms  of
action are used to achieve efficacy with limited toxicity (234, 235).
2.3 Other co-morbidities
In addition to diabetic complications, type 1 diabetes is frequently associated with other
chronic conditions such as other autoimmune diseases and psychiatric disorders. These co-
existing co-morbidities greatly increase the complexity of diabetes care, especially related
to a large number of prevalent symptoms and polypharmacy, as well as the use of health
care service and health care costs (236).
2.3.1 Other autoimmune diseases
Patients with type 1 diabetes are more likely to have other autoimmune diseases that are
characterized by the production of organ-specific autoantibodies, including autoimmune
thyroid disease, coeliac disease and Addison’s disease (15, 237). These autoimmune
diseases tend to co-exist not only in type 1 diabetes individuals, but also in family
members, implying a shared aetiology (238). Also some other organ-specific autoimmune
diseases, such as multiple sclerosis, rheumatoid arthritis and asthma, occur more often in
patients with type 1 diabetes than in healthy controls. No cure exists for multiple sclerosis,
rheumatoid arthritis or asthma. However, early diagnosis and effective pharmacological
treatment are critical in slowing the progression of the disease and controlling symptoms.
The most common disorder is autoimmune thyroid disease, affecting up to 30% of
patients with type 1 diabetes (239). Up to one-quarter of newly diagnosed type 1 diabetes
patients have thyroid autoantibodies (240-243), which predict a thyroid dysfunction, either
hypothyroidism or less commonly hyperthyroidism with or without an enlarged thyroid
gland (called goitre) (242). Hypothyroidism increases the risk of hypoglycaemia (244) and
also retards the linear growth of children (245). Patients with hypothyroidism require
thyroid hormone replacement therapy (i.e. levothyroxine sodium) (246). Hyperthyroidism
causes fluctuation in blood glucose, which may lead to deterioration of metabolic control
(7). Treatment consists of antithyroid medications (e.g. karbimazol) or thyroid ablation
with either radioactive iodine therapy or thyroidectomy (247). A current guideline from
the ADA recommends screening of children with type 1 diabetes for thyroid
autoantibodies soon after diagnosis, as well as measuring thyroid-stimulating hormone
(TSH) concentration after metabolic control’s stabilization at onset of diabetes. If TSH is
normal, rechecking should be done every 1-2 years or earlier if the patient develops
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symptoms of thyroid dysfunction or has an abnormal growth rate or unusual glycaemic
variation (7).
Coeliac disease (CD) occurs with increased frequency in patients with type 1 diabetes,
with a range between 1% and 16% (248-251). CD is characterized by intolerance to
dietary gluten. The gluten-triggered autoimmunity damages the small bowel mucosa,
leading to chronic malabsorption, multiple vitamin deficiencies and poor growth (252).
Moreover, in patients with type 1 diabetes variable absorption of carbohydrates can cause
blood glucose fluctuation, and malabsorption of carbohydrates increases the risk of
hypoglycaemia. A gluten-free diet reduces the symptoms and the rates of hypoglycaemia
(253). Current ADA guidelines recommend the measurement of autoantibodies soon after
the  diagnosis  of  diabetes  and  in  those  with  a  family  history  or  symptoms  of  CD  (7).
Moreover, subjects with positive antibodies should have an intestinal biopsy to confirm
the diagnosis. Many companies manufacture gluten-free products, which are more
expensive than so-called usual products. In Finland, patients with CD (doctor’s certificate
required)  can  apply  for  diet  reimbursement  from  the  Social  Insurance  Institution  of
Finland (i.e. Kela) (23.60 €/month in 2014) (www.kela.fi).
Addison’s disease causes destruction of the adrenal gland, resulting in primary adrenal
insufficiency. Compared with the general population, Addison’s disease is more common
in patients with type 1 diabetes, even though it occurs in only 0.5% of them (237). Patients
with symptomatic adrenal insufficiency should be treated with hydrocortisone and
fludrocortisone as a substitute for aldosterone (254).
Multiple sclerosis (MS) affects nerves in the brain and spinal cord, with focal
lymphocytic infiltration leading to damage of myelin and axons, causing loss of muscle
control, vision and sensation (255). The relative risk of MS has been reported to be three-
to fivefold in patients with type 1 diabetes (256-258).  The pharmacological treatment of
MS  depends  on  the  symptoms  and  severity  stages  of  the  disease  process.  The  first-line
immunomodulating drugs of choice are interferon-β or glatiramer acetate (Käypä Hoito
20.12.2012). Other treatment options, such as natalizumab or fingolimod, may be
considered as second-line therapies. All of these treatments are expensive and their
efficacy varies with the stage reached in the disease process (255).
Rheumatoid arthritis (RA) is characterized by persistent synovitis and systemic
inflammation of the joints, which can permanently damage the joints, cartilage and bone
(259). Only a few small studies have assessed the prevalence of RA among type 1 diabetes
patients. A Finnish study showed a two times higher risk of type 1 diabetes in patients
with juvenile idiopathic arthritis, while a study from the US reported a sixfold higher risk
than in the general population (260, 261). The treatment of RA consists of a combination
therapy, including disease-modifying anti-rheumatic drugs, such as methotrexate, as well
as non-steroidal anti-inflammatory drugs and steroids (259). Moreover, the development
of new biologic agents has expanded the treatment possibilities (259).
Asthma is an inflammatory disease of the airways that is characterized by recurrent
episodes of bronchial obstruction (262). An increasing prevalence of asthma has been
reported during the past decades in many countries (263). Also a positive association
between the occurrence of type 1 diabetes and symptoms of asthma has been observed in
Europe and elsewhere (264). Asthma is usually treated with inhaled corticosteroids with or
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without a long-acting beta antagonist, as well as with quick-relief medication (such as
short-acting beta antagonists or oral/intravenous corticosteroids) (262).
2.3.2 Psychiatric disorders
Depression, anxiety, diabetes-related distress, eating disorders and other mental health
symptoms are common in patients with diabetes and may negatively affect the overall
management of diabetes (7). These co-morbid psychiatric disorders may contribute to poor
self-care and adherence to the medication regimen, reduce the quality of life and produce
higher rates of morbidity and mortality, consequently increasing health care costs (265-
269). According to a meta-analysis, the prevalence of depression was almost four times
higher in patients with type 1 diabetes than in non-diabetic controls (12% vs. 3.2%) (270).
The prevalence was even higher when the symptoms were combined with the use of anti-
depressant medications (271). Routine assessment of the patient’s psychological and
social situation is therefore essential as part of the management of diabetes; referral to
appropriate services (such as a mental health specialist) should be considered, when
necessary  (7).  Depending  on  the  form  and  severity  of  the  psychiatric  disorders,  the
treatment usually consists of a combination of pharmacotherapy (e.g. antidepressants,
antipsychotics, anxiolytics) and psychological interventions (272).
2.4 Factors affecting costs of medication
As described above, insulin therapy is the most essential part of the care of patients with
type 1 diabetes. Moreover, pharmaceutical interventions play an important role in
controlling hypertension and other risk factors as well as in treating related co-morbidities.
This section provides an overview of the Finnish health care system and structural features
affecting the prices of medications. These factors have an impact on medication utilization
and costs in patients with type 1 diabetes.
2.4.1 Overview of the Finnish health care system
All residents in Finland have a right to health care and social services. At present, the
Finnish health care system is decentralized largely to the municipalities. Local authorities
have the responsibility of organizing the delivery of public health services, including
primary, specialized and long-term care. Primary health care can be arranged at each
municipality independently or at the local government joint service areas (with at least
20 000 inhabitants). In general, local authorities can decide the scale, scope and model of
municipal services within the limits of legislation. To fulfil its responsibility for
organizing specialized care, each municipality must belong to one of the 20 hospital
districts. Hospital districts provide specialized medical care services that cannot be
incorporated into primary health care. Access to specialized care requires referral from
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either a municipal or a private physician. Moreover, each hospital district belongs to one
of five university catchment areas that co-ordinate the provision of specialized medical
care and provide highly specialized medical services. In addition to the public sector,
private health care providers (i.e. enterprises or non-governmental organizations) can sell
their services to local authorities, joint municipal authorities or directly to clients. Public
health services are financed by the municipalities out of local taxation and user fees.
Regional and university hospitals are financed by federations of participating
municipalities.  The  State  also  makes  transfer  payments  to  local  authorities.  The  amount
depends on the size of the population, the population structure and morbidity. (273, 274)
Currently, the system is undergoing a thorough reform to ensure meeting the main
goals of guaranteeing equal services countrywide and implementing a cost-effective and
high-impact service structure (275). The arrangement and provision of services will be
treated as separate entities. After the reform, the responsibility for organizing the services
will rest with five social welfare and health care regions, while the municipalities and joint
municipal authorities will continue to provide services by themselves or by procuring
services from organizations and companies (275).
In Finland, children with type 1 diabetes are treated mostly in paediatric clinics in
central  or  some  local  hospitals.  Depending  on  the  areas  of  Finland,  adults  with  type  1
diabetes either have regular visits to specialized outpatient clinics or see their general
practitioner at health centres. In most cases, type 2 diabetes care is organized by the health
centres or the occupational health care system. Diabetes drugs and blood glucose self-
monitoring devices are available free of charge or at low cost to all diabetes patients (276).
2.4.2 Finnish National Health Insurance
The statutory Finnish National Health Insurance (NHI) covers all permanent residents in
Finland  as  part  of  social  security.  It  is  co-ordinated  by  the  Social  Insurance  Institution,
which is an independent body under public law and falls under the direct supervision of
the Finnish Parliament. Health insurance is divided into two pools: earned income
insurance and medical care insurance. Earned income insurance constitutes sickness,
parenthood and rehabilitation allowances and part of the occupational health care. Medical
care insurance involves reimbursements for medication expenses and private sector health
care services (including dental care, doctors' fees, examination and treatment charges), as
well as travel expenses and rehabilitation services according to the statutory
reimbursement rate. Earned income insurance is financed by a statutory contribution from
employees and employers (calculated as a fixed proportion of employee wages), and
medical care insurance equally by the insured (deducted from income, pension and other
benefits) and the State. (274)
2.4.3 Drug reimbursement system
Of the total sales of pharmaceuticals, approximately three-quarters are prescription-only
medications used in outpatient care, about 10% over-the-counter medications and about
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15% medications used in inpatient care (277-279). The NHI offers a three-level
reimbursement system for medication prescribed in outpatient care in order to promote the
availability of high-quality, cost-effective and reasonably priced medications to all
residents in Finland. The system was established in Finland in 1964 and is currently based
on the Health Insurance Act 1224/2004 (279). The system consists of the Basic Refund
Category (35% of the price in 2014) and the Lower (65% of the price in 2014) and Higher
(100% of the price in 2014, a 3.00 € co-payment is charged for each medicine purchased
at one time) Special Refund Categories (Health Insurance Act 1224/2004, amended by Act
622/2012) (277, 279). These categories are set according to the severity of the disease and
the necessity of drug treatment. The Lower Special Refund Category consists of 10
diseases that are serious and chronic, e.g. hypertension, asthma or CHD. The Higher
Special Refund Category includes 34 serious and chronic diseases where drug treatment is
necessary for patients and where the drug restores or replaces normal bodily functions, e.g.
diabetes, malignant diseases or post-transplant conditions (279). Moreover, when out-of-
pocket medicine expenses (the non-reimbursable sum) in a calendar year exceed the
established limit (610 € in 2014, www.kela.fi), the exceeding portion is reimbursed in full,
and thereafter, only a 1.50 € co-payment is charged for each medicine purchased at one
time, as well as any proportion of the medication’s price exceeding the reference price.
Notably, medications administered in hospitals or in other institutionalized care are not
included in the reimbursement system. Pharmaceutical companies negotiate directly with
the hospitals to determine the prices of medications (273). Medications administered in
hospitals are covered by the hospital budget (financed by the municipalities, which
transfer funds to hospitals). Consequently, the cost of bed-days in hospitals includes
medications administered during the hospital stay.
2.4.4 Marketing authorization and price of medicinal products
A medicinal product must have a marketing authorization before it can be placed on the
market and made available to consumers (279). Marketing authorizations are granted
either by the European Commission (handled by the European Medicines Agency, EMA)
or by the Finnish Medicines Agency (FIMEA) (279). In principle, pharmaceutical
companies can set their wholesale prices freely. However, the costs of medicinal products
are reimbursed only when the holder of the marketing authorization has applied for
reimbursement. The Pharmaceuticals Pricing Board (PPB, HILA) approves the
reimbursement status of the medicine and confirms its reasonable wholesale price (279).
The  PPB,  operating  under  the  Ministry  for  Social  Affairs  and  Health,  decides  which
medicinal products (generics, parallel trade and patented drugs) are to be included in the
reimbursement system and confirms their wholesale prices and reimbursement rates within
180 days of receipt of the application. The PPB also requests the Social Insurance
Institution to submit an opinion on whether the criteria for granting reimbursement status
and for a reasonable price are fulfilled, as well as an opinion on the budget impact from
the NHI. A confirmed reasonable wholesale price is the maximum price at which the
product may be sold to pharmacies and hospitals.  The PPB can also target and limit  the
payment of the Basic Refund of certain drugs to a precisely defined diagnosis and severity
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stages, such as drugs used in the treatment of multiple sclerosis, certain rheumatoid
diseases or erectile dysfunction. Moreover, the Board makes decisions related to the
reference price system (i.e. reference price groups, reference prices, products in each
group). (279)
The  PPB’s  decisions  are  based  on  an  application  submitted  by  the  holder  of  the
marketing authorization. The application must include an assessment of the product’s
therapeutic value, necessity and economic efficiency as well as sales and usage estimates.
Moreover, it must include a description of the position of the drug among other equivalent
drug treatments, the product’s patent status and prices in other European Economic Area
member states. If the product contains a new active substance, a health economic
evaluation should be included. In practice, a medicinal product must hold the basic
reimbursement status for at least two years until it is eligible for special reimbursement
status. (279)
The  retail  price  of  the  drug (total cost of drug and the sum from  which  the
reimbursement is calculated) includes the share of the manufacturer and wholesaler, the
pharmacy margin, the tax-like pharmacy fee and the Value Added Tax (VAT) based on
the drug tariff issued by the Government which all pharmacies must follow. Table 2
shows the calculation formula for retail prices of prescription medications. The retail price
is the same in all pharmacies in Finland.
Table 2. Calculation formula for retail prices of prescription medications based on the Medicinal
Tariff Decree 1087/2002 and the new Decree on Pharmaceutical Tariff 713/2013 valid from
1.1.2014 (in parentheses).
Wholesale price (€) Retail price
0–9.25 1.5 x wholesale price + 0.50 € (1.45 x wholesale price) + VAT1
9.26–46.25 1.4 x wholesale price + 1.43 € (1.35 x wholesale price + 0.92 €) + VAT
46.26–100.91 1.3 x wholesale price + 6.05 € (1.25 x wholesale price + 5.54 €) + VAT
100.92–420.47 1.2 x wholesale price + 16.15 € (1.15 x wholesale price + 15.63 €) + VAT
> 420.47 1.125 x wholesale price + 47.68 € (1.1 x wholesale price + 36.65 €) + VAT
+ The handling fee of each medicinal product 0.39 € (2.17 €) 1Value Added Tax
2.4.5 General trends in pharmaceutical costs
Pharmaceutical expenditure has increased rapidly in Finland in the past two decades and
has been one of the fastest-growing components of the total health expenditure (273).
Although there is a wide variation among countries, the growth in pharmaceutical
spending is a worldwide phenomenon. Reasons for increasing pharmaceutical costs
include ageing of the population, introduction of new and relatively expensive drugs,
increasing number and prevalence of diseases susceptible to drug treatment, extension of
drug indications (i.e. disease prevention and treatment of less significant ailments and
symptoms) and increasing overall volume of pharmaceuticals (278). In Finland, the
wholesale prices of drugs are about the average in Europe, while due to the VAT and
37
pharmacy fee, the retail prices are above the average (280). The patients’ co-payments for
reimbursable drugs have increased over time.
To promote cost-effective prescription strategies and restrain growth in pharmaceutical
spending, several legislative measures to regulate pricing and reimbursement procedures
have been implemented in Finland as well as in other countries over the past decade.
Despite the continuous increasing trend of medication consumption and pharmaceutical
spending, these measures have, at least temporarily, restrained the increasing trend in the
sales of medications and reimbursement expenditure (Figure 1). While in the 1990s and
early 2000s the real costs (deflated with cost of living index) of prescription medication
used in outpatient care increased on average by 9% from the previous year, the annual
growth slowed in 2002–2011, being on average about 0.7% (281).
In 2009, when the reference price system was introduced and generic substitution was
extended to cover drugs holding an analogous process patent, the total sales of
pharmaceuticals decreased by 1.3% from the previous year. Notably, for the first time in
Finnish reimbursement history, also reimbursement payments decreased by 1.6% from the
previous year in 2010 (282). However, these numbers demonstrate only temporal trends
since the sales of pharmaceuticals as well as reimbursement expenditure have started to
grow again in 2011.
 The following section provides information about some legislative measures that have
directly or indirectly affected the general development of medication costs in Finland. The
main reforms and changes to regulate pricing and reimbursement procedures are presented
in Table 3.
Figure 1. Observed costs (at current prices) of prescription medication and their reimbursement
in 1997–2012 (277, 279).
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2.4.6 Drug cost containment by legislative measures
In 1995, turnover tax for pharmaceuticals was replaced by a VAT of 12%. This change
increased the retail prices of medicines by about 7% (283, 284). In 1998, the VAT
applicable for pharmaceuticals was reduced from 12% to 8%. At the same time, the
medicine tariff affecting pharmacies’ sales margins was changed in a more degressive
(gradually decreasing rate in sums below a certain amount) direction, and prices of
stockpiled medicines decreased since the compulsory stockpiling surcharge was abolished.
Therefore, a slight plateau was observed in the medication costs during that year.
However, in response to the economic crisis, the VAT was again increased to 9% in 2010
and finally to 10% in 2013. At  the  same time,  the  reimbursement  rates  in  the  Basic  and
Special Refund Categories were decreased. However, the threshold of the patient’s out-of-
pocket medicine expenses was also decreased, benefitting especially those requiring
multiple medications (www.kela.fi).
In 2006, the fixed deductible sum per purchased medication was given up. Instead, a
certain percentage of the drug price is reimbursed on the basis of the relevant
reimbursement category. However, the average reimbursement rate remained essentially
the same since the Basic Refund Category was decreased from 50% to 42% and the Lower
Special Refund Category from 75% to 72%. The Higher Refund Category (100%) was not
changed, but a 5.00 € co-payment payable per purchase was replaced with a 3.00 € co-
payment charged for each medicine purchased at one time. As a consequence of this
reform, the number of patients receiving reimbursement of medication costs increased by
about  10%  in  2006  (285).  However,  also  the  wholesale  prices  were  cut  by  5%,  and  the
total costs of prescription medicines decreased slightly, but only temporarily, from the
previous year for the first time (285). The latest wholesale price cut was implemented in
2013, as the wholesale prices of medicines outside the reference price system were
decreased by 5%. At the beginning of 2014, the new medicine tariff was established
(Medicinal Tariff Decree 713/2013) in which the retail prices of the most expensive drugs
were decreased and the least expensive drug prices were increased. Also the handling fee
was increased.
Generic substitution was adopted in April 2003. This enables a prescribed original
medicinal product to be replaced by a less expensive generic product with equivalency in
terms of active ingredient strength, dissolution and bioavailability, unless the doctor or the
buyer declines the replacement (286, 287). The list of approved substitutable drugs is
maintained by the FIMEA, and the price corridor for different groups of substitutable
drugs is updated four times a year, following price notifications submitted from the
marketing authorization holders. During the first year of generic substitution the average
price of substitutable drugs decreased by more than 10%. Over half of the savings were
generated by lipid-lowering drugs and antidepressants (286). Despite the fact that the
generic drugs are less expensive than the branded ones, the generic substitution has also
fostered competition between the original manufacturers and the manufacturers of generic
substitutes. Of note, following generic substitution and price competition, the consumption
of cardiovascular drugs has increased by 10%, but their sales value has increased by only
1% (288).
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Table 3. Main reforms and changes in the reimbursement system and prices of drugs between
1994 and 2013 in Finland (www.kela.fi) (279, 283-285).
Year Reforms and changes Main objectives of the reforms
1994  The PPB1 responsible for setting
wholesale prices
 To control prices of drugs
1995  Turnover tax replaced by VAT2 of 12%  To increase government revenues
1996  Generic substitution3 was replaced by
generic prescribing
 To reduce pharmaceutical spending
1998  VAT reduced to 8% Compulsory stockpiling surcharge
abolished
 Pharmacies’ margin more degressive
 To control prices of drugs
2003  Generic substitution introduced  To reduce pharmaceutical spending To increase competition between
pharmaceutical companies
2006  Fixed deductible sum per purchased
drug  abolished and Refund Categories
changed
Basic: from 50% (the fixed deductible
sum 10 €) to 42%
Special Lower from 75% (the fixed
deductible sum of 5 €)  to 72%
Special Higher from 100% (+5 €/
purchase) to 100% +3.00 €/drug
 Wholesale prices cut by 5%
 Biosimilars entered the EU market
 To reduce reimbursement payments
 To reduce pharmaceutical spending
2009  Reference price system introduced Generic substitution extended to cover
drugs holding an analogous process
patent
 To reduce pharmaceutical spending
 To increase  competition between
pharmaceutical companies
2010  VAT increased to 9%  To increase government revenues
2013  Refund Categories decreased
Basic from 42% to 35%
Special Lower from 72% to 65%
 Threshold of the patient’s out-of-pocket
medicine expenses decreased
 VAT increased to 10%
 Wholesale prices of drugs outside the
reference price system cut by 5%.
 To reduce reimbursement payments
 To benefit those requiring multiple
drugs
 To increase government revenues
 To reduce pharmaceutical spending
1Pharmaceuticals Pricing Board, 2Value Added Tax, 3Voluntary generic substitution became
operational in 1993
In April 2009, generic substitution was complemented by the reference price system
(278). At the same time, generic substitution was extended to cover drugs with holding an
analogous process patent. Under the reference price system, certain medications
containing the same active substance in an equal composition and being sold in
comparable package sizes are allocated to the same reference price group. Thus, each
medication in the same group carries the same price regardless of its market price. The
reference price groups are based on the list for substitutable medicinal products approved
by the FIMEA, and the reference prices are determined on a quarterly basis by the PPB. A
reference price is calculated within the group from the most inexpensive product by
adding 1.50 € if the price is less than 40.00 € and by adding 2.00 € if the price is 40.00 €
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or more. Reimbursements for medications covered by the system are paid on the basis of
the  reference  price  rather  than  the  retail  price.  Customers  who  refuse  to  switch  to  a
cheaper drug are reimbursed according to the reference price and will have to pay the
difference themselves. Only the doctor may prohibit substitution by making a note of this
on the prescription (278).
The first year of reference pricing and extended generic substitution generated total
cost savings of 110 million € (278). The savings were the greatest in antipsychotics (27
million €), lipid-modifying agents (19 million €) and agents acting on the RAAS (13
million €). These drugs also generated the greatest savings in reimbursement costs. About
90% of the savings were attributable to generic substitution being extended to cover drugs
holding an analogous process patent; about three-quarter of these savings arose from
atorvastatin (i.e. lipid-modifying agent) and losartan (i.e. ARB) as well as quetiapine and
olanzapine  (i.e.  antipsychotics).  Until  the  end  of  2009,  about  half  of  all  reimbursable
medicinal products with marketing authorization were included in the reference price
system (278).
Biosimilar medicines have since 2006 been accepted to the EU markets. Biosimilars
are follow-on versions of original (“reference”) biological medicines (such as growth
hormones or erythropoietins) (289). They are not identical to generics due to their
complex nature and production methods. Biosimilars are independently developed after
the patent of the original product has expired but and are less expensive than the original
products (289).
2.4.7 Pharmaceutical patents
Although these legislative measures led to substantial temporal savings both in the sales of
medicines and in the reimbursed expenditure, the costs of medications continue to increase
because new drugs are more expensive than old ones, at least as long as they are protected
by their patents. In terms of sales, the largest medication groups in 2012 were the
antineoplastic and immune-modulating agents, as well as the drugs affecting the
alimentary tract and metabolism (279). In fact, in recent years many new drugs belonging
to these groups, such as drugs for cancer, rheumatoid arthritis and diabetes, have been
developed and have reached the market. To recoup the costs of research and drug
development, the manufacturers may charge a relatively high price for a new patented
drug. Because only minimal numbers of pharmaceutical agents developed enter the
market, the successful drug development process must also cover the development costs of
unsuccessful drugs. Moreover, pharmaceutical companies also make substantial
investments in the marketing of the new drugs to physicians and pharmacies (290).
The life cycle of a drug can be divided into three phases: 1) research and development
of a drug until the drug obtains a marketing authorization, 2) the period during which the
pharmaceutical company has the exclusive right to sell the drug and 3) the period after the
patent expires, allowing generic or biosimilar competition (291). To assure the safety,
efficacy and availability of a new drug, the pharmaceutical industry is heavily regulated by
the Government, covering the entire life cycle of a medication.
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A pharmaceutical patent provides the manufacturer with an exclusive right to sell the
new medicine for up to 20 years from the date of the patent filing (Patents Act, 550/1967,
section 40, subsection 1). In practice, drug development is an expensive, time-consuming
and uncertain process that takes years to complete. On average, it takes 10–12 years and
costs about $1 billion to discover and develop a new drug (Pharma Industry Finland,
http://www.pif.fi/en). Therefore, by the time a new drug has been launched to the market
and been granted a reimbursement status, the manufacturers may have less than 10 years
left of the patent exclusivity.
Until 1995, patents could not be granted for medicinal products in Finland; only an
analogous process patent protecting the production method was available. Only after 1995
was a product patent provided by the Finnish legislation. Moreover, before 2005 the data
exclusivity period in Finland for new drugs, which was the only way to restrict the
introduction of generic products, was only six years. From the viewpoint of manufacturing
companies, weaker analogy process patents and a relatively short data exclusivity period
have contributed to a development where marketing authorizations for generic products
have often first been applied in Finland. Until 2006, generic substitution was applied also
to products with valid analogy process patents, but thereafter they were excluded
(Government Proposal 108/2005). In 2009, drugs with an analogous process patent
became substitutable within the generic substitution regime and were subjected to price
competition again (278).
To compensate for the long development times of drugs and the relatively short
effective patent times, pharmaceutical companies have since 1993 been able to obtain a
supplementary protection certificate to extend the duration of the exclusive right up to a
maximum of five years [Regulation (EC) 469/2009]. After harmonization at the European
Union level in 2005, pharmaceutical companies may enjoy eight years of data exclusivity
(i.e. their pre-clinical and clinical trial data may not be referenced in the regulatory filing
of another, typically generic, company for the same drug substance) with an additional
two-year term of marketing exclusivity (i.e. after a period of 10 years from granting of the
marketing authorization to the innovator company, the generic company can also market
their product) and a potential one-year extension for new therapeutic indications
(Directive 2004/27/EC).
However, during the market exclusivity period a new patented drug may face
competition from other products for the same disease or products having a near-
comparable effect or chemical structure as the original medicinal product with only minor
differences (so-called me-too drugs) (292). Moreover, parallel imported medicinal
products may create price competition. In the European Union, based on the principle of
free movement of goods (Treaty on the Functioning of the European Union, Article 34-
36), other (parallel importer) than the holder of the marketing authorization can buy the
patented medications from countries where the drugs are cheaper (e.g. Mediterranean
countries) and import them to the more expensive ones (e.g. Germany and Scandinavian
countries), thus obtaining lucrative margins (293). In Finland, the first marketing
authorizations for parallel import products were granted in 1996, but parallel import has
generated only marginal savings. The proportion of parallel import products is only 1–2%
of the Finnish pharmaceutical markets (290). Also, pharmaceutical companies have
adopted several strategies to extend the period of the market exclusivity of their drugs
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(294). They may obtain additional patents by developing new formulations (only minor
differences from the original drug) that promote patient compliance through reduced
dosing or side-effect profile, or by developing new routes of administration or new
indications of drugs.
2.5 Diabetes guidelines
Type 1 diabetes is a challenging and complex disease to be managed successfully, with the
major responsibility for the day-to-day care resting with the patients and their families.
Over the past decades, numerous diabetes guidelines have been developed to assist
clinicians and other health care workers in making evidence-based management decisions.
This, in turn, may lead to better diabetes care outcomes by bringing the best knowledge to
daily care, minimizing unnecessary variation of care and optimizing the effectiveness of
care (295, 296). There are several existing international and national diabetes guidelines,
as well as guidelines generated by joint interests [e.g. European Society of Cardiology and
European Association for the Study of Diabetes (ESC/EASD) guidelines for the
management of diabetes and CVD] (297).
2.5.1 American Diabetes Association (ADA) Guidelines
The ADA has been actively involved in the development of diabetes care standards and
guidelines (7).  The ADA guidelines are one of the leading diabetes guidelines;  the ADA
recommendations have strongly influenced other diabetes guidelines (298). The ADA
provides, on an annual basis, recommendations on the screening, diagnostic and
therapeutic actions applicable to most people with diabetes (7). These recommendations
are regularly updated based on new evidence, or in some cases, to clarify earlier
recommendations, by the ADA’s multidisciplinary Professional Practice Committee. The
guidelines are evidence-based wherever possible, but may also have been drawn from
accumulated professional knowledge and consensus agreement. Therefore, the ADA has
adopted a quality grading system showing the level of evidence that supports each
recommendation. A-level evidence is based on large well-designed clinical trials or well-
conducted meta-analyses, B level is supportive evidence from well-conducted cohort
studies or a case-control study, and C level is supportive evidence from poorly controlled
or uncontrolled studies. “E” refers to an expert consensus or the recommendation being
based on clinical experience (7).
2.5.2 Glycaemic, BP and lipid control
The ADA guidelines include targets and strategies for glycaemic, BP and lipid control
applicable to most adults with diabetes. Over the years, these targets have been revised
based on new evidence. For decades, in response to the DCCT and the United Kingdom
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Prospective Diabetes Study (UKPDS) data, the ADA has recommended maintaining
HbA1C levels below 7% in adults with diabetes (299). The treatment target for LDL-C has
become more stringent with time, especially in those with known CVD (300). However,
the cut-off value for systolic BP has been under constant debate. Recently, the treatment
target for systolic BP has been revised from less than 130 mmHg to less than 140 mmHg.
The previous systolic BP target had been derived from observational studies rather than
randomized controlled clinical trials (141). Randomized clinical trials (where all patients
had  type  2  diabetes)  demonstrated  the  benefit  of  lowering  systolic  BP  to  below  140
mmHg, but the evidence is limited (301, 302).
Recent ADA guidelines emphasize a more individualized approach in the management
of diabetes by taking into account the patient’s individual preferences, co-morbidities and
other patient-specific factors when deciding the patient’s treatment goals and strategies
(7). Consequently, based on a benefit-risk assessment, the more stringent targets for
HbA1C (i.e. 6.0–6.5%) may be reasonable for younger, healthier patients with a short
duration of diabetes, a long life expectancy and no CVD if they can be achieved without
excessive hypoglycaemia. In contrast, the less stringent HbA1C targets (i.e. 7.5–8.0%) may
be better suited for older and more frail patients with multiple co-morbidities, a long
duration of diabetes and a history of severe hypoglycaemia (7, 303). Also a lower systolic
BP target, e.g. less than 130 mmHg, may be appropriate for younger patients with a long
life expectancy or for those who carry a high risk of stroke if it can be achieved with fewer
drugs and without significant adverse effects (141).
2.5.3 Achievement of treatment targets
Despite strong evidence that intensified glycaemic, BP and lipid control reduces the risk of
microvascular complications and cardiovascular disease and improves the prognosis of
patients with DN, implementation of the evidence-based treatment targets is challenging in
clinical practice. Table 4 summarizes the studies during the last two decades that have
reported the achievement of HbA1C, BP and LDL-C targets either simultaneously in
patients with diabetes or the achievement of each target separately in patients with type 1
diabetes.
Cut-off values of treatment targets, data collection time and study population differ in
these studies. Moreover, the majority of the patients had type 2 diabetes, and very few of
the studies reported the achievement of the three target values in the same individual
simultaneously in patients with type 1 diabetes. In general, these studies show
conspicuous discrepancies between evidence-based treatment targets and actual clinical
results since only a minority of the patients had reached the targets proposed by the ADA.
This suggests that some patients may have a suboptimal medication regimen (i.e.
insufficient daily doses or numbers of the drugs) or poor adherence to the treatment and
lifestyle changes. Especially patients with hypertension might require multiple drug
therapy to reach treatment targets (201). However, certain subgroups of the patients with
diabetes are considered to have treatment-resistant hypertension (RH). RH is defined as
failure to achieve the target BP even after using a minimum of three antihypertensive
drugs  at  maximally  tolerated  doses,  from  different  classes,  one  of  which  should  be  a
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Table 4. Achievement of HbA1C, blood pressure and LDL cholesterol targets among adult patients
with diabetes.
Cohort Data collection time and
treatment targets
Results
Ali et al., 2013, USA
(NHANES1) (12)
10 665; Diabetes;
National population-based
1999–2010
HbA1C < 7%
BP < 130/80 mmHg
LDL-C < 2.6 mmol/L
All three targets achieved
+ non-smoking status
1999–2000 2003–06  2007–2010
44%               57%         52%
40%               45%         51%
36%               47%         57%
5%                 10%          14%
Cheung et al., 2009,
USA (NHANES) (304)
17 306; Diabetes;
National population-based
1999–2006
HbA1C < 7%
BP < 130/80 mmHg
LDL-C < 2.6 mmol/L
All three targets achieved
1999–2002 2003–2006
43%                57%
39%                45%
36%                47%
7%                  12%
Braga et al., 2012,
Canada (305)
3002; Type 2 diabetes;
Primary care settings
2005–2006
HbA1C ≤ 7%
BP ≤ 130/80 mmHg
LDL-C < 2.5 mmol/L
All three targets achieved
39%
30%
53%
7%
Beaton et al., 2004,
New Mexico, USA
(306)
7114; Diabetes;
Managed care
organisation
1999–2000
HbA1C < 7%
Systolic BP < 130 mmHg
Diastolic BP < 80 mmHg
LDL-C < 2.6 mmol/L
37%
41%
54%
23%
Valle, 2010, Finland
(307)
967; Type 1 diabetes;
Finnish cohort
2009–2010
HbA1C < 7.5%*
BP < 130/80 mmHg
BP < 135/85 mmHg*
LDL-C ≤ 2.5 mmol/L
All three targets achieved
 (* + LDL-C < 2.6  mmol/L)
22%
28%
39%
58%
7%
Livingstone et al.,
2012, Scotland, UK
(308)
9276; Type 1 diabetes;
Scottish diabetes register
2008
HbA1C < 7%
BP < 130/80 mmHg
13%
men 30%; women 47%
Bryant et al., 2006,
Sydney, Australia (10)
96; Type 1 diabetes;
Sydney teaching hospital
2003
HbA1C < 7%
BP ≤ 130/80
LDL-C < 2.6 mmol/L
13%
treated 29%, untreated 60%
treated 60%, untreated 36%
1National Health and Nutrition Examination Survey
diuretic (309, 310). Also patients with controlled BP who are taking four or more
antihypertensive drugs may be considered resistant to treatment (310).
2.5.4 Adherence to medication
Poor adherence to medication regimens has frequently been reported in patients with
chronic conditions, including diabetes, hypertension and cardiovascular disease (311).
Adherence to a medication regimen is defined as patients taking their medication as
prescribed by their physician and continuing to take a prescribed medication (312, 313).
The WHO estimates that adherence to long-term therapies for chronic illness is as low as
50% in the developed world (314). In a prospective study, 40% of patients with newly
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diagnosed hypertension discontinued their antihypertensive medication during the first
year of treatment (315). Poor adherence may, however, be less common in patients with
diabetes. A recent study reported that only 20% of family practice patients with type 2
diabetes and hypertension showed poor adherence to their antihypertensive treatment
(316). In general, better adherence rates for medication use than for diet and physical
activity were reported in patients with diabetes (317-319). According to the Cross-
National Diabetes Attitudes, Wishes and Needs (DAWN) Study, self-reported adherence
to medication was 83%, to diet 39% and to exercise 37% in patients with type 1 diabetes
(317).
A systematic review, including 17 studies, showed that self-reported rates of adherence
to insulin therapy in patients with diabetes ranged from 43% to 86% (320). As expected,
higher adherence rates for insulin therapy have been reported by patients with type 1
diabetes than by patients with type 2 diabetes. This is certainly related to the more vital
role of insulin therapy for glycaemic control and the higher risk of life-threatening events
as  a  result  of  total  insulin  deficiency  in  the  patients  with  type  1  diabetes.  A small  study
showed that among young people with type 1 diabetes 28% of the patients obtained less
insulin than their prescribed dose (321). Notably, adolescents (10–19 years) had the
poorest adherence to insulin as compared with those younger than 10 years or those 20–30
years old. That study also reported that lower adherence was associated with more hospital
admissions for acute diabetes complications and diabetic ketoacidosis.
The consequences of medication non-adherence are not only related to poor clinical
outcomes but also to an increase in unnecessary health care costs (322-324). To improve a
patient’s adherence to a long-term medication regimen, it is important to recognize and
understand the factors that challenge medication adherence. The reasons for poor
adherence are often multifactorial, including patient-related factors (such as age,
education, depression, health literacy, substance abuse), environmental factors (such as
social network and support), health care provider factors (such as communication,
relationship with patients), health care system factors (such as access to care, transitions of
care, out-of-pocket costs of medication, health insurance) and disease- (symptoms,
duration, response to treatment) and treatment-related factors (adverse events,
polypharmacy, regimen complexity) (177, 311, 312, 324).
Lower adherence to medication has frequently been shown when the condition is
chronic and when the course of symptoms varies or the symptoms are not apparent and do
not physically hurt or the treatment is aimed at asymptomatic conditions to prevent
adverse events years later (312, 325-327). Therefore, adherence to the regimen may be
jeopardized when ACE inhibitor or ARB treatment has been prescribed for
microalbuminuric normotensive patients, when lipid-lowering therapy is initiated for
patients at CVD risk or when combinations of antihypertensive drugs are required to reach
BP targets.
Moreover, the complexity of the regimen, including numerous medications
(polypharmacy) and multiple dosing schedules, may be related to non-adherence (328).
Previous studies have shown that the percentage of adherence is inversely correlated with
the number of drugs and the frequency of doses (327). A recent study from managed care
settings assessed the effect of the previous prescription burden on future adherence when
antihypertensive and lipid-lowering therapy was added (329). The adherence rates during
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the first year after therapy initiation decreased to 41%, 35% and 30% in patients who were
taking none, one and two prescription medications, respectively, prior to starting the
antihypertensive and lipid-lowering medication. In a meta-analysis, the adherence rate
decreased significantly with increasing frequency of dosing; adherence to once-daily
dosing was 79%, twice-daily dosing 69%, 3 times per day dosing 65% and 4 times per day
dosing 51%. Another meta-analysis from 42 trials showed that using a fixed-dose
combination of antihypertensive therapies was associated with higher compliance and less
hospitalizations than the use of separate pills (330). Several strategies to improve dosing
schedules exist, including the use of pill boxes to organize daily doses, new technologies
such as reminders by personal digital assistants and simplifying the regimen to daily
dosing or prescribing fixed-dose combination therapies (312, 330).
Finally,  experience  or  fear  of  adverse  effects  is  one  of  the  most  common barriers  to
medication adherence (327). In the DCCT study, patients receiving intensive therapy were
two to three times more likely to experience a severe hypoglycaemic episode than those
receiving conventional therapy (183). Thus, fear of hypoglycaemia is likely to be an
important barrier to achieving blood glucose targets (331). Importantly, fear of
hypoglycaemia may lead to a tendency to accept and maintain hyperglycaemia, and this,
in turn, may lead later to diabetic complications (332). Patients with type 1 diabetes make
regular visits to the outpatient clinic or they see their general practitioner at 3- to 6-month
intervals. Adverse effect profiles should be considered not only when prescribing a new
drug, but also at every visit thereafter (312).
The review of the literature above revealed several factors that may have direct or indirect
effects on medication use and cost in patients with type 1 diabetes. Figure 2 summarizes
the main factors.
Figure 2. Factors affecting prescription medication use and cost in patients with type 1 diabetes.
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2.6 Economics of diabetes
This section explores the economic burden of diabetes. First, a brief overview of cost-of-
illness (COI) analysis is provided. This is followed by descriptions of the direct and
productivity (previously called indirect) cost of diabetes as well as the economic burden of
DN. Finally, findings related to the use and costs of medication, especially in outpatients
with type 1 diabetes, are presented.
As health care resources are limited, their efficient use is crucial. To optimize the use
of health care resources and to determine the cost-saving strategies for the management of
patients with diabetes, policy-makers should be familiar with the cost structure of diabetes
care as a whole and at various stages of the disease process, including the effects of the
most prevalent diabetes-related complications. Basically, two main approaches to evaluate
economic aspects of care exist: economic evaluation and COI analysis. The basic tasks of
economic evaluation are to identify, measure, value and compare the costs and
consequences of alternative courses of action (333). COI is a descriptive study design that
identifies and measures a particular disease´s total costs to society, including direct,
productivity and intangible dimensions (334). It can also provide information about the
main cost  components and their  proportion of the total  costs,  the cost  variability and the
distribution of costs in the course of disease progression (335). COI can also consider
preventive measures by providing estimates of the savings that potentially accrue through
successful prevention, e.g. the amount that could be saved if a disease were to be
eradicated (335).
2.6.1 Cost-of-illness analysis
In the COI analysis, the direct medical costs include expenditures for hospitalization,
outpatient care, nursing home care, services of physicians and other health care specialists,
rehabilitation, special devices needed, diagnostic tests and medication. Non-medical costs
are transportation costs, relocation expenses and informal care. Productivity costs
represent productivity losses related to morbidity and mortality. Intangible costs refer to
the patient’s psychological pain, discomfort, anxiety and distress related to the disease,
and they are usually measured in forms of quality of life. (334, 335)
Moreover, the COI analysis can be described according to the perspective, approach
and methods chosen. The research question guides the most appropriate perspective. The
perspective could be that of the patients (e.g. out-of-pocket costs), the employers (e.g. cost
of worker’s compensated insurance premiums and loss of productivity), the insurance
company (e.g. cost of claims), the government (e.g. cost of public health services) or the
society, which is the most comprehensive and commonly used perspective in COI studies
(336).
COI analysis can be either prevalence- or incidence-based. The prevalence-based
approach refers to the total number of cases within a specified time period (typically one
year), while the incidence-based approach refers to the new number of cases arising in a
predefined period of time (335). Thus, a prevalence-based study involves estimates of the
costs occurring in the given term and an incidence-based study calculates the value of
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lifetime costs for new cases of disease. In the prevalence-based approach, COI studies
may yield useful information to decision-makers by drawing their attention to conditions
where the burden has been underestimated or by providing a picture of the major cost
components, and thus, the areas where the cost containment policies would have the
greatest impact (336). The incidence-based approach is especially useful when estimating
the savings of the preventive measures, when analysing the management of the disease
from  onset  until  death  or  when  showing  how  the  costs  are  distributed  during  illness
progression. This could encourage the development of clinical practice guidelines aimed at
increasing effectiveness and efficiency of disease management (335).
Finally, two basic methods exist for quantifying the resources: top-down (“population-
based”) and bottom-up (“person-based”) methods (337). The top-down approach is based
on aggregate data (available from national health care statistics or registers) on mortality,
morbidity, hospital admissions, general practice consultations, disease-related costs and
other health-related indicators. Costs are calculated by multiplying the total health care
expenditures by the proportion of health care services used by the disease group. In the
bottom-up approach, the resources used are calculated from individuals with the health
problem in question; the average cost of treatment (sum of all components of treatment) is
multiplied by the prevalence of the health problem in question (338). The average per-
person costs may be extrapolated to the whole population using relevant epidemiological
data. The bottom-up approach is a more comprehensive one, allowing identification of
differences in demographic and clinical characteristics between patients (337).
By estimating the resources used and lost as a result of a particular disease, COI
studies provide an important economic guide for policy development, priority settings and
management of disease (339). Thus, COI studies may provide a framework for cost
estimation, and hence, may direct health economic research towards cost-effective
methods for diabetes care. The chronic nature of diabetes and its association with many
complications lead to a considerable economic burden on society. The next section
provides information about the economic costs of diabetes. The section also illustrates the
major cost drivers as well as the effects of the complications on costs.
2.6.2 Costs of diabetes
As the number of people with diabetes grows worldwide, the disease imposes an
increasing economic burden on national health care budgets. Globally, approximately 11%
of the annual health care expenditures were spent on diabetes in 2013 (3). However, there
is a substantial disparity between countries; only 20% of the global health expenditure
comes from low- and middle-income countries, where about 80% of the people with
diabetes reside (3).  While the US alone constituted about 36% of the global expenditure
on diabetes, China, the country with the largest population with diabetes, comprised only
7% of the world total. Also in Finland and several other European countries, the annual
health care costs for diabetes represent more than 10% of the health care expenditure, and
these costs are to a large extent due to the escalating costs of complications (13, 14). A
recent Finnish study estimated that the health care costs of diabetes together with the lost
49
labour inputs of afflicted patients will reduce the Finnish gross domestic product (GDP)
by over 1% in the long run (340).
Over the last few years, several economic studies of diabetes from different countries
and continents have been published. In general, these studies have confirmed that diabetes
causes a significant burden not only to the health care system but also to individuals and
society as a whole. It is challenging, however, to compare the total costs of diabetes
between different countries because different studies vary markedly in study designs,
settings, populations, data sources, study periods and publication years. Moreover,
methodological differences and inclusion of different cost components exist. Also, the
accuracy of the data sources used may vary considerably. Typically, a clear distinction
between the various types of diabetes has not been made, or the majority of patients have
had type 2 diabetes. In addition, the costs have rarely been calculated separately for the
different diabetic complications or severity stages of disease.
A systematic review (336), in which a total of 30 COI studies of diabetes (published
between 2007 and 2011) were included, highlighted the variability of the studies. The
annual direct costs of diabetes ranged from US$146.1 million in Iran to US$174 billion in
the US, and the annual direct cost per patient from US$150 in India to US$14 060 in the
US. The authors of the review highlighted two main findings. Hospitalization seemed to
be the major direct cost driver. Moreover, the lack of standardized COI methods, and
variability in study designs, perspectives and included cost categories made direct
comparisons virtually impossible.
The ADA has regularly reported the economic cost of diabetes in the US. They have
built the Cost of Diabetes Model by combining information from the peer-reviewed
literature, government statistics, original analyses and medical claims databases. A
prevalence-based approach was used to estimate the medical costs by demographic group,
health service categories, and medical conditions. The number of people with diagnosed
diabetes continues to rise. While in 2002, about 12.1 million people had been diagnosed
with diabetes in the US (341), this figure had increased to 17.5 million in 2007 (9).
However, the latest updated report (342) estimated that nearly 22.3 million people (about
7% of the US population) had been diagnosed with diabetes in 2012. At the same year, the
total estimated cost of diabetes reached $245 billion, including $176 billion for direct
costs and $69 billion for productivity loss incurred. The total costs had increased more
than 40% from the year 2007.
The largest components of the medical expenditures were hospital inpatient care
(43%), followed by prescription medication to treat diabetic complications (18%),
antidiabetic agents and diabetes supplies (12%), physician office visits (9%) and
nursing/residential facility stays (8%). Notably, prescription medications, insulins, and
other antidiabetic agents represent over one-quarter (28%) of all health expenditures
attributed to diabetes. The health care expenditure per patient was $13 700 per year; it was
about two to three times higher than the expenditure would have been without diabetes.
Notably, about 59% of the direct medical cost was derived from the population aged 65 or
more, and about 88% of the indirect cost was attributed to the population under 65 years
of age. A distinction between the various diabetes types was not made in that study, and
hence, type 1 diabetes was not a specific research priority.
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Despite the challenge of distinguishing the cost of different diabetes types from
medical claims, Dall et al. (343) estimated the cost by diabetes types in 2007 based on the
same  Cost  of  Diabetes  Model  built  by  the  ADA  (9).  Moreover,  medical  claims  were
analysed to estimate the proportion of diagnosed diabetes cases (according to the criteria
characteristic to each diabetes type used in previous studies) and excess medical costs by
diabetes  type.  The  authors  estimated  that  about  5.7%  (~1.0  million)  of  the  17.5  million
people with diagnosed diabetes had type 1 diabetes.  About $19.4 billion of the total costs
were associated with type 1 diabetes (8.6%). Medical costs accounted for $10.5 billion and
indirect costs for $4.4 billion. Costs associated with type 2 diabetes were $159.5 billion
(including medical costs of $105.7 and indirect costs $53.8). Although the costs associated
with type 2 diabetes were significantly higher, the economic burden per case of diabetes
was greater in type 1 diabetes than in type 2 diabetes, and the difference increased with
age. While the total cost per case of type 2 diabetes was $9200 to $9700 across all age
groups, the cost was $4044 for people with type 1 diabetes who were younger than 44
years and $35 365 for those aged 65 or older. That increase was mainly due to higher
utilization of institutionalized care in the older age group. However, the results of that
study should be treated with some caution. The cost analysis was largely based on claims
data, which tends to be less accurate than medical records when identifying patients with a
special condition (e.g. diabetes type).
The economic burden of diabetes was estimated by Jarvala et al. (13) in Finland in
2007. The data of the inpatient care, outpatient visits in specialized care, prescription
medication and productivity loss (workday absence due to sickness, premature retirement,
premature mortality) were collected from the national registers between 1998 and 2007.
Moreover, outpatient visits in primary care were estimated from the Health 2000 survey.
In that prevalence-based COI study, the costs were assessed from a societal perspective.
The number of patients with diagnosed diabetes was 284 832, and of these 39 575 (14%)
had type 1 diabetes in 2007. In the same year, the estimated total medical cost of diabetes
was 1.3 billion €, the majority of which was the incremental cost of diabetes (830 million
€). The incremental cost of diabetes was calculated by using the average medical costs of
the population (the average medical costs of the people with diabetes – the average
medical costs of the population). The cost of productivity loss was also 1.3 billion € in
2007.
In patients with type 1 diabetes who had at least one complication, medical costs were
on average 2.4 times higher, and in patients with type 2 diabetes and one complication 3.2
times higher than the cost of diabetes in patients without any complications. The largest
component of medical costs was specialized inpatient care (26%), followed by medication
(25%) and primary inpatient care (18%). The total medication costs were about 324.8
million € in 2007, and these costs increased by approximately 7.9% per year between 1998
and 2007 (adjusted to 2007 euro levels by using the Consumer Price Index). In patients
with type 2 diabetes, the total medication costs were 263 million € and the costs per
patient 1040 € in 2007. The corresponding numbers in patients with type 1 diabetes were
61.7 million € and 1450 €.
In a case-controlled, prevalence-based study, Kangas (20) estimated the use of health
care services as well as total and incremental direct costs of health care in individuals with
diabetes in Helsinki, Finland in 1997. Data of the consumption and direct costs of care
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services were obtained from different registers, including outpatient and inpatient services,
medications, self-care equipment and travel costs. Dental, psychological and occupational
health services were not included. Outpatient and inpatient costs were studied on the basis
of average prices and actual expenditures. The national estimate for the total costs of
services of the population was also assessed by extrapolating the results from Helsinki to
the national level. The costs of care for people with type 2 diabetes were two times higher
and for patients with type 1 diabetes four times higher than for those without diabetes. For
both types of diabetes, about one-third of the patients had at least one complication and
these patients accounted for two-thirds of the total treatment costs. Complications brought
a 10-fold increase in medical costs of care for people with type 1 diabetes and a 20-fold
increase for people with type 2 diabetes. The costs of medication were about 16% of the
total costs, and diabetes drugs accounted for one-third of these costs.
It is complicated to compare these two Finnish studies due to methodological
differences. While Kangas (20) estimated the incremental costs of diabetes by using age-
and gender-matched controls without diabetes, Jarvala et al. (13) calculated the
incremental costs of diabetes by using the average medical cost of the Finnish population.
The former method may give a more precise figure of the incremental costs. The study
was conducted in one city only, and the results were then extrapolated to the national
level. However, Jarvala et al. estimated the costs by using for the most part nationwide
register data, which may give a more relevant and comprehensive picture, even if the risk
of misclassification may increase in register-based studies. The Kangas study is over 15
years old, and many factors related to management of diabetes have since changed. Thus,
the cost estimates are unlikely to be accurate estimates of the current costs of diabetes.
Nevertheless, the older study showed how important is to differentiate the costs between
the two diabetes types, as proportion, age and gender of patients as well as the  treatment
and related problems may vary between type 1 and type 2 diabetes.
2.6.3 Economic burden of diabetic nephropathy
Only a few studies have been conducted that have estimated the economic burden of DN.
In these studies, the majority of the patients have had type 2 diabetes. These studies have
different study designs, perspectives and cost components. Also the accuracy of data
sources has varied between the studies. None of the studies was conducted in Finland.
Nonetheless, this section illustrates the economic burden associated with the progression
of DN.
Gordois  et  al.  (88)  quantified  and  compared  the  rates  and  annual  direct  costs  of  DN
(including patients with microalbuminuria, overt nephropathy and ESRD). The COI model
was constructed to estimate the annual costs. In the US the costs were estimated from the
perspective of the health care payer and in the UK from the perspective of the National
Health Service. In the US, the estimated number of patients with diagnosed diabetes was
11.1 million, 0.83 million of whom had type 1 diabetes, while the corresponding figures in
the UK were 1.4 million and 0.17 million. The total annual costs of DN were estimated to
be $16.8 billion in the US and $1.2 billion in the UK. For type 1 diabetes, the estimated
costs were $1.9 billion in the US and $231 million in the UK. In the US for every 10%
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increase in the prevalence of microalbuminuria the total annual costs increased by 2%.
Moreover, every 10% increase in the prevalence of overt nephropathy increased the costs
by  5.5%  in  the  US  and  by  some  7%  in  the  UK.  In  both  countries,  people  with  type  1
diabetes  incurred  a  relatively  large  amount  of  the  total  cost  of  DN.  In  the  US,  the
proportion  of  patients  with  type  1  diabetes  was  7.5%,  but  they  accounted  for  9% of  the
total  costs  of  DN.  Similarly,  in  the  UK  the  proportion  of  type  1  diabetes  patients  was
about 12%, but they accounted for 20% of the total costs of DN. These figures could be
explained by the larger number of patients with ESRD and a new kidney transplant in the
patients with type 1 diabetes. Importantly, the evaluation was conducted already 13 years
ago. Moreover, some inaccuracy of the estimates may have led to underestimation or
overestimation of the total costs. Despite these shortcomings, the study confirmed the
enormous economic burden of DN on the health care system.
Nichols et al. (344) estimated the direct medical costs of 7758 hypertensive patients
with type 2 diabetes according to the level of proteinuria. They also compared the costs
between the patients whose DN did and did not progress. The data were obtained from the
Kaiser Permanente North-West diabetes registry and the patients were followed for up to
eight  years  for  progression  of  DN.  At  baseline,  67%  of  the  patients  were
normoalbuminuric, 28% microalbuminuric and 5% macroalbuminuric. Unadjusted mean
annual costs at baseline were $6455 for those with normoalbuminuria, $7398 for those
with microalbuminuria and $8087 for those with macroalbuminuria. The mean pharmacy
costs did not differ significantly between those with normo- and microalbumiuria ($2333
vs. $2510). However, these costs were higher in individuals with macroalbuminuria
($2781, P < 0.001) than in those with normoalbuminuria. About half of the patients with
normoalbuminuria progressed to a higher stage, and about one-third of the patients with
microalbuminuria progressed to macroalbuminuria during the follow-up. Only 5% of the
patients with macroalbuminuria progressed to ESRD. The authors reported that the mean
costs increased by 37% following progression from normo- to microalbuminuria ($7424
vs. $10 188); and 41% following progression from micro- to macroalbuminuria ($8753 vs.
$12 371), after adjustment for demographic and clinical characteristics. That study showed
that the progression to a more severe stage of DN was strongly associated with higher
medical costs. However, all patients were diagnosed with type 2  diabetes.
In a retrospective German study (345), 118 diabetes patients’ direct and indirect costs
related to DN were estimated in 2002. Costs per patient were calculated from the societal
and health insurance perspective according to the three stages of DN: microalbuminuria,
macroalbuminuria and renal insufficiency. From the societal perspective, the costs per
patient related to DN were 2019 € and from the health insurance perspective 1332 €. From
the societal perspective, the costs were similar between micro- and macroalbuminuric
patients (685 €), but were considerably higher in patients with renal failure (10 223 €).
The corresponding numbers from the health insurance perspective were 222 €, 398 € and
7862 €. The main cost drivers were dialysis (38%), retirement (19%) and medication
(14%). In this study, only DN-related costs were estimated, and therefore, these results are
more likely to underestimate the real costs. DN is often associated with other adverse
conditions, such as hypertension, neuropathy, retinopathy, hypercholesterolaemia,
hyperlipidaemia and coronary heart disease. In fact, it is impossible to restrict the costs
only to those due to nephropathy only. Moreover, classification between the types of
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diabetes was not done and also the number of cases was low. The authors assumed that the
annual resource use with respect to stage of DN is equal in patients with type 1 and type 2
diabetes.
2.6.4 Use and costs of medication
Prescription medications represent the second largest proportion of the total costs of type 1
diabetes (20, 346). In Finland, the costs of prescription medications accounted for
approximately one-third of the total costs of type 1 diabetes (20). Insulin therapy is one of
the main elements of the direct costs of type 1 diabetes. Often, individuals with diabetes
also have a high overall usage of medications, independent of the treatment needed for
diabetes itself.
There are several studies concerning medication use and costs of diabetes. These
studies have focused on medication use and cost solely (16-19) or the drug costs have
been evaluated as part of the total medical costs in patients with diabetes (58, 346-348).
Moreover, some of the studies have focused on diabetes medications only (349, 350).
 The following section illustrates some general trends in the use and costs of
prescription medications in patients with diabetes. The first three studies are cross-
sectional and the other two show longitudinal trends. In order to focus on the use and costs
of prescription medications in patients with type 1 diabetes, only such cross-sectional
studies where patients have been stratified according to diabetes types (type 1 and type 2)
were included. Table 5 summarizes the results of different studies concerning the costs of
prescription medications in patients with diabetes and their controls. The table also shows
costs of diabetes drugs.
In a population-based study, Bruno et al. (16) compared prescription drug use and
costs in patients with diabetes (n= 33 797) and non-diabetic individuals (n= 863 879) in a
large  population-based  cohort  in  the  city  of  Turin,  Italy.  About  5%  (n=1704)  of  the
patients had type 1 diabetes. The data were obtained from the Piedmont Diabetes Registry,
hospital discharges and prescription data sources. All prescriptions registered over a 12-
month period in 2003–2004 were examined. The overall mean prescription cost per year
was 831 € in patients with diabetes and 183 € in non-diabetic individuals. Estimates
derived from the age- and sex-adjusted model showed almost threefold higher mean costs
in patients with diabetes than in non-diabetic individuals. Notably, the mean costs were
almost  eight  times  higher  in  patients  with  type  1  diabetes  than  in  controls.  Glucose-
lowering drugs accounted for almost 19% of the total costs (45% in type 1 and 17% in
type 2 diabetes). Cardiovascular drugs were three times more often prescribed to those
with diabetes than to non-diabetic individuals. One-third of the diabetic patients received
anti-thrombotic treatment, mainly aspirin (19% of type 1 and 33% of type 2 diabetes). Of
the patients, 28% used lipid-lowering drugs (17% of type 1 and 29% of type 2 diabetes).
Only  one-third  of  the  patients  were  prescribed  drugs  for  the  prevention  of  CVD  and
chronic kidney disease such as ACE inhibitors, statins and aspirin. The authors estimated
that from the public health perspective the costs of medication would increase in the future
if the evidence-based diabetes guidelines were implemented in clinical practice more
effectively.
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Reunanen et al. (17) estimated the overall use and costs of medications and co-morbidity
of drug-treated diabetes patients, compared with sex- and age-matched control subjects in
Finland. The data were obtained from the national drug registers. From the registers, 16
955 type 1 diabetes and 68 717 type 2 diabetes patients were identified in 1995. The use of
almost all kinds of medication was greater in diabetes patients than in controls. The mean
costs of medications for individuals with type 1 diabetes were 12 times greater than the
costs of medications taken by control subjects. Insulin treatment accounted for 62% of the
costs, but even after excluding the costs of insulin, the mean costs were still over five
times greater than the costs of medications for control subjects. Regarding the patients
with type 2 diabetes, the mean costs were three times greater than in controls, and when
the diabetes drugs were excluded the costs were two times higher. Type 1 diabetes patients
used all types of cardiovascular medications more often than controls. This study was,
however, cross-sectional concerning the drug costs and the co-morbidities in one year,
1995, with varying duration of diabetes. The study was conducted almost 20 years ago,
and meanwhile, the management of diabetes has changed and many new drugs have
reached the markets. Therefore, these results may not reflect current medication use and
costs in patients with diabetes in Finland.
Evans et al. (19) described the prescribing rates of drugs in patients with diabetes and
non-diabetic individuals in Tayside, Scotland, in 1995. A population-based diabetes
register  was  used  to  identify  patients  with  type  1  and  type  2  diabetes.  A  computer
algorithm was used to identify patients with type 1 diabetes. Patients who were diagnosed
when younger than 35 years of age and with a requirement for insulin were categorized as
type 1 diabetes patients. There were 406 526 patients in Tayside, and of these 7843 had
diabetes (974 type 1 and 6869 type 2 diabetes). A database of all prescriptions dispensed
in the community was used to investigate the drug utilization. Drugs were categorized
according to four drug categories: gastrointestinal, cardiovascular, central nervous system
and infections.
The mean dispensed prescribing rates for all drugs (diabetes medications excluded)
were  higher  across  all  age  groups  for  patients  with  diabetes  than  for  individuals  without
diabetes. After adjusting for age, the patients with type 1 diabetes were 2.07 times more
likely and the patients with type 2 diabetes were 1.70 more likely to be dispensed a drug
item  than  people  without  diabetes.  Patients  with  diabetes  accounted  for  7.3%  of  the
prescriptions dispensed (0.7% of the patients with type 1 diabetes and 6.6% of the patients
with type 2 diabetes). The research group highlighted the higher usage of all prescription
drugs in patients with diabetes. However, type 2 diabetes constituted a particular burden
because there were 8 times more of them, and they used more drugs than type 1 diabetes
patients.
Rathmann et al. (18) illustrated how outpatient prescription medication use and costs
in patients with diabetes have changed in a decade in Germany. A total of 46 017 patients
with diabetes and 46 017 age- and sex-matched controls in 2004 were compared with
29 956 patients with diabetes and 13 226 controls in 1994. The mean annual number of
prescriptions per drug-treated patient was higher in patients with diabetes than in controls,
with little change over time. Prescription costs were in general about 30–50% higher for
most of the drug groups in 2004 than in 1994. The annual prescription costs per patient
with diabetes was about 560 € in 2004, equaling a 60% (standardized) increase from the
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year 1994. The average cost of diabetes drugs increased 100% over time, and with respect
to medication other than diabetes drugs, a 40% increase was observed. The increase was
mainly due to cardiovascular and lipid-lowering drugs. In 2004, insulin and analogues
accounted for about 22% of the drug costs and oral antidiabetic drugs for about 8% of total
costs (in 1994, the corresponding numbers were 17% and 6%). In 2004, new drugs (i.e.
insulin,  glitazones,  glinides)  accounted  for  15%  of  the  total  costs.  In  that  study,  the
majority  of  the  patients  had  type  2  diabetes,  as  only  those  over  30  years  of  age  were
included. Notably, prescription costs were assessed using the manufacturer’s selling
prices, which were about 50% of the pharmacy sales prices.
In a retrospective study, Currie et al. (348) estimated the costs of primary care
prescribing and consultations in patients with type 1 and type 2 diabetes, with a matched
cohort of people without diagnosed diabetes in the UK over a 10-year period (1997–2007).
The second aim of the study was to characterize the pattern of treatment efficacy in terms
of the main vascular disease risk factors: glycaemia, hypertension and lipidaemia. Data
were obtained from the Health Information Network, including about 300 UK practices.
The database contained information on all medical diagnoses and prescribed medications
as  well  as  laboratory  values  and  BP  readings.  A  total  of  11  300  patients  with  type  1
diabetes (8.9%) and 114 752 patients with type 2 diabetes were identified from the
database.
The overall mean prescribing costs per year increased markedly: by 77% (from £573 to
£1014) in patients with type 1 diabetes and by 89% (from £391 to £740) in patients with
type 2 diabetes from 1997 to 2007. The rate of increase was lower for the matched control
subjects, 35% and 61%, respectively. The diabetes-specific costs (including the costs of
glucose lowering and monitoring) represented 58% of the prescribing costs in patients
with  type  1  diabetes  and  20%  of  the  costs  in  patients  with  type  2  diabetes.   During  the
follow-up,  in  patients  with  type  1  diabetes,  the  mean  HbA1C remained static since it
decreased by only 0.1% (from 8.8% in 2001 to 8.7% in 2007), representing a 1%
improvement. It the same time period, the systolic BP decreased from 135 to 131 mmHg
and diastolic BP from 77 to 76 mmHg, representing a 5% improvement, and total
cholesterol decreased from 5.4 to 4.6 mmol/L, representing a 25% improvement. The use
of antihypertensive and lipid-lowering drugs increased substantially during the follow-up
(from 8% to 85% in patients with type 1 diabetes and from 8% to 29% in controls).
To  sum  up,  all  of  the  studies  described  above  compared  the  use  and  costs  of
medication between patients with diabetes and non-diabetic controls. The cross-sectional
studies showed that the costs and prescribing rates of medications were higher in patients
with type 1 diabetes than in controls, even when the diabetes medications were excluded.
Moreover, two longitudinal studies illustrated how the average costs of medications have
increased in patients with diabetes over time. However, none of the studies assessed the
drug use and costs according to the predefined disease stage and diabetic complications.
Also, longitudinal studies of medication use and costs of type 1 diabetes are rare,
especially in Finland. Therefore, the present study focused on identifying subgroups of
patients, stratified by complication status, and on clarifying major cost drivers with the
intent of improving understanding of the cost structure of diabetes care.
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3 AIMS OF THE STUDY
As health care resources are limited, elucidating and containing the costs of diabetes care
are of vital societal importance. Patients with type 1 diabetes at different disease severity
stages are more likely to require different levels of resources. Therefore, it is important to
identify potential subgroups of patients and major cost drivers in order to improve
understanding of the cost structure of diabetes care.
There is strong evidence that guideline-based care can improve patient outcomes, and
implementation of diabetes guidelines has been found to be cost-effective. Hence, it is
crucial to analyse the extent to which target values of the ADA guidelines are met in
normal clinical settings and how achievement of the most relevant targets affect the
prognosis of the patients. These factors have a decisive role in use and cost of medication.
Specific aims of the study were as follows:
I. To examine the 11-year cumulative cost of prescription medications according to the
presence of severe complications (ESRD, MVD) and duration of diabetes.
II. To assess trends in prescription medication use and costs by various stages of DN
(normo-, micro- and macroalbuminuria) before the development of ESRD.
III. To evaluate trends in prescription medication use and costs in two different kidney
transplant cohorts.
IV. To estimate BP control, antihypertensive treatment and prevalence of RH according to
the various stages of DN.
V. To investigate how the ADA treatment targets of HbA1C, BP and LDL-C had been
met, and whether these achievements have had any impact on the risk of CVD events
and all-cause mortality.
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4 SUBJECTS AND STUDY DESIGN
All patients analysed in this study are part of the nationwide, multicentre, ongoing Finnish
Diabetic Nephropathy Study (FinnDiane) with the main aim of identifying genetic,
clinical and environmental risk factors for diabetic complications among patients with
type 1 diabetes. The study was launched in 1997 and to date approximately 4800
individuals have been recruited from 92 centres all over Finland (Figure 3 A), including
all 5 university central hospitals, all 16 central hospitals, most of the regional hospitals
(28/33) and 43 primary health care centres. Type 1 diabetes was defined by age at onset of
diabetes < 40 years and C-peptide deficiency ≤ 0.3 nmol/L or initiation of insulin
treatment within one year of the diabetes diagnosis if C-peptide was not measured.
Figure 3. Geographical distribution of the FinnDiane patients (A) and the regional population
density in Finland (B) (data from Statistics Finland). The figure is modified from Mäkinen (351).
The data include about 10% of adult patients (≥ 18 years old) with type 1 diabetes in
Finland,  and  the  geographical  distribution  of  the  patients  is  similar  to  the  distribution  of
the Finnish background population (Figure  3  B).  All  adult  patients  with  type  1  diabetes
were recruited regardless of the duration of diabetes or the presence of complications, and
hence, had an equal probability to participate. The local ethics committees have approved
the study protocol, and the study was carried out in accordance with the principles of the
Declaration of Helsinki. Informed consent was obtained from all patients participating in
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the study. Besides an ongoing baseline phase of the study, a prospective phase was
launched in 2004, covering about 1600 patients’ follow-up visits. Moreover, data were
also obtained from the medical files and various national registers, namely the Care
Register for Health Care (HILMO), the Causes of Death Register, the Drug
Reimbursement Register (DRR) and the Drug Prescription Register (DPR). Study designs
and clinical characteristics of the type 1 diabetes patients in each study are presented in
Table 6.
4.1 Study I
This longitudinal prospective study comprised 3717 patients diagnosed with diabetes
before 1998. Mean age of the patients was 39.1 ± 11.4 years, mean duration of diabetes
30.9 ± 11.4 years and 51% were men. Patients were divided into four complication status
groups: neither MVD nor ESRD, MVD only, ESRD only or both MVD and ESRD. Data
on MVD and progression to ESRD were retrieved from follow-up visits, medical files or
the Causes of Death Register for all patients until the end of the year 2008. The FinnDiane
data were linked to the DPR in order to obtain information on all purchases of outpatient
prescription medications between 1998 and 2008. Annual and 11-year cumulative costs
were calculated according to the presence of complications as well as duration of diabetes,
divided into 10-year duration groups of diabetes in 1998 (0–9, 10–19, 20–29, 30–39 and
≥ 40 years).
4.2 Study II
In this prospective study, we included a total of 1905 type 1 diabetes patients, 47% of
whom were  men.  Mean age  of  the  patients  was  39.8  ±  11.9  years  and  mean duration  of
diabetes 19.4 ± 11.1 years. All patients diagnosed before 1995 for whom complete data
were available on renal status between 1995 and 2005 were included. In 1995, based on
AER, patients were divided into three groups: normoalbuminuria, microalbuminuria and
macroalbuminuria. Patients with ESRD were excluded. Purchases of drugs were obtained
from the DPR and information on co-morbidities from several national registers: from the
HILMO,  the  Causes  of  Death  Register,  the  DRR  and  the  DPR.  The  criterion  for  co-
morbidity was a consistent diagnosis across the data sources. In this study, we estimated
longitudinal trends (1995–2005) in the outpatient prescription medication use and costs by
various stages of DN prior to ESRD. We compared annual cost levels and time effect, as
well as profiles of medication between all three renal status groups. If the patient had
progressed to the higher albuminuria level, she/he contributed data to the corresponding
albuminuric category.
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4.3 Study III
Data on 330 patients with type 1 diabetes (mean age 42.5 ± 8.4 years and mean duration of
diabetes 30.4 ± 7.9 years; 62% men) and cadaveric kidney transplant until 2008 were
obtained from the FinnDiane database. Patients were typically hospitalized three to four
weeks after the operation and the drugs dispensed during the hospital stay were not
recorded in any registers. Therefore, the patients were followed for a maximum of nine
years  after  the  first  month  of  transplantation.  In  this  study,  the  use  and  costs  of
prescription medication between the earlier (transplanted 1986–1999, n=180) and the later
(transplanted 2000–2008, n=150) transplant cohorts were compared. All purchases of
outpatient prescription drugs were obtained from the DPR between 1995 and 2009. Data
on co-morbidities were obtained until 2009, as described before. The main focus was to
estimate overall trends in diabetes, immunosuppressive and other drugs (other than
diabetes or immunosuppressive drugs) in both transplant cohorts. Moreover,
immunosuppressive regimens were compared between the cohorts.
4.4 Study IV
This cross-sectional study included 3678 patients with type 1 diabetes with complete data
on  systolic  and  diastolic  BP as  well  as  on  nephropathy  status.  Mean age  of  the  patients
was 38.0 ± 12.0 years and mean duration of diabetes 22.1 ± 12.3 years. About 51% of the
patients were men. The baseline data were collected between 1995 and 2008. About 60%
had their  baseline visit  before 2000. For all  patients,  results are shown according to two
different BP targets: < 130/85 mmHg, which was the ADA target until 2000, and < 130/80
mmHg, which was the target between 2001 and 2013.  Patients were divided into five
nephropathy status groups: normo- (n=2370), micro- (n=488) and macroalbuminuria
(n=526) as well as dialysis (n=123) and kidney transplantation (n=171).
The FinnDiane data were linked to the DPR in order to obtain information on the
purchases of antihypertensive medication used in outpatient care six months prior to the
baseline visit. Patients were further divided into groups based on whether they had reached
the BP targets or not and whether the antihypertensive medication was used or not at
baseline. Uncontrolled BP was defined as failure to reach the BP target despite the use of
antihypertensive treatment, whereas RH was defined as failure to reach the BP target, even
after using a minimum of three antihypertensive drugs from different classes, one of which
was a diuretic. In this study, we also estimated the factors related to RH.
4.5 Study V
In this prospective study, we included 3151 patients with type 1 diabetes (mean age 37.1 ±
11.6 years,   mean duration of diabetes 21.1 ± 11.8 years,  49.9% men) for whom we had
complete data on HbA1C, systolic and diastolic BP and LDL-C. The baseline data were
collected between 1995 and 2004. Patients were classified into two DN status groups:
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those without DN (normo- or microalbuminuria) and those with DN (macroalbuminuria or
ESRD). We studied whether each individual, simultaneously, had met the ADA treatment
targets of HbA1C, BP and LDL-C or not. Moreover, we assessed whether these target
achievements had any impact on the risk of CVD events and all-cause mortality. The so-
called hard CVD events (MI, revascularization procedures and stroke) were identified
from the HILMO and Causes of Death Register by December 2011. All causes of deaths
were obtained from the Causes of Death Register by December 2012. Information on
purchases of antihypertensive and lipid-lowering drugs were obtained from the DPR six
months before and after the baseline visit. A preliminary analysis, where all eight
treatment achievement groups were included, showed that hypertension had an
overwhelming  effect  on  the  CVD  risk,  as  the  risk  did  not  differ  between  the  groups  in
which the BP was not on target. Thus, we divided the patients into three achievement
groups: at least BP on target, BP not on target and none of the three on target.
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5 METHODS
5.1 FinnDiane Study protocol
At each participating study centre, patients were recruited by nurses and physicians.
Baseline and prospective visits were carried out according to the same protocol. During
the visits, the patients underwent a thorough clinical investigation that took place in
conjunction with a regular visit. Details of clinical characteristics of patients, including
age at diagnosis, insulin therapy and diabetic complications, were obtained from the
medical records by the physician using a standardized questionnaire. During the visit also
BP and anthropometric variables were measured. Moreover, blood samples were drawn
after a light breakfast for subsequent assays, and urine collections were performed for the
measurement of the AER. In addition, each participant completed a detailed questionnaire
on life-style, smoking habits and family history. Finally, information on all purchases of
prescription medication was obtained from the national DPR and data on co-morbidities
from several registers, verified from medical files.
5.1.1 Anthropometric measurements and blood pressure
Weight was measured in light clothing with a standardized scale, registered to the closest
0.1 kg and height to the closest  1 cm. Body mass index (BMI) was calculated as weight
divided by height squared (kg/m2). Waist circumference was measured midway between
the lowest rib and iliac crest and hip circumference from the widest part of the gluteal
region. Waist-to-hip ratio (WHR) was calculated as waist divided by hip circumference.
BP was measured twice with a two-minute interval in the sitting position after 10 minutes’
rest using either a mercury sphygmomanometer or an automated standardized BP device.
The mean of these two readings was used in the analyses.
5.1.2 Assessment of renal status and function
Renal  status  was  defined  on  the  basis  of  the  measured  AER in  at  least  two out  of  three
urine collections. Until November 2002, AER was determined by radioimmunoassay
(Pharmacia, Uppsala, Sweden), and thereafter, by immunoturbidimetry (Hitachi 911
analyser, Roche Diagnostics, Hoffman-La Roche, Basel, Switzerland). Patients were
grouped  into  four  classes:  normal  AER  (AER  <  20  μg/min  or  <  30  mg/24  h),
microalbuminuria (20 ≤ AER < 200 μg/min or 30 ≤ AER < 300 mg/24 h), macro-
albuminuria (AER ≥ 200 μg/min or ≥ 300 mg/24 h) and ESRD (i.e. dialysis or kidney
transplantation).
Serum creatinine was determined (at the central laboratory) by the kinetic Jaffe
reaction using a Hitachi 911 E analyser, with normal reference for males of < 115 μmol/L
and  for  females  <  100  μmol/L,  until  January  2002,  and  thereafter,  by  a  photometric,
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enzymatic method using a Hitachi 917 or Modular analyser, with normal reference for
males of 50–95 μmol/L and for females for 40–90 μmol/L. The correlation coefficient
between the two methods was 0.988.
 Renal function was based on eGFR. In Studies I and II, renal function was calculated
by the MDRD-4 (104) and in Studies IV and V by the CKD-EPI (106) equation. On the
basis of eGFR, patients were divided into five groups according to the KDOQI guidelines:
Stage 1, eGFR ≥ 90 mL/min/1.73 m2 (normal kidney function), Stage 2, eGFR 60–89
mL/min/1.73 m2 (mildly reduced function), Stage 3, eGFR 30–59 mL/min/1.73 m2
(moderately reduced function), Stage 4, eGFR 15–29 mL/min/1.73 m2 (severely reduced
function) and Stage 5, eGFR <15 mL/min/1.73 m2 (very severe or end-stage kidney
failure).
5.1.3 Glycaemic control and insulin sensitivity
HbA1C was determined locally at each centre using standardized assays. Traditionally,
HbA1C has been reported as a percentage of total haemoglobin (Studies I–III). To ease
comparisons between laboratories from different countries, the International Federation of
Clinical Chemistry and Laboratory Medicine (IFCC) has recently recommended that
HbA1C concentration be reported in mmol of HbA1C per mol of haemoglobin (mmol/mol).
Thus, HbA1C is reported as both percentages and mmol/mol in Studies IV and V.
Insulin sensitivity was determined by an equation for the estimated glucose disposal rate
(eGDR) (352) modified for the use of HbA1C, instead of HbA1:
eGDR = 24.4 – 12.97 * WHR – 3.39 * AHT – 0.60 * HbA1C
(AHT is 1 if patient has antihypertensive treatment and/or BP ≥140/90 mmHg, otherwise
0).
5.1.4 Lipids and lipoproteins
Serum lipids and lipoproteins were measured centrally from the blood samples at the
research laboratory of Professor Marja-Riitta Taskinen at the Helsinki University Central
Hospital, Helsinki, Finland. Total cholesterol and triacylglycerol were determined
enzymatically by a Cobas Mira analyser (Hoffman-La Roche, Basel, Switzerland) until
January 2006, and thereafter, by a Konelab 60i analyser (Thermo Fisher Scientific,
Waltham, MA, USA). Serum HDL-C concentrations were determined enzymatically using
a  HTS  7000  plus  Bio  Assay  Reader  (Perkin  Elmer,  Waltham,  MA,  USA).  LDL-C  was
calculated with the Friedewald equation [total cholesterol - HDL-C – (triacylglycerol)/2.2]
(209).
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5.1.5 Definition of macrovascular disease
In Study I, macrovascular disease (MVD) was defined as the presence of coronary heart
disease, acute MI, stroke, coronary revascularization and amputation. All amputations
were pooled regardless of the aetiology. In Study V, the category “CVD events” denotes
revascularization procedure, MI, stroke and cardiac causes of deaths.
5.2 Registers
5.2.1 Drug Prescription Register
The Social Insurance Institution has maintained the DPR since 1994. The register contains
information on costs of medications prescribed, purchased and reimbursed in outpatient
care. The register includes the patient’s identification code, purchase date and cost of the
drug (retail price). Drugs are categorized according to the Anatomical Therapeutic
Chemical (ATC) classification, based on the valid ATC index version (2009–2013). In the
ATC classification system, drugs are divided into different groups according to the organ
or  system  on  which  they  act  and  their  chemical,  pharmacological  and  therapeutic
properties (279). Drugs are classified in groups at five levels. Drugs are divided into 14
main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd
and 4th levels are chemical/pharmacological/therapeutic subgroups, and the 5th level is the
chemical substance. As an example,
ATC classification of insulin glargine (Lantus ®), A10AE04:
A alimentary tract and metabolism (1st level, anatomical main group)
A10 drugs used in diabetes (2nd level, therapeutic subgroup)
A10A insulin and analogues (3rd level, pharmacological subgroup)
A10AE insulin and analogues, long-acting (4th level, chemical subgroup)
A10AE04 glargine insulin (5th, chemical substance)
5.2.2 Drug Reimbursement Register
Since  1964,  the  Social  Insurance  Institution  has  also  maintained  the  DRP.  It  contains
information on entitlement to full or partial special reimbursement of drug costs for certain
chronic diseases, which are classified by specific reimbursement code. Fulfillment of the
criteria for eligibility for special reimbursement must be proven by a certificate from the
treating physician. This register provides a source for co-morbidity data on the patients
suffering from some specific chronic diseases and conditions.
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5.2.3 Care Register for Health Care
The Care Register for Health Care, HILMO (named the Hospital Discharge Register until
1993),  maintained by the National Institute for Health and Welfare,  contains all  dates of
hospital admissions and discharges since 1969, each patient’s unique personal identifier
and  up  to  four  diagnoses  with  the  International  Classification  of  Diseases  (ICD).
Moreover, in 1994, this register was expanded to cover day surgery and long-term care
and in 1998 also outpatient visits to hospitals.
5.2.4 Causes of Death Register
The Causes of Death Register was established by Statistics Finland in 1936, when death
certificates were issued by medical doctors systemically across the country. The statistics
on causes of death are compiled from data obtained from death certificates, which are
supplemented with data from the population information system of the Population
Register Centre. These statistics, updated on an annual basis, include all Finnish residents
who have died during the preceding year in Finland and abroad. Since 1996, the statistics
have been compiled according to the 10th revision of the ICD.
5.3 Statistical methods
In all studies, the data are expressed as means with standard deviation (SD) for normally
distributed variables, as medians with interquartile range for non-normally distributed
values and as percentages. Differences between groups for normally distributed variables
were tested by using ANOVA, for non-parametric data using the Kruskal-Wallis test or
the Mann-Whitney U test and for categorical variables using Pearson’s chi-square (χ2) test
or two-tailed Fisher’s exact test, as applicable. All analyses in Studies I–III were
performed using SAS 9.2 version and in Studies IV and V using the SAS 9.3 version (SAS
Institute Inc., Cary, NC, USA). A P value of < 0.05 was considered significant.
Because some patients incurred markedly high medication costs, the distribution of the
costs  was  asymmetrically  skewed  to  the  right,  which  is  a  typical  distribution  for  health
care costs. Therefore, in Study I, generalized linear mixed models (GLMM) under gamma
distribution and log link (353) were used to evaluate the 11-year cumulative costs and
covariates associated with these costs. The medication costs were adjusted to 2008 or 2009
euro levels by using the Consumer Price Index (CPI, obtained from the Statistics Finland).
The GLMM framework allows fitting of correlated data under the non-normal distribution
assumption. Gamma distribution was chosen to remove heteroscedasticity in the error
variances (i.e. capacity to fit errors that are distributed differently from the normal) and to
achieve precise estimates (354). Moreover, the GLMM framework allows grouping
medication costs into discrete time intervals and takes into account the different follow-up
time of each patient during the study period. The cost data were presented as least-square
means with 95% CI (i.e. the LSMEANS statement in the PROC GLIMMIX procedure).
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 In Study I, separate models were applied for those without (neither MVD nor ESRD)
and with complications (MVD only, ESRD only, both MVD and ESRD).  The costs in the
models were adjusted for age, sex, BMI and contributing years (i.e. patients’ follow-up
years from 1998 until death or end of the follow-up by December 2008). In addition, all
variables with a P value of < 0.05 were included in the final multivariate models (duration
of diabetes, total insulin dose/day, complication status, contributing years of MVD and
ESRD). The GLMM framework is also appropriate for repeated measures. Therefore, the
GLMM  under  gamma  distribution  and  log  link  were  used  to  explore  time  trends  and
differences in medication costs by renal status groups during the period between 1995 and
2005 (Study II) as well as the medication costs nine years after kidney transplantation in
two different transplant cohorts (Study III). The annual average cost estimates were
produced based on the above-mentioned LSMEANS statement.
 In Study II, the annual costs of medications were adjusted for age, sex, BMI, hospital
days, contributing years (from 1995 to 2005) and mortality (alive on 31 December 2005)
as well as for co-morbidities (asthma, cancer, mental disorders, neurological diseases and
rheumatoid arthritis), as applicable. Before this adjustment, in an additional analysis the
total cost of medication was deflated by using the Wholesale Price Index (WPI) for
medicines. Statistics Finland prepares the WPI for medicines upon request, submitting it
to Pharma Industry Finland on an annual basis.  The calculation of the index is based on
wholesale prices of medications that have been on the market for at least two years. Thus,
the index represents trends in wholesale prices (pharmaceutical companies´ and
wholesalers´ share of the prices) of the medications. However, as shown in Table 2, the
retail prices are an approximately linear transformation of wholesale prices. The results of
this additional analysis are shown later, but not in the original study II.
 In Study III, the costs were adjusted for age at the time of kidney transplantation, sex,
transplantation year, mortality as a dummy variable (alive or dead on 31 December 2009,
alive=1, dead=0), hospital days after kidney transplantation and re-entry to dialysis as well
as co-morbidities [asthma and chronic obstructive disease (COPD), cancer, mental
disorders, neurological diseases (epilepsy, multiple sclerosis, Parkinson’s disease),
cardiovascular disease (ischaemic heart disease and stroke) and rheumatoid arthritis], as
applicable.
In Study IV, a multivariate logistic regression analysis was applied using a stepwise
selection procedure to test which variables were independently associated with RH. The
studied predictors were sex, age, HbA1C, insulin dose, laser treatment, triacylglycerol,
HDL cholesterol, presence of CHD, nephropathy status, waist-to hip-ratio, eGFR and 24-h
urinary sodium excretion rate. Results are presented as odds ratios with 95% CI.
Finally, in Study V, the 10-year cumulative incidence of CVD events and all-cause
mortality was analysed by the Kaplan-Mayer method according to the three achievement
groups in those without and with DN, as well  as when patients were classified into four
stages of renal function (Stages 4 and 5 pooled together). The log-rank test was used to
evaluate differences between achievement groups. The data were further analysed by Cox
regression models, which provide hazard ratios (HRs) with 95% CI for the development of
CVD event and death. The multivariate models were adjusted for duration of diabetes, sex,
eGFR, waist-to-hip ratio and use of antihypertensive medication.
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6 RESULTS
6.1 Use and costs of prescription medication (I-III)
6.1.1 Complication status and cumulative costs of medication (I)
Approximately a one-quarter of the patients had severe diabetic complications: about 10%
had  MVD  only,  6%  had  ESRD  only  and  7%  suffered  from  both  MVD  and  ESRD.  In
general, patients with complications were older, had longer duration of diabetes and were
more often men. As might be expected, they also had higher BP, worse dyslipidaemia and
poorer glycaemic control than those without MVD and ESRD. They also had lower eGFR
and  insulin  dose  per  day.  Patients  with  ESRD  had  an  earlier  onset  of  diabetes.  About
three-quarters of the patients with complications died during the follow-up, but the
mortality  rate  was  the  highest  (~50%)  among  those  with  both  MVD  and  ESRD.  The
observed annual costs per patient were 1000 € in those without complications, 1600 € in
those with MVD only, 8000 € in those with ESRD only and 7500 € in those with both
MVD and ESRD.
Figure 4 Eleven-year cumulative cost of diabetes medication, medication related to co-morbidity
and all medications (deflated to 2008 euro levels by using the CPI) in patients with type 1 diabetes
by complication status. Data are presented as least-square means with 95% CI (gamma GLMM).
Costs were adjusted for age, sex, BMI, complication status and contributing years of follow-up
time. In addition, diabetes medication costs were adjusted for total insulin dose/day, cost of
medications related to co-morbidity for duration of diabetes and contributing years of ESRD and
all medication costs for total insulin dose/day and contributing years of ESRD.
0 10 20 30 40 50 60 70 80
No MVD/ESRD
MVD only
ESRD only
Both MVD/ESRD
Cumulative costs (1000 €)
All medications Medications related to co-morbidity Diabetes medications
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The least-square mean 11-year cumulative costs of prescription medication were 56%
higher in patients with MVD, but increased fourfold when ESRD was present or both
MVD  and  ESRD  were  present,  compared  with  the  cost  of  the  patients  without  any
complications (Figure  4). Although the costs of diabetes medication were stable
regardless of complication status, the medication costs related to co-morbidity increased
significantly according to the complication status group, being up to 15 times higher in
patients with both MVD and ESRD (3800 € vs. 60 500 €).
Figure  5 depicts  the  proportions  of  the  cumulative  costs  by  different  types  of
medications in each complication status group. Diabetes medication accounted for almost
three-quarters of the total cost for patients without MVD or ESRD, whereas the
corresponding proportion was 40% for patients with MVD only and about 8% for patients
with ESRD or both complications. Cardiovascular medications were the second highest
contributor  to  the  total  costs  (30%)  in  those  with  MVD  only,  while  the  proportion  was
12%  for  patients  without  complications,  7%  for  patients  with  ESRD  only  and  9%  for
patients with both MVD and ESRD. Immunosuppressive drugs accounted for 38% and
peritoneal  dialytics  for  28%  of  the  total  costs  in  the  group  with  ESRD  only.  With  both
MVD and ESRD, the proportions were 33% and 27%, respectively. Notably, the share of
EPO was 10% of the total costs if ESRD was present.
Figure 5. Proportions of the 11-year cumulative costs of different types of medication according
to the complication status in patients with type 1 diabetes.
6.1.2 Duration of diabetes and cumulative costs of medication (I)
To determine how duration of diabetes affects cumulative costs, the patients were divided
into five 10-year duration groups in 1998 within each complication status group. Notably,
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when ESRD was present the adjusted least-square mean cost of diabetes medication was
lower (5050–5820 €) and the cost of medication related to co-morbidity was substantially
higher (63 060–68 770 €) in all 10-year duration groups, compared with patients without
complications (corresponding numbers 7890–8580 € and 2470–4740 €). However,
duration of diabetes had only a minor effect on the costs within each complication status
group. Those without complications and with the shortest duration of diabetes (0–9 years)
had slightly higher cost of diabetes medication (8580 € vs. 7930 €, P = 0.01) and lower
cost of medication related to co-morbidity (2470 € vs. 4180 €, P = 0.05) than those with
the  longest  duration  (≥ 40  years).  Similarly,  patients  with  MVD and shorter  duration  of
diabetes (10–19 and 20–29 years) had higher cost of diabetes medication (7610 € vs.
6150 €, P = 0.0001 and 6740 € vs. 6150 €, P = 0.03) than those who had had diabetes for
40 years or more.
6.1.3 Trends in use and costs of medication by various stages of DN before
the development of end-stage renal disease (II)
At the beginning of the follow-up, about 70% (n = 1334) of the patients had normal AER,
while 10% (n = 206) belonged to the microalbuminuria and 20% (n = 365) to the
macroalbuminuria group. During the follow-up 12% of normoalbuminuric, 45% of
microalbuminuric and 37% of macroalbuminuric patients progressed to a higher level of
albuminuria or ESRD. The mean follow-up time was 10.8 (±0.9) years, and 123 patients
died during the follow-up.
6.1.3.1 Total cost of medication
The total cost of medication increased in all groups over time (Figure  6). The average
annual increase in the normoalbuminuria group was 3.5%, in the microalbuminuria group
3.3% and in the macroalbuminuria group 5.2%. Also cost levels differed significantly
between the groups (P < 0.0001). In 1995, the annual costs per patient were 1310 € (95%
CI 1230–1400) in those with normal AER, 1450 € (1300–1600) in those with
microalbuminuria and 1770 € (1620–1930) in those with macroalbuminuria. In 2005, the
corresponding figures were 1950 € (1830–2080), 2110 € (1910–2320) and 2900 € (2650–
3180). Of note, the increase levelled off during the last year of follow-up. Moreover, the
cost profiles differed between the groups (interaction between group and time: P = 0.04).
As seen in Figure  6, the cost profile in the macroalbuminuria group diverges from the
other two groups over time.
71
Figure 6. Annual cost trends (least-square means with 95% CI, gamma GLMM) of all prescription
medication (deflated to 2009 euro levels by using the CPI) according to the different stages of DN
in patients with type 1 diabetes. Costs were adjusted for age, sex, renal status, contributing years
of follow-up time, BMI, hospital days and mortality (alive in 2005) as well as for co-morbidities
[asthma and COPD, cancer, mental disorders, neurological diseases (Parkinson’s disease, MS,
epilepsy) and RA]. P < 0.01**, P < 0.001*** (reference year 2005).
As expected, the total costs of medication were substantially lower when the WPI for
medicines was used to deflate the costs (Figure  7)  relative  to  deflation  with  the  CPI
(Figure 6); on average, the costs were about 35% lower using the WPI instead of the CPI
in all three nephropathy status groups.  However, the trends of the total costs were similar
irrespective of the index used; medication costs increased over time in all groups (P
< 0.0001), and cost levels (P < 0.0001) and cost profiles (interaction between group and
time: P = 0.04) differed significantly between the groups.
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Figure 7. Annual cost trends (least-square means with 95% CI, gamma GLMM) of all prescription
medication (deflated to 2009 euro levels by using the WPI for medicines) according to the different
stages of DN in patients with type 1 diabetes. Costs were adjusted for age, sex, renal status,
contributing years of follow-up time, BMI, hospital days and mortality (alive in 2005) as well as
for co-morbidities [asthma and COPD, cancer, mental disorders, neurological diseases
(Parkinson’s disease, MS, epilepsy) and RA]. P < 0.01**, P < 0.001*** (reference year 2005).
(Lithovius et al. unpublished results).
6.1.3.2 Diabetes medication
Figure  8 shows the costs of diabetes medication according to the renal status groups.
Between 1995 and 1997, the costs increased annually by 2.9% (P <0.0001). As expected,
the costs decreased in 1998 due to the VAT reduction. Thereafter, the costs were constant
for four years, until a rapid increase occurred between 2002 and 2004 (by 12.9% annually,
P < 0.0001). No differences were observed in cost profiles between the groups (interaction
between group and time: P = 0.99). However, the cost was slightly lower in the
macroalbuminuria group than in the normo- (P = 0.002) or microalbuminuria (P = 0.0007)
groups. The share of the diabetes medication of the total cost changed over time. In
patients  with  normal  AER,  the  share  was  over  80% in  1995,  but  it  decreased  to  65% in
2005. The corresponding numbers were 73% and 62% for patients with microalbuminuria
and 50% and 40% for patients with macroalbuminuria.
6.1.3.3 Cardiovascular medication
Cardiovascular drugs were the second highest contributor to total costs in the micro-
and macroalbuminuric patients. The cost share has increased over time in all groups: from
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Figure 8. Annual cost trends (least-square means with 95% CI, gamma GLMM) of diabetes
medication (deflated to 2009 euro levels by using the CPI) by different stages of DN in patients
with type 1 diabetes. Costs were adjusted for age, sex, renal status, contributing years of follow-up
time, BMI, hospital days and mortality (alive in 2005). P < 0.001*** (reference year 2005).
11% to 40% among normoalbuminuric, from 49% to 74% among microalbuminuric and
from 81% to 94% among macroalbuminuric patients. The most commonly used
cardiovascular medications were agents acting on the RAAS and lipid-modifying drugs.
Figure 9 presents the costs of agents acting on the RAAS and lipid-modifying drugs
by renal status groups, as well as the proportions of patients who had purchased these
drugs during the follow-up. Although the costs of both drugs (P < 0.0001) were higher in
patients with macroalbuminuria than in the other groups, no differences were observed
between the normo- and microalbuminuria groups. The costs of the agents acting on the
RAAS decreased slightly (by 2.8% annually) until 2002, but thereafter the decrease
speeded up, being on average 9.9% per year. With regard to lipid-modifying agents, the
costs were rather constant until 2001, but then the costs began to decline sharply (by
12.6% annually). Interestingly, at the same time, the consumption of both drugs increased
in all  renal status groups.  The proportion of the patients who purchased agents acting on
the RAAS increased from 6% to 27% in patients with normal AER, from 42% to 66% in
microalbuminuric patients and from 69% to 87% in macroalbuminuric patients over time.
The consumption of lipid-modifying drugs increased from 0% to 20% among
normoalbuminuric patients, from 1% to 32% among microalbuminuric patients and from
12% to 57% among macroalbuminuric patients. Thus, the consumption of these drugs was
also the highest in patients with macroalbuminuria.
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6.1.4 Trends in use and cost of medication after kidney transplantation (III)
In general, the patients from the earlier cohort (transplanted in 1986–1999) were younger
at the time of transplantation than the patients from the later cohort (transplanted in 2000–
2008). Obviously, due to a longer follow-up time, they were also more likely to re-enter
dialysis, had more hospital days and had a higher mortality rate.
6.1.4.1 Costs of medication
Total annual costs of medication per patient decreased from 11 290 € to 8760 € in the
earlier cohort and from 12 800 € to 9790 € in the later cohort during the follow-up (P
< 0.0001). Figure 10 shows the cost trends of immunosuppressive, diabetes and other
drugs according to the two transplant cohorts. The cost profiles of immunosuppressive
drugs were similar (P = 0.9), showing decreasing trends in both cohorts. The decrease was
the steepest between the first and the second year; the cost decreased by 16.8% in the
earlier cohort and by 6.4% in the later cohort. The cost was higher in those transplanted
after the millennium (P < 0.0001), although the gap narrowed towards the end of the
follow-up. The costs of diabetes drugs decreased in both cohorts at the beginning of the
Figure 10. Annual cost trends (least-square means with 95% CI, gamma GLMM) of
immunosuppressive drugs, diabetes drugs and drugs other than diabetes or immunosuppressive
drugs (deflated to 2009 euro levels by using the CPI) in patients with type 1 diabetes nine years
after kidney transplantation in two different transplant cohorts. The costs were adjusted for age at
kidney transplantation, sex, transplantation year and hospital days after transplantation.
1 In addition, costs adjusted for mortality (alive on 31 December 2009) and re-entry to dialysis.
2 In addition, costs adjusted for re-entry to dialysis. 3 In addition, costs adjusted for mortality (alive
on 31 December 2009).
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follow-up, but stabilized thereafter. The costs of other drugs were higher in the later cohort
(P <  0.0001),  but  no  differences  were  observed  in  the  cost  profiles (P = 0.3) or annual
costs per patient over time (P = 0.09). On the whole, the effect of diabetes and other drugs
on the total costs was minor.
6.1.4.2 Immunosuppressive regimen
Figure 11 depicts the proportion of different immunosuppressive regimens during the
nine-year follow-up by transplant cohort. This figure illustrates how the
immunosuppressive regimens have changed over time. The most common regimen was
the combination of cyclosporine, azathioprine and corticosteroid in the earlier cohort,
while the combination of cyclosporine, mycophenolate mofetil (MMF) and corticosteroid
prevailed in the later cohort. Notably, in those who were transplanted in 2000 and
thereafter the use of steroids decreased considerably during follow-up, and the
combination of cyclosporine and MMF became more common. Almost all patients had
purchased steroids during the first year of follow-up. In the earlier cohort, about 80% of
patients had steroids in the regimen during the following years, while in the later cohort
the proportion was approximately 40%. About one-quarter of the patients from the later
cohort had purchased tacrolimus during the first seven years. The corresponding
proportion was less than 10% in those who had transplantation before 2000. The average
cost of the combination of cyclosporine and azathioprine was 4900 € (95% CI 4760–
5040), cyclosporine and MMF 9030 € (8770–9300) and tacrolimus and MMF 8860 €
(8470–9260). Thus, the costs were substantially higher when MMF rather than
azathioprine was in the regimen (P < 0.0001).
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Figure 11. Immunosuppressive regimens in patients with type 1 diabetes nine years after kidney
transplantation in two different transplantation cohorts. TX=kidney transplantation,
CsA=cyclosporine, Aza=azathioprine, MMF= mycophenolate mofetil, Tac=tacrolimus.
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6.2 Diabetes guidelines: Implementation of recommendations
(IV, V)
 6.2.1 BP control and antihypertensive treatment by stages of DN (IV)
Of all patients, 60.9% had not reached the BP target of < 130/85 mmHg (target until 2000)
and 70.3% the target of < 130/80 mmHg (target between 2001 and 2012) at baseline. The
patients who failed to reach the targets were older, had longer duration of diabetes and
were more often men. They also had poorer glycaemic and lipid control and more micro-
and macrovascular complications. About 37% of all patients had antihypertensive
treatment.
As illustrated in Figure 12 a, the numbers of patients with antihypertensive treatment
and the prevalence of uncontrolled hypertension varied greatly between the DN status
groups. In patients with normoalbuminuria, about 14% were on antihypertensive
treatment, and with regard to the target of < 130/85 mmHg nearly 75% of them had
uncontrolled BP. The corresponding numbers were 61% and 71% for patients with
microalbuminuria, 90% and 80% for patients with macroalbuminuria, 89% and 88% for
patients with dialysis, and 91% and 90% for patients with transplantation. The numbers
were obviously worse with the target of < 130/80 mmHg, but the trend was similar
(Figure 12 b).
Figure 13 shows the number of antihypertensive drugs in use. The figure illustrates the
division of those who reached and those who failed to reach the target into different
groups with regard to the number of drugs. Notably, 58% of patients with normal AER
who had not reached the BP target, and 61% of the patients with microalbuminuria were
taking only one antihypertensive drug (Figure 13 a, b). On the other hand, more than half
of the dialysis and 40% of macroalbuminuric and transplanted patients who failed to reach
the BP target had at least three drugs in their regimen (Fig. 13 c, d, e). Almost all patients
with antihypertensive treatment had an ACE inhibitor or an ARB in their regimen.
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Figure 12. Blood pressure control based on the ADA BP target < 130/85 mmHg (a) and  < 130/80
mmHg (b) in patients with type 1 diabetes according to the different stages of DN. Tx, kidney
transplantation.
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Figure 13. Number of antihypertensive drugs
in use in those who reached the BP target
(white bar, a total of 100%) and in those who
did not (grey bar, a total of 100%) by various
stages of DN (BP target < 130/85 mmHg).
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6.2.2 Resistant hypertension (IV)
The prevalence of RH (failure to achieve the target BP [< 130/85 mmHg] after using ≥ 3
antihypertensive drugs from different classes, one of which is a diuretic) was 7.9% for all
patients with type 1 diabetes and 21.2% among the antihypertensive drug-treated patients
(Figure 14).  However,  the  prevalence  of  RH  increased  alongside  the  worsening  of  DN
(Figure 15). In the normoalbuminuria group, the prevalence was 1.2% of all and 8.7% of
drug-treated patients. The corresponding numbers were 4.7% and 7.8% for
microalbuminuric patients, 28.1% and 31.2% for macroalbuminuric patients, 36.6% and
41.3% for patients on dialysis and 26.3% and 28.8% for kidney-transplanted patients.
Figure 14. Prevalence of uncontrolled and resistant hypertension (BP ≥ 130/85 mmHg) of all and
antihypertensive drug-treated patients with type 1 diabetes.
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Figure 15. Prevalence of RH (BP ≥ 130/85 mmHg) of all (white bars) and antihypertensive drug-
treated (grey bars) patients with type 1 diabetes according to the different stages of DN.
Table 7 demonstrates that higher age, lower eGFR, higher waist-to-hip ratio, higher
triacylglycerol and micro- and macroalbuminuria were independently associated with RH
(Model 1). Moreover, 24-h urinary sodium rate was measured in a subset of the patients.
Thus, an additional analysis showed that dietary sodium intake was also independently
associated with RH (Model 2).
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Table 7. Variables independently associated with RH in patients with type 1 diabetes.
Model 1 (N=3384)
Variable OR (95% CI) P value
Age (years) 1.04 (1.02–1.05) < 0.0001
eGFR (mL/min/1.73 m2) 0.97 (0.96–0.97) < 0.0001
Normoalbuminuria 1.0 -
Microalbuminuria 2.58 (1.43–4.67) 0.002
Macroalbuminuria 5.61(3.20–9.84) < 0.0001
WHR (per one-tenth increase) 1.44 (1.15–1.80) < 0.0001
Triacylglycerol (mmol/L) 1.19 (1.01–1.40) 0.04
Model 2 (N=2203)
Variable OR (95% CI) P value
Age (years) 1.04 (1.02–1.07) < 0.0001
eGFR (mL/min/1.73 m2) 0.96 (0.95–0.98) < 0.0001
Normoalbuminuria 1.0 -
Microalbuminuria 2.86 (1.37–5.95) 0.005
Macroalbuminuria 6.93 (3.54–13.54) < 0.0001
Triacylglycerol (mmol/L) 1.22 (1.01–1.49) 0.04
24-h sodium excretion rate
(mmol/24 h; per 10 units increase)
1.05 (1.02–1.09) 0.002
Stepwise multivariate logistic regression analysis. Predictors in the model: sex, age, HbA1C, insulin
dose, laser treatment, triacylglycerol, HDL-C, presence of CHD, nephropathy status, WHR, eGFR
and 24-h urinary sodium excretion rate. Dialysis and kidney transplantation patients were
excluded.
6.2.3 Glycaemic, BP and lipid control and prognosis of patients (V)
6.2.3.1 Achievements of HbA1C, BP and LDL cholesterol
At baseline, a total of 2136 normo- and 437 microalbuminuric patients were classified into
the group without DN, and 428 macroalbuminuric and 150 ESRD patients into the group
with  DN.  Thus,  altogether  18%  of  the  patients  had  DN.  There  were  333  CVD  events
during 33 707 person-years, with a median of 11.2 (IQR 9.6 – 13.0) years of follow-up,
and 302 deaths during 34 917 person-years, with a median of 11.4 (IQR 10.1 – 13.1)
years. Table 8 shows all eight achievement groups. Notably, less than 4% of the patients
without DN and only one person with DN had achieved the ADA treatment targets of
HbA1C, BP and LDL-C, simultaneously. By contrast, 34% of those without DN and 63%
of those with DN had failed to reach all three targets.
84
Table 8.  Achievements of HbA1C, BP and LDL-C targets1 based on ADA guidelines in patients
with type 1 diabetes according to the prevalence of DN, situation at baseline.
HbA1C BP LDL-C No DN n (%) DN n (%) P value All n (%)
2573 (81.7) 578 (18.3) < 0.0001 3151 (100)
+ + + 99 (3.9) 1 (0.2) < 0.0001 100 (3.2)
+ + ̶ 116 (4.5) 11(1.9) 0.004 127 (4.0)
+ ̶ + 66 (2.6) 11 (1.9) 0.4 77 (2.4)
̶ + + 365 (14.2) 25 (4.3) < 0.0001 390 (12.4)
+ ̶ ̶ 106 (4.1) 25 (4.3) 0.8 131 (4.2)
̶ + ̶ 578 (22.5) 72 (12.5) < 0.0001 650 (20.6)
̶ ̶ + 368 (14.3) 69 (11.9) 0.1 437 (13.9)
̶ ̶ ̶ 875 (34.0) 364 (63.0) < 0.0001 1239 (39.3)
1HbA1C<7% (<53 mmol/mol), BP <140/80 mmHg, LDL-C <2.6 mmol/L. A plus (+) indicates that the
target has been reached and a minus (–) that it has not.
About half of the patients without DN and nearly one-third of the patients with DN had
achieved one of the three targets (Figure 16). In addition, one-fifth of the patients without
DN and only 8% of the patients with DN had reached two of the three targets. About 15%
of  the  patients  without  DN and 8% of  the  patients  with  DN had  HbA1C below 7%.  The
corresponding proportions of the patients who achieved the BP target of < 140/80 mmHg
were 45% and 19%. Finally, 35% and 18% had reached the LDL-C target of < 2.6
mmol/L.
Figure 16. Achievements of treatment targets in patients with type 1 diabetes according to the
prevalence of DN, situation at baseline. Cut-off values: HbA1C < 7%, BP < 140/80 mmHg and
LDL-C < 2.6 mmol/L,
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6.2.3.2 Ten-year risk of cardiovascular disease
Without DN, the 10-year cumulative risk of CVD was 3.8% (95% CI 2.7 – 4.8) for those
who had at  least  BP on target at  baseline,  4.4% (2.7 – 6.2, P = 0.3) for those whose BP
was not on target and 8.1% for those who reached none of the targets. The corresponding
shares with DN were 17.4% (95% CI 11.1 – 23.2), 29.9% (23.0 – 36.2, P = 0.03) and
28.4% (24.9 – 31.8, P = 0.009) (Figure 17). Among the patients with DN, the CVD risk
was 90% higher if BP was not on target [HR 1.9 (95% CI 1.1 – 1.3)] and increased
twofold if none of the targets were met [HR 2.2 (1.4 – 3.6)], compared with those who had
at  least  BP on  target  after  adjustments  for  duration  of  diabetes,  sex,  eGFR,  waist-to-hip
ratio and use of antihypertensive medications (Table 9). No significant differences were
observed in the risk between the achievement groups without DN. However, the Cox
regression model showed borderline significance in those who failed to reach all three
targets [HR 1.44 (0.99 – 2.09), P = 0.06].
Figure 17. Ten-year cumulative risk of CVD event in patients with diabetes without and with DN
according to the three achievement groups: all three targets met or at least BP in control (black
line), BP not on target (blue line), none of the three on target (red line). Treatment targets: HbA1C
< 7% (< 53 mmol/mol), BP < 140/80 mmHg, LDL-C < 2.6 mmol/L.
6.2.3.3 Ten-year risk of all-cause mortality
Figure 18 illustrates  the  risk  of  all-cause  mortality  in  both  DN  status  groups.  In  those
without DN, the risk was 2.9% (95% CI 2.0 – 3.9) if BP was on target, 2.7% (1.3 – 4.1, P
= 0.9) if BP was not on target and 5.3% (3.8 – 6.7, P = 0.003) if none of the targets had
been reached. The corresponding figures with DN were 18.4% (95% CI 12.2 – 24.1),
27.9% (21.4 – 33.9, P = 0.4) and 27.1% (23.6 – 30.3, P = 0.3). In those with DN, after
adjustment no differences were seen between the three achievement groups (Table 9).
Even though the risk of death without DN was higher in those who failed to reach all three
targets, after adjustment no differences were observed between the groups.
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Figure 18. Ten-year cumulative risk of all-cause mortality in patients with diabetes without and
with DN according to the three achievement groups: all three targets met or at least BP in control
(black line), BP not on target (blue line), none of the three on target (red line). Treatment targets:
HbA1C < 7% (< 53 mmol/mol), BP < 140/80 mmHg, LDL-C < 2.6 mmol/L.
Table 9. Cox regression models for CVD events and all-cause mortality in patients without and
with DN.
CVD event No DN DN
Variable HR (95% CI), P HR (95% CI), P
BP in control 1.0 1.0
BP not in control 0.96 (0.59–1.56), 0.9 1.93 (1.11–3.33), 0.02
Failed to reach all three
targets 1.44 (0.99–2.09), 0.06 2.22 (1.38–3.56), 0.001
Duration of diabetes (years) 1.08 (1.06–1.09), < 0.0001 1.06 (1.04–1.08), < 0.0001
Male sex 1.11 (0.72–1.71), 0.6 1.10 (0.76–1.60), 0.6
eGFR (ml /min/1.73 m2) 0.99 (0.98–1.00), 0.2 0.98 (0.98–0.99), < 0.0001
Waist-to hip ratio (per one-
tenth increase) 1.29 (1.00–1.67), 0.05 1.18 (0.95–1.47), 0.1
Antihypertensive treatment 1.93 (1.36–2.73), 0.0002 0.92 (0.50–1.71), 0.8
All-cause mortality No DN DN
Variable HR (95% CI), P HR (95% CI), P
BP in control 1.0 1.0
BP not in control 0.96 (0.95–0.98) 1.16 (0.70–1.90), 0.6
Failed to reach all three
targets 1.18 (0.77–1.80), 0.4 1.20 (0.79–1.81), 0.4
Duration of diabetes (years) 1.06 (1.04–1.07), < 0.0001 1.01 (1.01–1.05), 0.003
Male sex 0.92 (0.56–1.50), 0.7 1.27 (0.87–1.85), 0.2
eGFR (ml /min/1.73 m2) 1.00 (0.98–1.01) ,0.4 0.98 (0.98–0.99), <0.0001
Waist-to hip ratio (per one-
tenth increase) 1.60 (1.05–2.14), 0.001 1.45 (1.17–1.80), 0.0007
Antihypertensive treatment 1.57 (1.05–2.36), 0.03 0.96 (0.52–1.77), 0.9
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7 DISCUSSION
Overall, the findings from the large nationwide FinnDiane Study presented in this thesis
highlight the importance of early intervention to prevent or delay diabetic kidney disease
in patients with type 1 diabetes. Although diabetes itself generates high medication costs,
the progression to more severe stages of DN increases the costs dramatically, even before
the  development  of  ESRD.  Another  important  finding  is  that  the  prevalence  of
uncontrolled and resistant hypertension is a common problem in patients with advanced
renal disease. It is, however, important to emphasize that glycaemic, BP and lipid control
are also suboptimal among those without or with early signs of diabetic complications. In
addition, evidence suggests that successful implementation of the treatment targets of
HbA1C, BP and LDL-C proposed by the ADA would be useful for the optimal prevention
of CVD and mortality in patients with type 1 diabetes.
7.1 Utilizing national registers
For research purposes, Finland offers several comprehensive and high-quality register
databases maintained by the National Institute for Health and Welfare, the Social
Insurance Institution and Statistics Finland. Data collection and utilization are regulated by
legislation that ensures individuals’ rights to privacy and confidentiality. The system of
unique identification codes enables not only linking of person-level data across different
administrative registers, but also combining of register data with various observational
study designs, such as retrospective cohort studies with longitudinal or cross-sectional
study designs (355). Even though these registers are established for administrative
practices and needs, they have good coverage and validity and a large dataset can be
obtained at relatively low costs (356). With careful study planning and by transforming
the data from the original registers to a suitable form for research purposes, these registers
provide an excellent resource for investigating medication utilization and costs. To create
a more comprehensive overview of the longitudinal trends in prescription medication use
and costs, information from the large validated population-based DPR has been combined
with data collected in the FinnDiane Study.
For the purposes of this thesis, the same individual’s purchases of drugs could
conveniently be collected retrospectively from the DPR database, and it was possible to
create a longitudinal record for her/him. Combining register data allows tracking and
comparing of changes in utilization of medication over time in different subgroups (e.g. in
patients with type 1 diabetes by various stages of DN). It is also possible to search drugs
from the register under special classes and create longitudinal figures (such as
immunosuppressive regimens in two different transplant cohorts) or to identify patients
who have purchased certain drugs (such as the use of antihypertensive medications prior
to baseline by stages of DN).
To obtain information on co-morbidities, several independent sources were utilized:
the  HILMO,  the  DRR  and  the  DPR  (Studies  II,  III  and  V).  The  first  register  refers  to
inpatient information, while the others are sources of outpatient information. Moreover,
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within the FinnDiane Study, self-reported data on several co-morbidities, including
rheumatoid arthritis, asthma, depression and epilepsy, were collected by questionnaires. In
addition, data on mortality, including time and causes of deaths, were obtained from
Statistics Finland, which maintains the national archive of death certificates. To ensure a
high level of ascertainment, we cross-linked all of these data sources, and the criterion for
a diagnosed co-morbidity was that there was no inconsistency across the different data
sources used. In approximately 90% of the cases, information on a particular co-morbidity
was  found  in  at  least  two  data  sources.  In  addition,  from  the  HILMO  we  were  able  to
calculate hospital days for each patient during the study period.
 7.2 Strengths and limitations of the study
The  main  strength  of  this  project  is  the  large  sample  size  and  the  longitudinal  study
design. All participants in the five studies are part of the nationwide, multicentre,
prospective FinnDiane Study, which includes about 10% of all Finnish adult patients with
type 1 diabetes. All patients with type 1 diabetes were formerly treated at hospitals’
outpatient clinics. In recent years, however, many adult patients with type 1 diabetes,
especially without severe complications, have been transferred to the primary health care
units. To avoid sampling bias, the FinnDiane Study population is recruited from all levels
of the health care system: from primary health care to university central hospitals, and it
covers patients with different severity stages of disease.  It is also noteworthy that
although the FinnDiane Study is not, by strict definition, population-based, a selection bias
is unlikely as the geographical distribution of the patients is similar to the general
distribution of inhabitants in Finland. Moreover, the study population is well-characterized
regarding clinical factors, medical history and classification of diabetic complications.
The main focus in this thesis was to investigate the prescription medication costs and
use in outpatients with type 1 diabetes over time.  As discussed above, data collected from
the DPR allow the creating of longitudinal records of medication use and costs.
Nevertheless,  the costs of medications obtained from the DPR explain only a part  of the
total health care costs and about three-quarters of the total sales of medications. Nearly all
over-the-counter medications and all medications dispensed during hospital stay or stay in
other institutional care units are not recorded in the DPR. Notably, in contrast to peritoneal
dialytics, haemodialysis fluids are mainly administered by the hospital and not registered
in the DPR. Unfortunately, it is difficult to obtain accurate data on inpatient costs at the
patient level, as such data are not available from any national database.  The only way to
obtain such data would be to examine the costs of every patient separately from the
medical files, which would not necessarily be accurate, especially when assessing
longitudinal trends. The risk of hospitalization and death typically increases with advanced
renal disease. Thus, the results presented in this thesis may underestimate the actual use
and cost of medications. To minimize bias, these confounders have been controlled
(mortality, hospital days) in multivariate models.
Although the coverage and accuracy of the DPR are high, only reimbursed medications
are recorded in the register. As described above, the costs of medicinal products are
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reimbursed only after the holder of the marketing authorization has applied for
reimbursement and a reasonable wholesale price from the PPB. The Board can also restrict
the  basis  for  reimbursement  to  a  precisely  defined  diagnosis  or  severity  stage  of  the
disease. Moreover, several legislative measures have affected the content and coverage of
the DPR. The fixed deductible rate per purchase was abolished in 2006. Thus, inexpensive
drugs which did not reach the limit are missing up to 2006, but thereafter are recorded in
the register. Since 2007, medications funded by the employer are also documented in the
register. Since all patients have been affected by the above-mentioned changes in the same
way, it is likely that these changes have only a minor effect on the results.
Notably, the real doses and frequencies of the use of drugs are not available from the
DPR. Instead, the Defined Daily Doses (DDDs) calculated from the volume of sales of
pharmacies and hospitals by wholesalers and from the assumed theoretical average doses
per day for each patient have been included in the register (277). Thus, the DDD is only a
rough estimate of the consumption (i.e. technical expendient, which is not necessarily
equal to the real dose of drug) and therefore is only suitable for studying consumption of
the drugs on the population level (277). Therefore, we did not use that imprecise variable,
but identified the number and classes of medications purchased (from the desired time
period), providing more relevant estimates than DDD for the purposes of this study.
Nevertheless, it is important to bear in mind that some medications sold may be unused by
the patient.
In the current study, the medication costs were deflated (either to 2008 or 2009 euro
levels) by using the CPI.  The index has frequently been used in drug studies and is
recommended by the Social Insurance Institution (279). The CPI describes the price
development of goods and services purchased in Finland by household residents. The CPI,
as a general measure of inflation, is calculated with a method in which the prices of
different  commodities  are  weighed  as  shares  of  consumption  using  the  Laspeyres’  price
index formula. However, the weight of medicines is marginal, as the weight of health care
overall is only 5% and medicines form only a proportion of this. In addition, the prices of
reimbursable medicines are in the index net of reimbursement, which means that the
consumer prices of 100% reimbursable diabetes medicines are zero plus a small co-
payment (Statistics Finland).
As described above, in order to keep medication prices at a reasonable level, the prices
of pharmaceuticals are regulated by law in Finland and in other European countries.
Generic substitution and the reference price system as well as the cut in wholesale prices
have reduced the prices of reimbursable medications, despite the simultaneous increase in
taxes  and  patients’  co-payments  for  these  drugs.  It  is  therefore  well-founded  to
contemplate the use of indices other than the CPI in analysing the trends in drug costs.
An additional analysis shows substantially lower costs of medications when the costs
were deflated by using the WPI for medicines. As described earlier, the index is based on
wholesale prices of medications that have been on the market for at least two years. The
calculation of the index follows Fisher’s price index formula. The recent index material
consists of the price data of approximately 6000 drug packages. In 2013, about 76% of
drugs sold in Finland were included in the calculation (Nadia Tamminen, Pharma Industry
Finland, 8.1.2015). As presented in Table 2, the retail price of the drug includes the shares
of the manufacturer and wholesaler, the pharmacy’s margins and taxes. In 2012, the
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combined share of the pharmaceutical company and wholesaler was about 60% of the
retail price, while the proportion of the pharmacy was about 25% and the proportion of the
state about 15% (http://www.pif.fi).
As the CPI and the WPI for medicines have developed in opposite directions
(http://www.pif.fi), it is probable that our results overestimated the actual costs of
medications. In contrast, by using the WPI for medicines the costs would have been
underestimated, as the WPI represents the trends in wholesale prices (pharmaceutical
companies´ and wholesalers´ share of the prices) of the medications, but not the overall
trends in drug costs. Despite these shortcomings, the drug costs increased with worsening
of renal disease, already before the development of ESRD. Irrespective of which index is
used, the trends remain the same. However, to avoid these biases in the future, it would be
desirable to develop a Retail Price Index for medicines for research purposes.
7.3 How does progression of DN affect medication use and costs
(I, II)?
Results from Study I show that the presence of MVD and ESRD increases the 11-year
cumulative cost of outpatient prescription medication substantially in patients with type 1
diabetes. Notably, the impact of renal failure on the costs is enormous. In Finland (Finnish
Kidney Register)  and other countries (88),  the prevalence of ESRD among patients with
type 1 diabetes is about 1–2.5%. Extrapolation of the results to all type 1 diabetes patients
with ESRD in Finland showed that about 1.5% of the patients incur more than 10% of all
outpatient prescription medication costs. The cost of diabetes medication remains rather
stable irrespectively of the prevalence of complications or duration of diabetes. These
costs were even lower in patients with ESRD or with both conditions than in those without
complications. This observation is in accordance with patients with decreased GFR
requiring a reduced amount of insulin (357). Thus, the increase of the costs in patients
with these severe complications was entirely due to the costs of medication related to co-
morbidity. This is not a surprise since renal failure is likely to display several co-
morbidities including cardiovascular disease, secondary hyperparathyroidism, electrolyte
disturbances and anaemia, as well as bone and mineral metabolism disorders, necessitating
multiple pharmacological therapies.
Type 1 diabetes itself may generate 8 to 12 times higher medication costs than in non-
diabetic controls (16, 17). However, there is also a large variation in costs among the
patients  with  type  1  diabetes  at  different  severity  stages  of  DN,  already  before  the
development of ESRD. Overall, Study II shows that the costs of prescription medications
have increased in normo-, micro- and macroalbuminuric patients over time. This trend
corresponds to the general development of medication costs in Finland. The cost
difference between normo- and microalbuminuric patients was, however, rather small, and
the gap narrowed towards the end of follow-up. One potential explanation could lie in the
early utilization of pharmacological treatments in patients at risk of renal disease, perhaps
also in patients with upper normal AER or with other risk factors, including elevated BP
and lipid abnormalities. Moreover, some patients may follow a non-albuminuric pathway
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to renal impairment (97). In the FinnDiane Study population, about 5% of patients had
impaired renal function (eGFR < 60 mL/min/1.73 m2) with normal AER at baseline.
Finally, there is also increasing evidence of spontaneous remission of albuminuria in
patients with type 1 diabetes (121), probably as a consequence of pharmacological
treatment, i.e. aggressive treatment of glycaemia, elevated BP and dyslipidaemia.
Especially  the  use  of  agents  acting  on  the  RAAS  has  proven  to  be  effective  in  slowing
down the progression of renal disease (194-197).
In contrast, the cost difference between the micro- and macroalbuminuria groups was
large, and this gap expanded towards the end of follow-up. Obviously, even before the
development of ESRD, progression to more severe stages of DN increases the prevalence
of multiple co-morbidities and, certainly, the consumption of medications. During the
follow-up period several new and more efficient drugs, such as insulin analogues, ARBs,
statins, phosphate binders, paricalcitols, calcimimetics and EPO, entered the market. As
mentioned in the literature review, these new drugs are more expensive than the older
ones, at least as long as they are protected by their patents.
In  general,  the  findings  observed  in  Studies  I  and  II  are  consistent  with  those  of
previous studies, showing increases in the direct costs of diabetes at the stage of renal
failure  (9,  88),  but  also  at  the  various  stages  of  DN  before  the  development  of  ESRD
(344). However, direct comparisons of the findings are difficult due to different study
designs, study populations, time periods, cost components and classifications of kidney
disease. Also the accuracy of data sources varies between the studies. Despite a wide
range of studies on medication costs in patients with diabetes, very few of these have
considered medication costs according to the different severity stages of DN in patients
with type 1 diabetes.
7.4 Which drugs are the major cost drivers (I–III)?
In patients without severe complications, the major contributor to the medication costs
during the 11-year follow-up was diabetes medication (nearly 70% of total costs),
followed by the cardiovascular medications (~10%) and other drugs (~20%). Although the
proportion of diabetes medications was still the highest in patients with MVD only, nearly
one-third of the costs were caused by cardiovascular medications and about one-quarter by
other drugs. However, in the presence of ESRD or both complications, the major cost
drivers were immunosuppressants, peritoneal dialytics and EPO, together accounting for
76% of the total costs in those with ESRD only and for 70% in those with both MVD and
ESRD. As might be expected, the major cost drivers in the patients with kidney
transplants were immunosuppressive drugs, while the proportion of diabetes medication or
other drugs of the total costs was rather small. However, patients who were transplanted
after the millennium had higher costs of immunosuppressive drugs than the earlier cohort.
The newer immunosuppressants, MMF and tacrolimus, are more expensive than the older
ones, and for obvious reasons were more common in the later cohort. Previous cost-
effectiveness studies have shown that these new drugs reduce the risk of acute rejection
and offer at least short-term economic advantages (358).
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Shares of various medications of the total costs have also changed over time. Diabetes
medications are the major cost driver, but their proportion of the total costs has decreased
in all renal status groups prior to ESRD between 1995 and 2005. At the same time, the
proportion of cardiovascular medications has increased in normoalbuminuric patients,
while their share has been rather constant in the micro- and macroalbuminuria groups.
However, the shares of medications other than diabetes or cardiovascular drugs have
increased in all groups, especially in the macroalbuminuria group. Notably, in this group,
EPO has become one of the major cost drivers. Taken together, these changes may again
be explained by the increased use of newer medications such as statins or EPO. Also
implementation of new evidence-based guidelines to tackle diabetes and its complications
may be a contributing factor.
7.5 Effects of legislative measures on medication use and costs
(II)
Several legislative measures, such as a reduction in VAT, wholesale price cuts and generic
substitution, implemented in Finland over the past decades have only temporarily
restrained the increasing trend in medication expenditures (277, 288). The most likely
reason for the ascending trend is that the new patented drugs seem to have a substantial
effect on the total costs of drugs. During the follow-up we observed a similar increasing
trend, with a light temporal decrease in medication costs in patients with type 1 diabetes
prior to ESRD. Thus, the overall increasing trend in costs reflects the general development
of drug costs in Finland.
Generic substitution was introduced in Finland in 2003. While generic drugs are less
expensive than branded products, they may also foster competition between
pharmaceutical companies. As mentioned earlier, during the first year of generic
substitution, over half of the savings came from lipid-lowering drugs and antidepressants,
and one-tenth from agents acting on the RAAS (286). Interestingly, during the first year of
generic substitution the consumption of cardiovascular drugs increased by 10%, but their
sales value increased only by 1% (288). Correspondingly, Study II showed that in all renal
status groups prior to ESRD the costs of lipid-lowering drugs and agents acting on the
RAAS decreased towards the end of follow-up and prior to the introduction of generic
substitution. Similarly, the consumption of these drugs simultaneously increased. This
suggests that generic substitution has generated savings, but has not succeeded in curbing
the ascending trend of the total costs. The reference price system was adopted and generic
substitution was extended to cover drugs holding an analogue process patent in 2009.
Therefore, further research needs to be focused on more recent trends in medication
utilization and costs, also considering whether the reference price system has had any
effect on medication costs in patients with diabetes.
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7.6 Have patients been treated in accordance with ADA guide-
lines (IV, V)?
The ADA treatment guidelines emphasize the importance of controlling of HbA1C, BP and
LDL-C in patients with diabetes. Findings presented in this thesis confirm that a large gap
exists between evidence-based diabetes guidelines and clinical practice since only a
minority of patients with type 1 diabetes have reached the targets proposed by the ADA
for these three key components. It is important to note that one-third of the patients
without  and  two-thirds  of  the  patients  with  DN  had  not  attained  any  of  the  targets.
Moreover, it seems to be surprisingly rare for an individual to meet all three targets,
regardless  of  stage  of  renal  disease.  Results  from Study V show,  however,  that  DN is  a
strong predictor of failure to reach a single treatment target.
Despite advances in insulin preparations, delivery and glucose monitoring systems,
glycaemic control has not improved markedly in patients with type 1 diabetes in Finland
(307). Findings in Study V clearly indicate that glycaemic control is far from optimal
since the median HbA1C values remained above 8%, and only one-tenth of all patients
reached the cut-off value of < 7%. These findings are consistent with recent reports
showing that about 13% of patients with type 1 diabetes had reached the target HbA1C (10,
308).  In  light  of  the  DCCT/EDIC  data,  improvements  are  especially  needed  in  those
without complications and with shorter duration of diabetes, as intensive glycaemic
control implemented soon after the diagnosis of diabetes is associated with long-term
reduction in both micro- and macrovascular complications (i.e. “metabolic memory”)
(126).
To achieve optimal glycaemic control, self-management skills, such as home blood
glucose monitoring and flexible insulin dose adjustment for diet and physical activity, are
essential for successfully and safely managing diabetes. Notably, the prevalence of obesity
has  risen  in  patients  with  type  1  diabetes  (176),  which  can  become  a  barrier  to  optimal
glycaemic control. Therefore, in strategies to improve glycaemic control, more attention
should also be paid to lifestyle modification, such as weight loss, exercise, dietary changes
and  a  reduction  in  alcohol  use,  as  well  as  assessment  of  mood  disturbances  since  these
factors impose barriers to the management of diabetes (177). Previous studies have shown
that diabetes self-management education and support improves glycaemic control and
quality of life (359-361). Also from the economic point of view, these education
programmes have proven cost-effective (362). Given the fact that successful management
of diabetes is challenging and complex for patients and their families, and the major
responsibility for day-to-day care rests with the patients themselves, greater emphasis
should be focused on improving self-management skills, reducing diabetes-related distress
and improving communication between the patient and health care providers. The
importance of a permanent and long-lasting patient-doctor-nurse relationship must also be
stressed.
Despite current knowledge about the importance of management of hypertension and
the availability of effective antihypertensive drugs, a large proportion of the patients have
suboptimal BP control, which tends to worsen with progression of DN, irrespective of the
number of antihypertensive drugs used. In line with the ADA recommendations,
antihypertensive treatment was prescribed for most patients with micro- or
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macroalbuminuria or ESRD. Moreover, nearly all antihypertensive drug-treated patients
with normo-, micro- or macroalbuminuria had an ACE inhibitor or an ARB in their
regimen. Even though we can not determine from Study IV (cross-sectional) whether poor
BP control is a cause or consequence of DN, previous studies have shown an association
between hypertension and DN and have also demonstrated that lowering of BP, especially
with the use of ACE inhibitors and ARBs, may prevent the progression of DN (195-197).
Thus, our findings together with the earlier studies support greater efforts being directed to
those with early signs of kidney disease in order to prevent the progression to more severe
stages of DN.
This suboptimal control may partly be explained by poor adherence to antihypertensive
therapy, by suboptimal dosing or by inadequate use of combination therapy. About 60% of
the patients with normo- and microalbuminuria who had not achieved the BP target were
taking only one antihypertensive drug. However, more than half of the dialysis and 40%
of macroalbuminuric and transplanted patients did not reach the target despite the
concurrent use of ≥3 antihypertensive drugs. This suggests that the response to
antihypertensive treatment may be attenuated by worsening renal function. The results are
consistent with previous findings showing that advanced renal disease (both reduced
eGFR and increased albuminuria) is a risk factor for therapy-resistant hypertension (310,
363-365). Moreover, our findings show that BP represents an important marker of
increased  risk  of  CVD events  among DN patients.  Therefore,  our  data  suggest  that  it  is
important  to  identify  patients  with  high  CVD risk  early  in  the  course  of  diabetes  and  to
treat their BP with a more efficient pharmacological therapy; but at the same time careful
attention should be paid to improving adherence to treatment and lifestyle factors.
Although the study showed that BP seems to be more difficult to control with progression
of renal disease, BP is also poorly controlled among those without or with early signs of
diabetic complications.
In comparison with the non-diabetic population, type 1 diabetes is associated with a
higher prevalence of essential hypertension, even in the absence of DN (366, 367). The
present study shows, however, slightly worse achievements for BP than in the previous
studies with type 1 diabetes patients (367, 368). A possible explanation for these results
may be the fact that we used office-based BP recordings from a single occasion, measured
at the first FinnDiane Study visit (which might be more “exciting” than a regular visit),
and these BP readings do not necessarily reflect the blood pressure variation in the
patient’s usual environment. Thus, the results may overestimate the true prevalence of
hypertension since we were unable to rule out a potential white coat effect. On the other
hand, we did not assess the prevalence of masked hypertension, either. It may occur in
10% of patients with type 1 diabetes, and the prevalence could be even higher in patients
with albuminuria (369).
Regarding LDL-C achievements at the baseline visit, only 35% of patients without DN
and one-fifth  of  patients  with  DN reached  the  cut-off  value  of  LDL-C.  In  those  without
DN, the median LDL-C was 2.9  mmol/L  and  only  7%  of  them  were  treated  with  lipid-
lowering drugs. The corresponding numbers in those with DN were 3.3 mmol/L and 27%.
Findings from the clinical trials have shown clear risk reduction of major vascular events
in patients treated with statin therapy (212). Based on the current ADA guidelines, statin
therapy  was  recommended for  those  with  a  history  of  CVD and for  those  without  CVD
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who are aged over 40 years and have one or more other risk factors. In the present study,
the baseline data were collected between 1995 and 2004. Statins have since reached the
market. In Study II, we showed an increase in the proportion of patients purchasing lipid-
lowering medications during that time. It is, therefore, obvious that after the baseline visit,
the proportion of patients with statin therapy has increased, which probably has had a
beneficial effect on LDL-C levels.
7.7 How does resistant hypertension reflect the progression of
DN (IV)?
One of the novel findings in this thesis is the high prevalence of RH in patients with type 1
diabetes.  RH increased  alongside  the  worsening  of  DN:  while  less  than  one-tenth  of  the
antihypertensive drug-treated normo- or microalbuminuric patients met the criteria for
RH, up to one-third of patients with macroalbuminuria and 40 % of patients on dialysis
were classified as having RH. Notably, the rate was the highest in patients at the
predialysis phase (eGFR 15–29). While previous studies have assessed the prevalence of
RH in the general hypertensive population or the majority of the patients recruited to these
studies have had type 2 diabetes, we estimated the prevalence of RH in a large and
representative cohort of patients with type 1 diabetes in general and by stratifying patients
according to the stage of DN. These figures are higher in antihypertensive drug-treated
patients with type 1 diabetes than in the general hypertensive population: about 21% in
patients  with  type  1  diabetes  vs.  13%  in  patients  treated  for  hypertension.  Contrary  to
previous studies, we did not classify patients who had BP on target but were taking four or
more antihypertensive drugs, as resistant to treatment. Even though the definition is
arbitrary with regard to the number of drugs required, it assists health care professionals to
identify high-risk patients who may benefit from special diagnostic and therapeutic
consideration (310).
Findings from the present study suggest that a more aggressive and individualized
approach to tackle the BP problem is required in patients with type 1 diabetes (309, 370).
However, the downside is that aggressive treatment may cause harmful side-effects and
additional costs. The first important step is to confirm the presence of uncontrolled
hypertension and RH by using the correct BP measurement technique. The ambulatory
measurement may provide more accurate estimates of BP, thus enabling a more accurate
distinction between true and apparent RH (371). Moreover, the identification and reversal
of harmful lifestyle factors, discontinuation or minimization of interfering substances and
screening for secondary causes of hypertension should be considered. In addition, an
efficient pharmacological regimen should be tailored for each patient, and patients´
adherence to treatment should be assessed, with interventions to improve adherence
should they be necessary. Finally, when a specific secondary cause of hypertension is
suspected or BP remains elevated despite continuous treatment, referral to an appropriate
specialist is recommended.
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7.8 What might be the consequences of failure to achieve ADA
targets (V)?
Numerous studies have reported the beneficial effect of controlling risk factors, including
hyperglycaemia, hypertension and dyslipidaemia, in preventing CVD and premature death
in patients with diabetes. We evaluated how the implementation or lack of implementation
of the target values of these three key components, in the same individual simultaneously,
predicts the long-term prognosis of patients with type 1 diabetes in the normal clinical
setting. We found that failure to reach all of these ADA treatment targets is associated
with an increased risk of CVD and all-cause mortality. Although the risk of CVD events
and mortality was considerably higher in patients with DN, the failure to reach any of the
three targets doubled the risk also in those without DN. Therefore, our findings strongly
support the fact that successful implementation of the treatment targets for all of these key
risk factors would be worthwhile for the prevention of these severe complications.
One of the interesting findings is that in patients with DN the risk of CVD event was
significantly lower if BP was on target, while we did not find any differences in the risk
between those who did not achieve the BP target and those who failed to achieve all three
targets.  Thus,  BP  seems  to  have  an  overwhelming  effect  on  the  CVD  risk.  Despite
relatively high antihypertensive drug treatment rates, we show that about one-third of the
patients with DN may have therapy-resistant hypertension. Accordingly, a prospective
study of hypertensive chronic kidney disease patients showed that true RH was associated
with an increased risk of CVD events (372). Nevertheless, this might indicate how
challenging it is to treat hypertension in patients with chronic kidney disease, especially
when diabetes further complicates the treatment. As also demanded by the recent scientific
statement from the American Heart Association and the ADA, more work is needed to
improve the understanding of the pathogenesis of CVD, hypertension and diabetic kidney
disease in patients with type 1 diabetes (373). Nevertheless, our results suggest that these
patients  with  uncontrolled  BP  should  be  identified  and  their  BP  as  well  as  other  risk
factors should be addressed.
7.9 Can we identify high-risk patients by using cut-off values of
HbA1C, BP and LDL-C (V)?
Clinical guidelines have become an important tool for simplifying the complexity of
diabetes care, and outcomes from trials represent averages derived from selected groups of
people (374). The findings from the current study indicate that the cut-off values of
HbA1C, BP and LDL-C from the evidence-based guidelines do identify high-risk patients
and might therefore be used as a rough predictor for high-risk patients. This finding
should, however, be interpreted with caution for several reasons. First, the cut-off values
of these three components derived from the ADA guidelines are not necessarily relevant
for all patients with diabetes at different disease levels. The benefits for achieving these
treatment targets depend on a large number of patient factors such as age, life expectancy,
co-morbidities and self-management skills. The ADA guidelines provide one or two
trigger points for some components, depending on other related factors. For example, they
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recommend a more stringent LDL-C target for patients with CVD. On the other hand, the
more recent ADA guidelines emphasize a more individualized approach to the
management of diabetes by taking into account the patient’s individual preferences, co-
morbidities and other patient-specific factors when deciding on treatment goals and
strategies (7). In the present study, target achievement was calculated from a single
measurement obtained at baseline. Unfortunately, we do not have sufficient follow-up data
concerning all of these three key components. Therefore, we were unable to take into
account the impact of the treatment on CVD and death risk after baseline.
Several cardiovascular risk prediction models, including the Framingham and the
UKPDS Risk Engine models, are currently available. However, these models poorly
predict events in patients with type 1 diabetes (375). Therefore, there is an urgent need to
develop more accurate CVD risk prediction models for patients with type 1 diabetes in
order to identify these high-risk patients in clinical practice. One of the promising attempts
to develop such a model for this patient group was recently published by Soedamah-
Muthu et al. (376). They developed a prognostic model to identify high-risk patients early
in the disease process. The major outcomes included were CHD, stroke, ESRD,
amputations, blindness and death. The data were analysed from participants in the
EURODIAB Prospective Complications Study, and the model was also validated in three
different prospective cohorts, including the FinnDiane study cohort. In that model,
prognostic factors were age, HbA1C, WHR, ACR and HDL-C. However, other prognostic
factors, such as BP, LDL-C or smoking, were not included because of a weak additional
effect. Most of the participants were recruited more than two decades ago, and it is
possible that the frequency of the outcomes is different nowadays. Therefore, further
efforts to test such models are needed.
The cut-off value for systolic BP has been under constant debate for years. Recently,
the ADA revised the BP target from < 130/80 mmHg to < 140/80 mmHg, and this
threshold has since been adopted by many national recommendations. The primary data
for this new recommendation came from the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial, which found no significant differences in the rate of major
cardiovascular events or all-cause mortality when the systolic BP target was raised to <
140 mmHg (301, 302). While the previous target had been derived from observational
studies, the current target was based on randomized clinical trials. Even though all patients
in these trials had type 2 diabetes, this less stringent target is also recommended for
patients with type 1 diabetes by the ADA. Given the fact that a subset of the patients with
type 1 diabetes have a high risk of CVD and progressive kidney disease, a lower BP target
(such as < 130 mmHg) may still be more appropriate, especially for younger patients
(373). Relevant BP control trials focusing on type 1 diabetes to determine a specific target
of BP do not exist. Randomized clinical trials focusing on the role of BP in patients with
type 1 diabetes are warranted to identify appropriate BP targets and management (377).
7.10 Concluding remarks and future prospects
Pharmaceutical interventions play a fundamental role in the treatment of diabetes itself,
but also in the prevention and treatment of complications. Successfully implemented
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pharmacotherapy may generate savings in terms of money and intangible costs. Besides
reducing the total costs of the disease, it may also improve the prognosis of patients,
reduce the need for hospitalization, relieve pain and other symptoms, maintain the ability
to work and function and prolong life. The costs of pharmacotherapy should always be
seen as an essential part of the framework of holistic management of diabetes.
The findings presented in this thesis are observational, and therefore, we can not
directly demonstrate that a lower level of proteinuria will reduce the cost of medications.
Instead, we can assume that by preventing the onset or progression of DN, some patients
may generate lower medication costs for some period of time. It is also clear that renal
disease, especially ESRD, is the major driver of the medication costs. Despite evidence
that the incidence of ESRD has decreased, the number of patients with ESRD will
continue to rise worldwide due to the growing number of individuals with diabetes at
increasing younger ages. This group will have enough time to develop severe
complications, and a subset of them will have a high risk of micro- and macrovascular
complications.
During economically uncertain times, measures bringing direct benefits and cost
savings are often prioritized. The marked reductions in health care spending during the
preceding economic recession in the early 1990s have weakened the care of especially
patients with type 1 diabetes (378). Consequently, good clinical care has been
compromised particularly in young patients with type 1 diabetes; the number of diabetes
specialist nurses in diabetes care has been cut and the treatment of adults and young
patients who have reached 16 years has been moved to primary health care centres. As a
result, the prerequisites of good self-care have also been threatened, as treatment is
allocated to institutions that do not always have sufficient resources for training and where
there may be a constant lack of money and experienced, dedicated staff. Moreover, the
decentralization of diabetes care to both primary health care centres and specialized care
units might jeopardize the continuity of care. Finland is again facing an economic crisis,
which may cause further reductions in health care spending and cuts in preventive health
services. To guarantee successful management of type 1 diabetes as well as rational and
efficient use of health care resources, the main focus should be placed on minimizing the
risk of diabetic complications. Type 1 diabetes is a complex and psychologically
demanding disease in which the day-to-day care lies primarily with the patients. This
highlights the importance of long-lasting support and guidance from health care
professionals. Type 1 diabetes care should be centralized to units where there is sufficient
staff with different expertise to enable multiprofessional cooperation and constant
education.
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8 SUMMARY AND CONCLUSIONS
I The presence of ESRD increases the 11-year cumulative cost of prescription medication
considerably  in  patients  with  type  1  diabetes.  Extrapolation  of  the  results  to  all  type  1
diabetes patients showed that patients with ESRD represent only 1.5% of all patients, but
this group incurs more than 10% of all prescription medication costs. The cost of diabetes
medication remained quite stable regardless of the prevalence of severe complications and
duration of diabetes.
II Total costs of prescription medication have increased in patients with type 1 diabetes
over  time,  reflecting  the  general  development  of  drug  costs  in  Finland.  Generic
substitution has generated cost savings, but has not succeeded in halting the increasing
trend, as new and more expensive patented drugs have entered the market and have been
prescribed for these patients. Nevertheless, progression to more severe stages of DN has a
substantial  impact  on  costs,  also  before  the  development  of  ESRD,  which  suggests  that
early prevention and intensive treatment of kidney disease may generate marked cost
savings.
III Total costs of prescription medication have decreased during the 9-year follow-up after
kidney transplantation in patients with type 1 diabetes. The trend is mainly due to the costs
of immunosuppressive drugs. This finding is consistent with the recent guidelines that
recommend reducing doses of immunosuppressants over time in order to minimize
undesirable side-effects. The cost levels differed between the cohorts, depending on the
combination of immunosuppressive drugs in use. Those who had MFF in the regimen
generated higher costs.
IV The prevalence of uncontrolled and resistant hypertension increases with worsening of
diabetic kidney disease in patients with type 1 diabetes. Moreover, our findings suggest
that patients with normal AER and microalbuminuria might have a suboptimal
antihypertensive treatment since the majority of those who failed to reach the BP target
had  only  one  antihypertensive  drug  in  their  regimen.  Thus,  there  is  a  need  for  a  more
aggressive and individualized approach to improve BP control.
V This study confirmed that a large gap exists between evidence-based guidelines and
clinical practice, with only a minority of patients with type 1 diabetes reaching the ADA
targets of HbA1C, BP and LDL-C. Moreover, failure to achieve the targets is associated
with increased risk of CVD and premature death in these patients. Although the risk was
higher in patients with DN, the failure to achieve any of the three targets doubled the risk
also in patients without DN. This suggests that successful implementation of the treatment
targets of these three components is key for optimal prevention of CVD and mortality.
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